exv10w20







Exhibit 10.20



Pages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential section has been marked as follows: [***].




Collaboration Agreement




between



Institute of Grassland and Environmental Research



and



Ceres, Inc.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 1 of 75








 









 





TABLE OF CONTENTS




	 	 	 	 	 

	1. RESEARCH PROJECTS

	 	 	3	 
	2. MANAGEMENT COMMITTEE

	 	 	7	 
	3. EXCLUSIVITY

	 	 	8	 
	4. INTELLECTUAL PROPERTY

	 	 	11	 
	5. USE AND COMMERCIALIZATION RIGHTS

	 	 	14	 
	6. ENFORCEMENT OF JOINT INTELLECTUAL PROPERTY RIGHTS

	 	 	16	 
	7. CONFIDENTIALITY

	 	 	16	 
	8. PUBLICATIONS

	 	 	18	 
	9. PUBLICITY

	 	 	18	 
	10. RECORDS AND AUDITS

	 	 	19	 
	11. INDEPENDENT CONTRACTOR

	 	 	19	 
	12. CONVENTION ON BIOLOGICAL DIVERSITY

	 	 	19	 
	13. WARRANTIES

	 	 	20	 
	14. TERM AND TERMINATION

	 	 	23	 
	15. DISPUTE RESOLUTION AND APPLICABLE LAW

	 	 	25	 
	16. NOTICES

	 	 	26	 
	17. GENERAL

	 	 	27	 
	18. SPECIAL CONDITIONS IN CONNECTION WITH DEFRA AGREEMENT NF 0426

	 	 	28	 
	EXHIBIT A

	 	 	30	 
	DEFINITION OF COLLABORATION CROPS

	 	 	30	 
	EXHIBIT B

	 	 	31	 
	PREFERRED FORM OF RECEIPT FORM

	 	 	31	 
	EXHIBIT C

	 	 	32	 
	PREFERRED FORMS OF VARIETY EVALUATION AGREEMENT

	 	 	32	 
	EXHIBIT D

	 	 	50	 
	EXTERNAL FUNDING 

EXHIBIT E

	 	 	50

51	 
	EXISTING AGREEMENTS

	 	 	51	 
	EXHIBIT F

	 	 	56	 
	PRODUCTION AND COMMERCIALIZATION ACTIVITIES

	 	 	56	 
	EXHIBIT G

	 	 	57	 
	MODEL LICENSE AGREEMENT FOR NON-TRANSGENIC VARIETIES / NON-UK

	 	 	57	 
	EXHIBIT H

	 	 	74	 
	CERTAIN REMUNERATION PRINCIPLES

	 	 	74	 








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 2 of 75







 









 






COLLABORATION AGREEMENT




     THIS AGREEMENT is made this 1st day of April, 2007 (“Effective Date”), by and between
INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee,
registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas
Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware
corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United
States of America.



     WHEREAS, the Parties wish to establish a research program for undertaking specific,
collaborative projects after the Effective Date, to further the scientific research and commercial
objectives of CERES as well as the scientific research objectives of IGER;



     WHEREAS, the research programs contemplated by this Agreement and its schedules are consistent
with and in furtherance of IGER research programs;



     WHEREAS, CERES and IGER recognize that rights to intellectual property conceived or reduced to
practice in the performance of the Parties’ collaboration can be a strong incentive for CERES to
risk money and other resources needed to develop proprietary products for wide commercialization;



     NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the Parties have agreed and do
hereby agree as follows:




	1.	 	RESEARCH PROJECTS.





     1.1 CERES and IGER anticipate that from time to time they may undertake and conduct
certain joint and collaborative research projects (individually a “RESEARCH PROJECT” and
collectively “RESEARCH PROJECTS”). The Parties acknowledge and agree that the RESEARCH PROJECTS
will involve the contributions, whether financial or otherwise, of both Parties. The specific terms
and respective obligations of the Parties for each RESEARCH PROJECT will be negotiated by the
Parties and reflected in a schedule (“SCHEDULE”) signed by authorized representatives of both
Parties. Any such fully executed SCHEDULE shall become a part of this Agreement and subject to the
terms of this Agreement. Each Party shall diligently perform its activities in any given RESEARCH
PROJECT.



     1.2 All rights in property, tangible or intangible, used in the RESEARCH PROJECTS shall remain
with the Party providing such property, unless otherwise agreed between the Parties in this
Agreement, a SCHEDULE or a separate agreement.



     1.3 RESEARCH PROJECTS will relate to crop species defined in EXHIBIT A to this
Agreement (“COLLABORATION CROPS”).



     1.4 Each SCHEDULE will at least contain the following:




	 	•	 	research activities to be performed by each Party in detail








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 3 of 75







 









 






	 	•	 	timelines of such activities
	 
	 	•	 	goals, expected results and deliverables
	 
	 	•	 	milestones and “go” and “no-go” decision points
	 
	 	•	 	all reports to be delivered to the MANAGEMENT
COMMITTEE (Article 2) and the required delivery dates for the same
	 
	 	•	 	additional information on RESEARCH PROJECT
activities: breeding records and biological or other material generated
in such activities to be provided to the other Party, including delivery
method and time
	 
	 	•	 	location of activities
	 
	 	•	 	identity of RESEARCH PROJECT principal
investigators for CERES and IGER
	 
	 	•	 	identity and location of any SUBCONTRACTORS
(Article 1.13) to be used for the RESEARCH PROJECT activities
	 
	 	•	 	number of FTE’s made available by each Party for
the RESEARCH PROJECT, including names of any IGER PhD-level employees
	 
	 	•	 	other inputs and resources made available by each
Party for the RESEARCH PROJECT
	 
	 	•	 	financial contributions of each Party to the
RESEARCH PROJECT
	 
	 	•	 	provisions on intellectual property, including
lists of BACKGROUND INTELLECTUAL PROPERTY and any provisions which are
different from those set forth in this Agreement
	 
	 	•	 	provisions on use and commercialization rights
which are different from those set forth in this Agreement
	 
	 	•	 	provisions on expiration and early termination





     1.5 Unless a SCHEDULE provides for more frequent formal reporting, each Party shall provide to
the other Party a detailed, written annual report on its activities in each RESEARCH PROJECT, as
described in each SCHEDULE. In addition, upon the request of either Party at any time, the Parties
will discuss the RESEARCH PROJECTS, their status, the progress and results achieved, and they will
make available each RESEARCH PROJECT principal investigator (and other employees as needed, in the
discretion of the respective RESEARCH PROJECT principal investigators) at mutually agreeable times,
as needed, for such discussions; provided however, such contacts and discussions shall be
reasonable in frequency and duration so as not to be disruptive to the respective research
activities of each Party or the research activities of the RESEARCH PROJECTS. Each Party will also
voluntarily provide data, information and material generated in the RESEARCH PROJECT to the other
Party as required to further the Parties’ mutual goals defined in each RESEARCH PROJECT or in any
other agreement between the Parties. Each Party will have the right, upon reasonable notice to the
other Party, to visit any location where RESEARCH PROJECT activities are conducted for the purposes
of evaluating RESEARCH PROJECT progress and outcomes, and particularly to make observations of any
plants in growth chambers, greenhouses or fields that are a part of a RESEARCH





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 4 of 75







 









 




PROJECT. Each Party will comply with any reasonable safety and security measures which may be
imposed by the other Party when visiting such other Party’s location.




     1.6 Any transfer of information or material pursuant to this Agreement or any SCHEDULE will be
governed by the provisions of this Agreement on CONFIDENTIALITY (Article 7) and PUBLICATIONS
(Article 8). Any transfer of material shall be accompanied by a receipt form in the preferred
format attached as EXHIBIT B to this Agreement. Such receipt forms shall be signed by
representatives of both the sending and receiving Parties.



     1.7 Unless otherwise specified in a SCHEDULE, each Party shall bear its own costs and pay its
own SUBCONTRACTORS, with respect to its RESEARCH PROJECT activities.



     1.8 Where a SCHEDULE provides that CERES will make a financial contribution to certain
RESEARCH PROJECT activities performed by IGER, unless agreed otherwise in the appropriate SCHEDULE,
IGER will submit invoices after the end of each calendar quarter for the work performed during that
quarter. Each such invoice shall reflect only those costs that have been incurred in performance of
the RESEARCH PROJECT and shall provide a breakdown of costs similar to the detail set forth in the
budget of the related SCHEDULE. CERES will pay all such invoices within thirty (30) days after the
invoice date. Payments shall be remitted to:


Institute Secretary



Institute of Grassland and Environmental Research



Plas Gogerddan



Aberystwyth



Ceredigion



SY23 3EB



United Kingdom




     1.9 Each Party will conduct RESEARCH PROJECT activities exclusively in laboratories,
greenhouses or fields under full control of that Party or of its SUBCONTRACTORS authorized by this
Agreement. Each Party will take all reasonable precautions to prevent damage to, or unintentional
destruction of or release of any germplasm created in the RESEARCH ACTIVITIES.



     1.10 Each Party shall be responsible for its compliance with all applicable laws, rules and
regulations, including, without limitation, those relating to genetically modified organisms (to
the extent RESEARCH PROJECTS involve such organisms). Each Party shall obtain any and all permits
or authorizations or proceed to any notifications which may be required by such laws, rules and
regulations.



     1.11 Each Party will require any and all of its employees or students who will perform
activities in RESEARCH PROJECTS to be bound by a written agreement(s) that commits their
inventions, discoveries and other intellectual property to the Party-employer and requires
confidential treatment of Party and third-party confidential information.



     1.12 The RESEARCH PROJECT principal investigators named in each SCHEDULE shall be charged with
leading the RESEARCH PROJECT described therein.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 5 of 75







 









 






     1.12.1 RESEARCH PROJECT principal investigators may not vary the SCHEDULE of delivery,
amount, method of payment or any provision of a SCHEDULE. No such change shall be effective
unless and until it is reduced to writing in the form of an amendment to such SCHEDULE in
accordance with Article 17.1.




     1.12.2 Substitution by IGER of a RESEARCH PROJECT (a) principal investigator or (b) a
CERES-funded, PhD-level, IGER employee named or filling a defined position listed in a
SCHEDULE shall be subject to CERES’ prior written approval, which will not unreasonably be
withheld or delayed. IGER will notify CERES, in writing, of any substitution by IGER of a
non-CERES-funded, PhD-level employee named or who filled a defined position listed in a
SCHEDULE. CERES will notify IGER, in writing, of any substitution by CERES of a RESEARCH
PROJECT principal investigator or a PhD-level CERES employee named or who filled a defined
position listed in a SCHEDULE.



     1.13 Each Party may subcontract certain parts of its RESEARCH PROJECT activities to third
parties, or use third party consultants in connection with RESEARCH PROJECT activities, but only if
the subcontract or consultancy agreement is in writing and complies with the terms and conditions
set forth hereinafter. Such third parties with whom such a subcontract or consultancy agreement is
executed will be referred to as “SUBCONTRACTORS”.




     1.13.1 Any intended agreement with a SUBCONTRACTOR shall be identified in a SCHEDULE if
known at the time the SCHEDULE is executed by the Parties. IGER will obtain CERES’ prior
written consent before entering into any agreement with a SUBCONTRACTOR which is not listed
in a SCHEDULE.




     1.13.2 The following terms and conditions shall apply to IGER’s SUBCONTRACTORS: (a) the
SUBCONTRACTOR shall perform defined activities on behalf and for the benefit of IGER in
exchange for a fee or other tangible consideration; (b) the SUBCONTRACTOR shall deliver all
the results of the SUBCONTRACTOR’S activities under the subcontract to IGER only, and assign
ownership of or exclusively license any inventions made during the performance of the
subcontracting activities to IGER, without any further remuneration and (c) the
SUBCONTRACTOR shall not have the right to use any results, whether information or material,
for any purpose whatsoever other than the performance of the subcontract; provided however,
not-for-profit research institution SUBCONTRACTORS may be granted the right to use certain
information generated pursuant to the subcontract for their internal academic research and
educational purposes (i.e., not in collaboration with or for the benefit of any third
party). IGER will provide to CERES a draft copy of any subcontract IGER is planning to
conclude at least fifteen (15) days before the scheduled signature date and will provide a
true copy of any subcontract to CERES within thirty (30) days of its execution.




     1.13.3 It is anticipated that any agreements with commercial SUBCONTRACTORS will be
entered into by CERES. At CERES’ request, IGER will assist CERES in identifying
SUBCONTRACTORS for any field activities. The following conditions shall apply to CERES
SUBCONTRACTORS: CERES will inform IGER, in writing, of any SUBCONTRACTORS used by CERES for
the performance of RESEARCH PROJECT activities.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 6 of 75







 









 






     1.13.4 All SUBCONTRACTORS shall be bound by confidentiality obligations consistent with
the terms and obligations of this Agreement. All SUBCONTRACTORS shall be responsible for
their respective compliance with all laws, rules and regulations that govern their
activities.




     1.13.5 For variety evaluation and performance testing using not-for-profit research
institution SUBCONTRACTORS, the Parties agree that each transfer of plant material shall be
governed by a written agreement consistent with the preferred forms set forth in EXHIBIT
C to this Agreement.



     1.14 The Parties mutually agree that any applications for extramural funding for a RESEARCH
PROJECT, from governmental authorities or other public sources, will be subject to the prior,
written agreement, neither unreasonably withheld or delayed, by both Parties; provided however, the
Parties acknowledge that CERES and/or IGER has or has applied for certain government, extramural
funding prior to the Effective Date (EXHIBIT D to this Agreement), and such funding (or
possible funding, if awarded) shall not be construed as a breach of the obligations of this
Article.



     1.15 IGER agrees not to accept research funding from for-profit entities to perform any
RESEARCH PROJECT, whether in whole or in part, initiated under this Agreement without the prior
written consent of CERES.



     1.16 The Parties acknowledge and agree that certain RESEARCH PROJECT activities may be covered
by government funding set forth in EXHIBIT D and corresponding agreements set forth in
EXHIBIT E, as indicated in the relevant SCHEDULE(S). In particular, the Parties
acknowledge and agree that IGER will comply with its obligations under the DEFRA project NF 0426
“The generic improvement of miscanthus for biomass” (“DEFRA agreement NF 0426”), including without
limitation its obligation to meet the objectives set forth in such project and to report to DEFRA
on its results relating to such activities. The Parties further agree that such compliance will
not affect any provisions of this Agreement nor of any SCHEDULE, except if explicitly provided
otherwise, including without limitation the provisions on INTELLECTUAL PROPERTY in Article 4 and on
USE AND COMMERCIALIZATION RIGHTS in Article 5.




	2.	 	MANAGEMENT COMMITTEE.





     2.1 The Parties will establish a MANAGEMENT COMMITTEE to supervise the implementation,
execution and progress of this Agreement and its RESEARCH PROJECTS. The MANAGEMENT COMMITTEE will
consist of four (4) members, two (2) to be appointed by each Party and will meet at least once
every calendar quarter, in person or by telephone, on dates and at locations to be mutually agreed.
The representatives of each Party may invite other employees of that Party to meeting on an
as-needed basis, subject to prior notification of the other Party.



     2.2 Decisions of the MANAGEMENT COMMITTEE shall be made by unanimous agreement and recorded in
a manner prescribed by the MANAGEMENT COMMITTEE as a true record of the decisions. If the
MANAGEMENT COMMITTEE cannot come to a unanimous agreement on any matter then the status quo shall
apply.



     2.3 The responsibilities of the MANAGEMENT COMMITTEE shall be as follows:





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 7 of 75







 









 






	 	–	 	supervise and review the implementation of the RESEARCH PROJECTS;
	 
	 	–	 	approve principal investigators and project teams for RESEARCH PROJECTS;
	 
	 	–	 	determine the resources necessary to achieve the goals of each RESEARCH
PROJECT, within the limits of the RESEARCH PROJECT budget provided in the
relevant SCHEDULE;






	 	–	 	adjust the research activities defined in a RESEARCH PROJECT, subject to the
overall budget for that RESEARCH PROJECT in a given year;






	 	–	 	review achievement of goals and timelines; propose adjustments of goals or
timelines to the Parties;






	 	–	 	review achievement of agreed annual milestones for overhead payment purposes
and make recommendations relating to milestones to the Parties;






	 	–	 	review proposed publications and formulate recommendations to the Parties on
publications;






	 	–	 	review intellectual property matters relating to the implementation of this
Agreement and formulate recommendations to the Parties regarding such matters;






	 	–	 	review subcontracting matters and formulate recommendations to the Parties
regarding such matters;






	 	–	 	review reports to be provided pursuant to SCHEDULES;






	 	–	 	such other responsibilities as the Parties jointly may explicitly grant to
the MANAGEMENT COMMITTEE.






	3.	 	EXCLUSIVITY.





     3.1 In consideration of CERES’ development of new markets for the COLLABORATION CROPS and the
significant activities associated with the development of this market, IGER agrees to grant CERES
exclusive access to IGER’s plant improvement activities specifically involving the COLLABORATION
CROPS, whether through plant breeding, transformation, propagation methods or otherwise, subject
however to the exceptions expressly set forth in this Agreement.



     3.2 During the term of this Agreement, subject to the provisions of this Agreement on
subcontracting (Article 1.13 and its related subsections) and subject to the agreements entered
into by IGER prior to the Effective Date and defined in EXHIBIT E to this Agreement, as
such agreements exist on the Effective Date (“EXISTING AGREEMENTS”), IGER agrees to comply with the
obligations set forth hereinafter:




     3.2.1 for-profit third parties.




     IGER will not collaborate with or perform any activities for the benefit of or
grant any rights to any for-profit third party in the field of the COLLABORATION
CROPS without the prior written consent of CERES.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 8 of 75







 









 






a. CERES will not unreasonably withhold its consent for collaborations with
small companies (less than fifty (50) employees including world-wide
affiliates) established in the United Kingdom (“UK COMPANIES”), with respect
to research programs involving COLLABORATION CROPS in the field of
environmental impact, carbon sequestration, climate change mitigation,
agronomy, or compositional or conversion analysis, provided that (i) IGER will
receive the exclusive right (subject to Articles 5.1.2(a) and 5.2) to use and
exploit commercially the results of such research programs for GERMPLASM
IMPROVEMENT (as defined hereinafter) of the COLLABORATION CROPS, (ii) CERES
will have access to the results of such research programs to the extent
allowed by the relevant agreement between IGER and the third party and IGER
will use reasonable efforts to obtain such right for CERES, and (iii) there is
no conflict with CERES’ commercial interests.




b. CERES recognizes that IGER may receive requests from third parties to make
available germplasm of CERTAIN MISCANTHUS ACCESSIONS. IGER will have the
right to make available germplasm of CERTAIN MISCANTHUS ACCESSIONS to third
parties for research purposes (including breeding), subject to the terms and
conditions under which IGER holds such accessions. “CERTAIN MISCANTHUS
ACCESSIONS” shall mean the Miscanthus accessions collected by IGER in 2006
from China, Taiwan and Japan, as originally collected by IGER.




     3.2.2 not-for-profit third parties.




a. “GERMPLASM IMPROVEMENT” shall mean any activities to improve a crop,
including without limitation selection, breeding, transgenic improvement,
markers, propagation systems:




     IGER will not collaborate with or perform any activities for the benefit
of or grant any rights to any not-for-profit third party with respect to
GERMPLASM IMPROVEMENT of COLLABORATION CROPS without the prior written consent
of CERES. CERES will not unreasonably withhold its consent for research
programs with respect to GERMPLASM IMPROVEMENT of COLLABORATION CROPS with
academic institutions in the European Union under United Kingdom government or
European Union funding, provided that (i) IGER will have the exclusive right
to use and exploit commercially the results of such research programs obtained
by IGER, (ii) no COLLABORATION CROP germplasm will be made available by IGER
to any third party for selection, breeding or propagation work, or for genetic
transformation of such germplasm, except that IGER may make available
germplasm of CERTAIN MISCANTHUS ACCESSIONS for research purposes (including
breeding), subject to the terms and conditions under which IGER holds such
accessions, and (iii) if requested by CERES, IGER will use reasonable efforts
to obtain commercialization rights for CERES on results





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 9 of 75







 









 







obtained by third parties in such collaborative research programs or
breeding activities.




b. environmental impact, carbon sequestration, climate change or agronomy
studies, and compositional or conversion analysis:




     if IGER would enter into any agreement (or amendment of an existing
agreement including without limitation EXISTING AGREEMENTS) after the
Effective Date with a not-for-profit third party with respect to research in
the field of environmental impact, carbon sequestration, climate change
mitigation, agronomy, or compositional or conversion analysis relating to
COLLABORATION CROPS, such agreement must provide that (i) IGER will receive
the exclusive right (subject to Articles 5.1.2(a) and 5.2) to use and exploit
commercially the results obtained pursuant to such agreement for GERMPLASM
IMPROVEMENT of COLLABORATION CROPS and (ii) CERES will have access to the
results of such research programs to the extent allowed by the relevant
agreement between IGER and the third party and IGER will use reasonable
efforts to obtain such right for CERES.




3.2.3 IGER will provide a draft of any agreement intended to cover an activity
referred to in Article 3.2.1 a. or b. or 3.2.2 a. or b. to CERES, together with its
written request for consent where such consent needs to be obtained. CERES will
respond in writing within thirty (30) days or such other period of time as the
Parties may agree in writing. In exceptional urgent cases, when asked by IGER, CERES
will respond as soon as reasonably possible. Further, where Articles 3.2.1 or 3.2.2
refer to Ceres’ access to results or right to use and commercially exploit such
results, IGER will report such results to CERES in compliance with the terms hereof.




3.2.4 Whenever rights are granted to IGER pursuant to agreements referred to in
Articles 3.2.1 or 3.2.2 (“Third Party Agreement Rights”), the provisions of this
Agreement about the grant of rights by IGER to CERES will apply and such Third Party
Agreement Rights shall be treated as IGER INTELLECTUAL PROPERTY (unless they qualify
as JOINT INTELLECTUAL PROPERTY under the circumstances).



     3.3 During the term of this Agreement, IGER will notify CERES, in writing, of any
contemplated internal (i.e. not involving third parties but including government-funded) research
activities (i.e., non-RESEARCH PROJECTS) that specifically involve the COLLABORATION CROPS, except
research activities that relate solely to environmental impact, carbon sequestration, climate
change or agronomy studies. If CERES so requests, the Parties will negotiate in good faith to
agree on a new RESEARCH PROJECT and accompanying SCHEDULE or an amendment to an existing SCHEDULE
on the basis of such research proposal. If CERES does not request such negotiations, or if the
Parties fail to reach agreement on a new SCHEDULE (or amendment to an existing SCHEDULE) within
thirty (30) days (or such other time period as the Parties may agree) from IGER’s notice, IGER will
have the right, subject to Articles 3.2 and 5.3, to proceed to such internal research, and IGER
will provide a written report to CERES on the results of such research. CERES is hereby granted a
first option, to be exercised by written notice within thirty (30) days from





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 10 of 75







 









 




IGER’s aforementioned written report or such other time period as the Parties may agree to be
granted the same right as set forth in Article 5.3 to commercialize any results of such activities.





     3.3.1 If CERES exercises its option to commercialize under Article 3.3, CERES and IGER
shall negotiate the terms of a commercialization agreement that covers the reported result
with reference to any commercialization agreement then in existence between the Parties or
the model license agreement or remuneration principles included herein (as applicable). If,
despite the Parties’ good faith efforts, CERES and IGER are unable to agree upon the terms
and conditions of such agreement within one hundred and eighty (180) days after commencing
good faith negotiations, CERES shall have the right to start the dispute resolution
procedure in Article 15 for any outstanding unresolved issues.




     3.3.2 If CERES declines to exercise the option under Article 3.3 or fails to respond
within thirty (30) days of IGER’s notice under Article 3.3, then IGER shall then be free to
commercially exploit the results or offer rights in such results to third parties in any and
all crops.




     3.3.3 IGER will have no restrictions to undertake internal (i.e. not involving third
parties but including government-funded) research activities that involve COLLABORATION
CROPS but relate solely to environmental impact, carbon sequestration, climate change or
agronomy studies. IGER will use all reasonable efforts to inform CERES of the results of
any such activities.




	4.	 	INTELLECTUAL PROPERTY.





     4.1 “JOINT INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived,
discovered, developed and/or reduced to practice (i) jointly by one or more employees, agents, or
students of CERES and by one or more employees, agents, or students of IGER in the performance of
any RESEARCH PROJECT(S) or (ii) by one or more employees, agents or students of IGER in the
performance of any RESEARCH PROJECT(S) to the extent CERES provides a financial contribution for
such RESEARCH PROJECT, which is not less than twenty-five percent (25%) of either the overall cost
of such RESEARCH PROJECT or of the activity during which the invention was made, unless expressly
provided otherwise in a SCHEDULE; (b) patents, patent applications, plant variety rights, plant
variety right applications, reissues, continuations, continuations-in-part and divisionals claiming
such patentable inventions in any country of the world; (c) all trade secrets and copyrighted works
created jointly by one or more employees, agents, or students of CERES and by one or more
employees, agents, or students of IGER in the performance of any RESEARCH PROJECT(S); and (d) all
germplasm and plant varieties created in the performance of plant breeding activities in the
performance of any RESEARCH PROJECT(S).



     4.2 “CERES INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived,
discovered, developed, and/or reduced to practice by one or more employees, agents, or students of
CERES in the performance of any RESEARCH PROJECT(S), except as set forth in Article 4.1; (b)
patents, patent applications, plant variety rights, plant variety right applications, reissues,
continuations, continuations-in-part, and divisionals claiming such patentable inventions in any
country of the world; and (c) all trade secrets and copyrighted works created by one or more
employees, agents, or students of CERES in the performance of any RESEARCH PROJECT(S) .





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 11 of 75







 









 





     4.3 “IGER INTELLECTUAL PROPERTY” shall mean (a) all patentable inventions conceived,
discovered, developed, and/or reduced to practice by one or more employees, agents, or students of
IGER in the performance of RESEARCH PROJECT(S), except as set forth in Article 4.1; (b) patents,
patent applications, plant variety rights, plant variety right applications, reissues,
continuations, continuations-in-part, and divisionals claiming such patentable inventions in any
country of the world; and (c) all trade secrets and copyrighted works created by one or more
employees, agents, or students of IGER in the performance of RESEARCH PROJECT(S).



     4.4 “OTHER RESEARCH RESULTS” shall mean all data, information, procedures, techniques and
know-how generated in the performance of RESEARCH PROJECT(S), but expressly excludes JOINT
INTELLECTUAL PROPERTY, CERES INTELLECTUAL PROPERTY, and IGER INTELLECTUAL PROPERTY.



     4.5 “BACKGROUND INTELLECTUAL PROPERTY” shall mean (i) inventions, discoveries, materials, data
and information, whether patentable or not; including related know-how; (ii) patents, patent
applications, plant variety rights, plant variety right applications, reissues, continuations,
continuations-in-part and divisionals in any country of the world; and (iii) trade secrets or
copyrighted works, which are individually or collectively created, developed, made, acquired or
licensed in by CERES or IGER independent of the activities performed pursuant to this Agreement,
including its SCHEDULES.




     4.5.1 Any Party asserting that certain intellectual property is BACKGROUND INTELLECTUAL
PROPERTY shall have the burden of substantiating such claim, if necessary, with tangible
evidence, including but not limited to paper or electronic records.




     4.5.2 The Parties acknowledge and agree that all relevant BACKGROUND INTELLECTUAL
PROPERTY for a RESEARCH PROJECT should be set forth within the corresponding SCHEDULE. With
respect to each element of BACKGROUND INTELLECTUAL PROPERTY listed in a SCHEDULE, the
listing Party shall include the following: ownership or licensed rights (exclusive or
non-exclusive) held by the listing Party (if no ownership) with respect to the COLLABORATION
CROPS. Notwithstanding, subject to Article 4.5.1, failure to specifically set forth such
BACKGROUND INTELLECTUAL PROPERTY in a SCHEDULE will not foreclose a later claim that certain
intellectual property is BACKGROUND INTELLECTUAL PROPERTY.



     4.6 CERES and IGER shall have an undivided interest in JOINT INTELLECTUAL PROPERTY.
Consequently, any and all patent applications or plant variety rights applications that cover JOINT
INTELLECTUAL PROPERTY shall be assigned jointly to CERES and IGER as soon as practicable.




     4.6.1 All rights and title to CERES INTELLECTUAL PROPERTY and CERES BACKGROUND
INTELLECTUAL PROPERTY shall belong to CERES, and IGER shall not acquire any interest in the
same by its performance under this Agreement.




     4.6.2 All rights and title to IGER INTELLECTUAL PROPERTY and IGER BACKGROUND
INTELLECTUAL PROPERTY shall belong to IGER, and CERES shall not





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 12 of 75







 









 







acquire any interest in the same by its performance under this Agreement, except as
expressly provided in this Agreement.



     4.7 Each Party will notify the other Party, in writing (“INVENTION NOTICE”), within thirty
(30) days of reduction to practice or knowledge of conception or discovery of JOINT INTELLECTUAL
PROPERTY, and each INVENTION NOTICE will describe the JOINT INTELLECTUAL PROPERTY with sufficient
specificity to allow assessment by the other Party.



     4.8 The Parties shall consult as soon as possible but in any case within twenty (20) days of
receiving an INVENTION NOTICE whether to proceed to obtain intellectual property protection on the
disclosed JOINT INTELLECTUAL PROPERTY or whether to protect the same through other methods. CERES
shall have the first option to pursue such protection in its best judgment in the joint names of
both Parties. If CERES so elects by written notice within sixty (60) days of such initial
consultation, CERES shall be the “ADMINISTERING PARTY” for the purposes of this Agreement.




     4.8.1 The ADMINISTERING PARTY shall be responsible for retaining counsel, overseeing
the process of securing intellectual property protection (i.e., the preparation, filing and
prosecution of patent or plant variety rights application(s)) and maintaining intellectual
property protection for the mutual benefit of the Parties, in its best judgment, for that
which it has prosecution responsibility. In addition to other reporting responsibilities
provided below, the ADMINISTERING PARTY shall promptly notify the other Party following
retention of counsel. The Parties will provide, and cause their respective employees, agents
and students to provide, all reasonable assistance which may be required in connection with
the filing and prosecution of such intellectual property rights, including without
limitation the signing of documents.




     4.8.2 The ADMINISTERING PARTY shall keep the non-administering Party advised as to all
developments with respect to all patent and plant variety rights application(s) and issued
patents and plant variety rights covering jointly owned JOINT INTELLECTUAL PROPERTY, which
includes supplying copies of all papers received and filed in connection with such
applications and patents in sufficient time for the non-administering Party to comment
thereon.



     4.9 CERES agrees to bear all legal expenses incurred by CERES as an ADMINISTERING PARTY in
obtaining and maintaining patents and plant variety rights, U.S. and other, covering JOINT
INTELLECTUAL PROPERTY.



     4.10 If CERES does not elect to file an application for a patent or plant variety rights or
continue maintenance of a patent or plant variety rights in a particular country, consistent with
the consultation of Article 4.8, IGER may file such application, continue such prosecution, or
maintain such patent or plant variety rights at its own expense; provided however, that prior to
filing any such application IGER will not take any action or proceed to any filing which would lead
to the possible disclosure of information which CERES wishes to keep confidential, as notified by
CERES to IGER in writing. For any such application, patent or plant variety rights, IGER shall
serve as the ADMINISTERING PARTY. CERES shall have non-exclusive rights under the specific patent
application(s), plant variety right application(s), patent(s) and/or plant variety right(s) in the
country(ies) in which CERES declined to initiate or continue its participation, subject to paying
IGER





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 13 of 75







 









 




reasonable remuneration (whether as a royalty or in some other form as the Parties may agree)
to be negotiated in good faith, and in any case CERES shall remain free to use and practice the
JOINT INTELLECTUAL PROPERTY covered by such specific patent application(s)/patent(s) or plant
variety rights application(s)/plant variety right(s) for research and evaluation purposes.




     4.11 At each quarterly meeting of the MANAGEMENT COMMITTEE, CERES will report CERES
INTELLECTUAL PROPERTY on which patent applications were filed in the preceding quarter and the
general subject matter of patent applications reasonably anticipated to be filed in the near term,
and IGER will report IGER INTELLECTUAL PROPERTY on which patent applications were filed in the
preceding quarter and the general subject matter of patent applications reasonably anticipated to
be filed in the near term. In addition, the Parties may exchange information regarding their
respective INTELLECTUAL PROPERTY at other times as they deem fit.



     4.12 The provisions of this Article 4 and specifically but without limitation the definitions
in Articles 4.1 through 4.4 and Articles 4.6 and 4.7 shall apply to any results obtained in
RESEARCH PROJECTS, including results of activities covered by EXISTING AGREEMENTS, except if
expressly provided otherwise in a SCHEDULE or in Article 18.




	5.	 	USE AND COMMERCIALIZATION RIGHTS.






	 	 5.1	 	IGER Research Rights.






     5.1.1 Through the express grant of such rights in any SCHEDULE, CERES may grant IGER
the right to use CERES INTELLECTUAL PROPERTY to the extent required for, and for the sole
purpose of, the performance by IGER (or its SUBCONTRACTORS) of RESEARCH PROJECTS. SCHEDULES
may specify that similar rights are granted with respect to defined elements of CERES
BACKGROUND INTELLECTUAL PROPERTY.




     5.1.2 IGER shall have the right to use JOINT INTELLECTUAL PROPERTY and OTHER RESEARCH
RESULTS (a) for the purpose of the implementation of RESEARCH PROJECTS; (b) subject to
Article 3 and CERES’ prior written approval, for internal research purposes and research
under United Kingdom government or European Union funding in collaboration with academic
institutions in the European Union, provided that CERES’ approval may be conditional upon
(i) CERES receiving the exclusive right (subject to Articles 5.1.2(a) and 5.2) to use and
exploit commercially the results of such research in COLLABORATION CROPS, (ii) adequate
safeguards to prevent unauthorized use or disclosure of JOINT INTELLECTUAL PROPERTY, OTHER
RESEARCH RESULTS or results directly or indirectly based on any of the foregoing and (iii)
CERES reviewing and approving the terms and conditions of any agreement governing such
research activities.




	 	5.2	 	Commercialization Rights of IGER in the United Kingdom.






     5.2.1 “RELEASED VARIETY” shall mean any variety of a COLLABORATION CROP which
constitutes JOINT INTELLECTUAL PROPERTY and which is released for commercialization pursuant
to a SCHEDULE. IGER shall have the non-exclusive right to exploit commercially RELEASED
VARIETIES in the United Kingdom.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 14 of 75







 









 






     5.2.2 If the commercial exploitation of a RELEASED VARIETY in the United Kingdom by
IGER requires a license on CERES INTELLECTUAL PROPERTY or BACKGROUND INTELLECTUAL PROPERTY
of CERES, CERES shall negotiate in good faith with IGER or a designee of IGER about the
grant of such a license, provided however that CERES shall have no obligation to grant any
license on transgenes or transgenic technologies.




     5.2.3 Unless otherwise agreed by the Parties, IGER shall pay royalties to CERES under
its non-exclusive right set forth in Article 5.2.1 at a rate equal to one half of the
royalty rate in CERES’ exclusive license agreement for the same RELEASED VARIETY, and CERES
shall pay royalties at the same rate to IGER for sales by CERES, its AFFILIATED COMPANIES or
licensees in the United Kingdom.




	 	5.3	 	Commercialization Rights — Other.






     5.3.1 Subject to Articles 5.1 and 5.2, the Parties acknowledge and agree that CERES
shall have the exclusive right, with the right to grant sublicenses to this right, to use
and commercially exploit JOINT INTELLECTUAL PROPERTY (including but not limited to RELEASED
VARIETIES) and OTHER RESEARCH RESULTS for any and all uses and fields, including, but not
limited to, use in the COLLABORATION CROPS and crops other than the COLLABORATION CROPS. Any
commercialization (including, but not limited to, the grant of commercialization licenses)
of JOINT INTELLECTUAL PROPERTY and/or OTHER RESEARCH RESULTS shall result in CERES paying
IGER a reasonable remuneration (whether as a royalty or in some other form as the Parties
may agree) to be negotiated in good faith. The terms for remuneration will be specified,
with respect to specific RESEARCH PROJECTS, JOINT INTELLECTUAL PROPERTY and/or OTHER
RESEARCH RESULTS, either in the respective SCHEDULES or in other agreements to be executed
by the Parties.




     5.3.2 Subject to Articles 5.1 and 5.2, IGER grants CERES an exclusive, world-wide
license, with the right to grant sublicenses, to use and exploit commercially (a) IGER’s
interest in any JOINT INTELLECTUAL PROPERTY (including but not limited to RELEASED
VARIETIES) and OTHER RESEARCH RESULTS; (b) IGER INTELLECTUAL PROPERTY and (c) when and only
to the extent necessary for the commercialization or use of JOINT INTELLECTUAL PROPERTY
and/or OTHER RESEARCH RESULTS and/or IGER INTELLECTUAL PROPERTY for the COLLABORATION CROPS,
IGER BACKGROUND INTELLECTUAL PROPERTY, subject to paying IGER reasonable remuneration
(whether as a royalty or in some other form as the Parties may agree) to be negotiated in
good faith. Such license grants will be further specified in SCHEDULES to this Agreement
and/or other agreements to be executed by the Parties. Unless otherwise agreed by both
Parties, license agreements for non-transgenic RELEASED VARIETIES will be based on the Model
License Agreement for Non-transgenic Varieties in EXHIBIT G or such other model
license agreements as the Parties may agree upon. Certain remuneration principles to be
included in other license agreements, unless the Parties agree otherwise, are set forth in
EXHIBIT H.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 15 of 75







 









 






	6.	 	ENFORCEMENT OF JOINT INTELLECTUAL PROPERTY RIGHTS.





     6.1 CERES will have the right, at its own discretion and expense, to take any action to
enforce and to initiate and prosecute suits for infringement of jointly owned intellectual property
rights covering JOINT INTELLECTUAL PROPERTY. CERES and IGER will consult with each other upon a
course of action and enforcement strategy. CERES will be responsible for the conduct of any such
enforcement action, and IGER will reasonably cooperate with CERES to effect the enforcement action,
and if appropriate, determine a settlement position. CERES shall be responsible for retaining
counsel and shall promptly notify IGER following retention of counsel, and IGER agrees to be
represented by such counsel as may be required for any enforcement action or settlement. For
purposes of settlement, CERES shall be the contact with the Parties’ counsel as well as the
opposing Party(ies) and shall have the right to enter into settlements. CERES shall keep IGER
advised as to all developments with respect to the enforcement action and settlement discussions,
which includes supplying to IGER copies of all papers received and filed in sufficient time for
IGER to comment thereon. IGER may attend any and all meetings with the Parties’ counsel and the
opposing side for settlement purposes. IGER agrees to join voluntarily in any action brought by
CERES as a Party plaintiff/defendant, if necessary, at the expense of CERES. If necessary, IGER
agrees to enter into a joint defense agreement.



     6.2 In situations where a substantial commercial interest of IGER in the United Kingdom is
harmed by infringement, and CERES elects not to pursue any action to enforce and to initiate and
prosecute suits for infringement, IGER shall have the right to pursue any such action and CERES
will reasonably cooperate with IGER, if necessary, to permit IGER to properly enforce its rights.
IGER will be responsible for the conduct of any such enforcement action. IGER shall be responsible
for retaining counsel and shall promptly notify CERES following retention of counsel, and CERES
agrees to be represented by such counsel as may be required for any enforcement action or
settlement. For purposes of settlement, IGER shall be the contact with the Parties’ counsel as well
as the opposing Party(ies) and shall have the right to enter into settlements. IGER shall keep
CERES advised as to all developments with respect to the enforcement action and settlement
discussions, which includes supplying to CERES copies of all papers received and filed in
sufficient time for CERES to comment thereon. CERES may attend any and all meetings with the
Parties’ counsel and the opposing side for settlement purposes. CERES agrees to join voluntarily in
any action brought by IGER as a Party plaintiff/defendant, if necessary, at the expense of IGER. If
necessary, CERES agrees to enter into a joint defense agreement.



     6.3 Any damages received by a Party as a result of an enforcement action of rights to JOINT
INTELLECTUAL PROPERTY, after deduction of all enforcement related costs incurred by such Party,
shall be considered as revenues for the purpose of remuneration payments to the other Party, as set
forth in any applicable license/commercialization agreement between the Parties. In the absence of
any such license/commercialization agreement, the Parties will share such damages after deduction
of all enforcement related costs incurred by the Party receiving the damages, in proportion to
their relative financial contributions to the creation (i.e., research and development) of such
JOINT INTELLECTUAL PROPERTY.




	7.	 	CONFIDENTIALITY.





     7.1 As used in this Agreement, the term “Confidential Information” shall mean (a) all
non-public information and material received by one Party from the other in furtherance of the





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 16 of 75







 









 







collaboration contemplated by this Agreement and (b) any and all information, results including
material and observations generated in the performance of any RESEARCH PROJECT including,
without limitation, CERES INTELLECTUAL PROPERTY, IGER INTELLECTUAL PROPERTY, JOINT INTELLECTUAL
PROPERTY and OTHER RESEARCH RESULTS. Confidential Information can include, but is not limited to,
information concerning the disclosing Party’s operations, research, processes, techniques, data and
non-public materials.



     7.2 Subject to Article 7.3, for a period of five (5) years after the termination of the
related RESEARCH PROJECT, the receiving Party shall not use, except (a) for the benefit of the
Parties’ collaboration or (b) such use as is expressly allowed by this Agreement and/or disclose
any Confidential Information to any third party (i) without the prior written consent of the
disclosing Party if the Confidential Information was received from the other Party, or (ii) the
prior written consent of both Parties if the Confidential Information was generated during a
RESEARCH PROJECT, provided however that CERES shall have no restrictions regarding CERES
INTELLECTUAL PROPERTY or regarding any information of material resulting from RESEARCH PROJECT
activities in which IGER does not participate. Confidential Information shall only be made
accessible to each Party’s employees or students on a need-to-know basis and not to any third
party, subject to Articles 7.3 and 7.4. Manuscripts and papers published in scientific journals and
presentations made at public meetings that include Confidential Information are exempt from the
confidentiality obligations of this Article, provided the Parties followed the procedure set forth
in Article 8.



     7.3 The receiving Party shall have no obligations of confidentiality for information that:
can be established through written evidence to be in the possession of the receiving Party prior to
the disclosure by the disclosing Party; is or becomes public knowledge through no fault of the
disclosing Party; and/or is acquired from others not under an obligation of confidentiality to the
disclosing Party. In addition, the Parties, pursuant to the express terms of this Agreement or any
SCHEDULE or other agreement between the Parties, shall have the right to proceed to disclosures of
Confidential Information (a) as required to file for intellectual property protection or
registration or deregulation or approval of genetically modified organisms; (b) as required to
exercise commercialization rights granted in or on the basis of this Agreement and for related
marketing activities; (c) as required by laws, rules or regulation or court ordering such as,
without limitation, SEC regulations and IRS regulations; or (d) in CERES’ reasonable judgment for
the limited purpose of (potential) investors and business partners, but only with respect to the
Confidential Information defined in Article 7.1 (b) and not other Confidential Information of IGER.



     7.4 The Parties acknowledge and agree that IGER will comply with its reporting obligations to
DEFRA as required by the DEFRA agreement NF 0426 referred to in EXHIBIT E, provided that
IGER shall (i) not disclose any CERES BACKGROUND INTELLECTUAL PROPERTY, CERES INTELLECTUAL PROPERTY
or OTHER RESEARCH RESULTS obtained by CERES, (ii) use all reasonable efforts to ensure that the
confidentiality of all other results of RESEARCH PROJECTS is maintained to the extent allowed by
the applicable regulations, and (iii) provide a draft of any such report to CERES at least thirty
(30) days before the submission date and take CERES’ comments, if any, into account.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 17 of 75







 









 





8. PUBLICATIONS.




     8.1 The Parties agree that the researchers involved in the RESEARCH PROJECTS are
permitted to present methods and/or results of the RESEARCH PROJECTS at symposia and
professional meetings and to publish the same in journals or the like; provided however, the
disclosing Party must furnish copies of any proposed publication, presentation or disclosure
(collectively “Disclosure”) to the other Party at least thirty (30) days in advance of the specific
submission, presentation or other disclosure.



     8.2 The non-disclosing Party shall have the thirty (30) day notice period to object, in
writing, to such proposed Disclosure because it contains (a) potentially patentable subject matter
that needs protection or (b) BACKGROUND INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY or
INTELLECTUAL PROPERTY of the non-disclosing Party or OTHER RESEARCH RESULTS which need to be kept
confidential for compelling business reasons in the non-disclosing Party’s reasonable judgment. In
the event that the non-disclosing Party makes such objection, the disclosing Party will (x) if
applicable, elect to cooperate with the non-disclosing Party to obtain proper protection in
accordance with the provisions of Article 4 herein or (y) remove the objectionable subject matter
from the Disclosure. No delay caused by the non-disclosing Party under this Article shall extend
beyond three (3) months, wherein upon such delay, the disclosing Party shall be permitted to
proceed without being in breach of this Article.



     8.3 CERES and IGER shall use reasonable efforts to avoid any action that might jeopardize the
ability of the Parties, individually or jointly as the case may be, to obtain or retain
valid/enforceable intellectual rights in JOINT INTELLECTUAL PROPERTY, IGER INTELLECTUAL PROPERTY or
CERES INTELLECTUAL PROPERTY.



     8.4 Nothing in this Article 8 shall restrict disclosures that are allowed under Article 7.



     8.5 Upon recommendation of the MANAGEMENT COMMITTEE, the Parties may adopt alternative review
processes, in particular for information to be presented at symposia or professional meetings or
for activities directed towards legislative and regulatory bodies.




	9.	 	PUBLICITY.





     9.1 CERES will not identify IGER in any products, publicity, promotion, promotional
advertising or other promotional materials to be disseminated to the public, or use any trademark,
service mark, trade name, logo or symbol that is representative of IGER or its entities, whether
registered or not, or use the name, title, likeness or statement of any IGER faculty member,
employee or student, without IGER’s prior written consent. Any use of IGER’s name shall be limited
to statements of fact and shall not imply endorsement by IGER of CERES’ research, products or
services.



     9.2 IGER will not identify CERES in any products, publicity, promotion, promotional
advertising or other promotional materials to be disseminated to the public, or use any trademark,
service mark, trade name, logo or symbol that is representative of CERES or its entities, whether
registered or not, or use the name, title, likeness or statement of any CERES employee or student,
without CERES’ prior written consent. Any use of CERES’ name shall be limited to statements of fact
and shall not imply endorsement by CERES of IGER’s research, products or services.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 18 of 75







 









 





     9.3 Notwithstanding any provision of this Article, either of the Parties can disclose or
otherwise acknowledge, without restriction, the existence of this Agreement as well as the
collaborative relationship between the Parties without the prior
consent of the other Party. Notwithstanding the unilateral disclosure rights provided for in this Article, if the
disclosure or acknowledgement takes the form of a written release by the disclosing Party, the
disclosing Party shall provide the other Party a copy of any such unilateral disclosure prior to
its release so as to allow the other Party to comment and shall take such comments reasonably into
account. However, no advance copy needs to be provided of any releases referred to in Article
9.4(a) or 9.4(b) or of any releases which are identical to previous releases.



     9.4 The Parties intend to issue joint press releases regarding their collaboration. Any such
press release and any press release by either Party will be subject to the prior written approval
of both Parties; provided however, that (a) CERES shall have the right to otherwise disclose
information as may be required in CERES’ judgment to comply with SEC or IRS regulations or other
laws, rules or regulations governing disclosure of information and (b) IGER shall have the right to
otherwise disclose information as may be required in IGER’s judgment to comply with laws, rules or
regulations governing disclosure of information. Notwithstanding the unilateral disclosure rights
provided for in this Article, the disclosing Party shall provide the other Party a copy of any such
unilateral disclosure preferably prior to its release.



10. RECORDS AND AUDITS.




     IGER shall keep accurate and detailed records in accordance with good accounting practices of
all expenses and extramural income, if any, relating to the RESEARCH PROJECTS. All such records
shall be subject to inspection by an independent auditor designated by CERES and reasonably
acceptable to IGER within normal business hours with at least fourteen (14) days notice. Such
inspection rights shall terminate, with respect to each RESEARCH PROJECT, on the third anniversary
of the expiration or termination of such RESEARCH PROJECT.



11. INDEPENDENT CONTRACTOR.




     The relationship of the Parties is that of independent contractors. Nothing herein is intended
or will be construed to establish any agency, partnerships or joint ventures. Neither Party is
authorized or empowered to act as an agent for the other Party for any purpose, nor shall either
Party be bound by the acts or conduct of the other Party.



12. CONVENTION ON BIOLOGICAL DIVERSITY.




     12.1 The Parties agree that they shall at all times comply with the Convention on
Biological Diversity signed in 1992 at the Rio Earth Summit (“CBD”) in the implementation of this
Agreement, to the extent the CBD is applicable.



     12.2 Any germplasm of COLLABORATION CROPS made available by IGER for a RESEARCH PROJECT will
be identified in detail in the relevant SCHEDULE. The origin of the material, date of collection
and references to any agreements governing such material and/or the collection thereof will be
included. Reference to any such agreements existing on the Effective Date is included in
EXHIBIT E or in Article 13.2.1.8.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 19 of 75







 









 





     12.3 With respect to any germplasm made available by IGER for a RESEARCH PROJECT which is
covered by the CBD, CERES, in collaboration with IGER who will
provide all required assistance, will use reasonable efforts to obtain commercialization rights from the relevant
competent authorities in the countries where the germplasm was collected, allowing the grant of
rights to CERES as provided in this Agreement.



13. WARRANTIES.




     13.1 Representations and Warranties of CERES.




     “To the Knowledge of CERES” as used in this Article 13.1 shall mean: to the actual
knowledge, as of the Effective Date, of any member of the Board of Directors or any officer
of CERES or any employee of CERES who has actively participated in the negotiation of the
transactions contemplated by this Agreement.




     13.1.1 CERES represents and warrants to IGER that:




     13.1.1.1 CERES (a) is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware; (b) has all requisite power
and authority to conduct the business in which it is currently, or is currently
proposed to be, engaged; (c) has the corporate power and authority to execute and
deliver this Agreement; and (d) has the corporate power and authority to perform its
obligations under this Agreement;




     13.1.1.2 the execution, delivery, and performance by CERES of this Agreement
have been duly authorized by all necessary corporate action of CERES;




     13.1.1.3 this Agreement has been duly executed and delivered by CERES, and
constitutes the legal, valid and binding obligations of CERES enforceable against
CERES in accordance with its terms;




     13.1.1.4 as of the Effective Date, CERES has not received notice of, and is not
in default under, or with respect to, any contractual obligation, which, individually
or together with all such defaults, would have a material adverse effect on the
ability of CERES to perform its obligations under this Agreement;




     13.1.1.5 to the Knowledge of CERES, no approval, consent, compliance, exemption,
authorization or other action by, or notice to, or filing with, any governmental
agency or other person and no lapse of a waiting period is necessary or required in
connection with the execution, delivery or performance by, or enforcement against,
CERES of this Agreement or the transactions contemplated hereby;




     13.1.1.6 to the Knowledge of CERES, CERES has the right to make the conveyances
and grants in accordance with the Articles hereof, including, without limitation, the
license grants in this Agreement, and no such conveyance or grant violates or
constitutes an event that is or would be with the passage of time, in any





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 20 of 75







 









 







material
way, a violation, breach or default of, any material agreement or material obligation
to which CERES is a party or by which it is bound; and




     13.1.1.7 all former and current employees of CERES have executed written
agreements with CERES that assign to CERES all rights to any inventions,
improvements, discoveries or information relating to CERES’ business, subject however
to Section 2870 of the California Labor Code. To the Knowledge of CERES, no employee
of CERES has entered into any agreement with a former employer that would be violated
by his or her employment with CERES.





13.2 Representations and Warranties of IGER.





     “To the Knowledge of IGER” as used in this Article 13.2 shall mean: to the actual
knowledge, as of the Effective Date, of any member of the Executive Committee of IGER or of
any employee of IGER who has actively participated in the negotiation of the transactions
contemplated by this Agreement.




     13.2.1 IGER represents and warrants to CERES that:




     13.2.1.1 IGER (a) is a company limited by guarantee, registered in England No.
473456 and a registered Charity No. 272150, duly incorporated, validly existing and
in good standing under the laws of England and Wales; (b) has all requisite power and
authority to conduct the business in which it is currently, or is currently proposed
to be, engaged; (c) has the corporate power and authority to execute and deliver this
Agreement; and (d) has the corporate power and authority to perform its obligations
under this Agreement;




     13.2.1.2 the execution, delivery, and performance by IGER of this Agreement have
been duly authorized by all necessary corporate action of IGER;




     13.2.1.3 this Agreement has been duly executed and delivered by IGER, and
constitutes the legal, valid and binding obligations of IGER enforceable against IGER
in accordance with its terms;




     13.2.1.4 as of the Effective Date, IGER has not received notice of, and is not
in default under, or with respect to, any contractual obligation, which, individually
or together with all such defaults, would have a material adverse effect on the
ability of IGER to perform its obligations under this Agreement;




     13.2.1.5 to the Knowledge of IGER, no approval, consent, compliance, exemption,
authorization or other action by, or notice to, or filing with, any governmental
agency or other person and no lapse of a waiting period is necessary or required in
connection with the execution, delivery or performance by, or enforcement against,
IGER of this Agreement or the transactions contemplated hereby;




     13.2.1.6 to the Knowledge of IGER, and subject to the Assignment/License
referred to in Article 14.1 (e) (v), IGER has the right to make the conveyances and
grants in accordance with the Articles hereof, including, without





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 21 of 75







 









 







limitation, the
license grants, and no such conveyance or grant violates or constitutes an event that
is or would be with the passage of time, in any material way, a violation,
breach or default of, any material agreement or material obligation to which
IGER or any such Affiliate of IGER is a party or by which it is bound;




     13.2.1.7 all former and current employees of IGER have executed written
agreements with IGER that assign to IGER all rights to any inventions, improvements,
discoveries or information relating to IGER’s business. To the Knowledge of IGER, no
employee of IGER has entered into any agreement with a former employer that would be
violated by his or her employment with IGER; and




     13.2.1.8 EXHIBIT E sets forth an exhaustive list of all agreements and
commitments in existence on the Effective Date to which IGER is a party, or that
contain obligations or restrictions affecting IGER, in connection with the
COLLABORATION CROPS, except for the following agreements which are not included in
EXHIBIT E:




	 	1.	 	Agreement of July 12, 2004
between Bio-Renewables Limited, IGER and Plant Research
International B.V.;






	 	2.	 	Agreement dated the
23rd of June 2005 between [***] and IGER; and






	 	3.	 	Agreement dated October 18,
2006 between [***] and IGER.





     13.3 EXCEPT AS PROVIDED IN ARTICLES 13.1 AND 13.2, THE PARTIES ACKNOWLEDGE AND AGREE THAT
NEITHER PARTY HAS MADE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT
LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL
EITHER PARTY BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR
LOSS OF PROFIT ARISING OUT OF THE USE OF ANY JOINT INTELLECTUAL PROPERTY, CERES INTELLECTUAL
PROPERTY, IGER INTELLECTUAL PROPERTY, OTHER RESEARCH RESULTS OR BACKGROUND INTELLECTUAL PROPERTY
COVERED BY THIS AGREEMENT OR ANY SCHEDULE OR ARISING OUT OF THE IMPLEMENTATION OF THIS AGREEMENT,
EVEN IF SUCH PARTY IS ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.



     13.4 Nothing in this Agreement is or shall be construed as:




(a) a warranty or representation by either Party as to the validity or scope of any
patent rights or plant variety rights;




(b) a warranty or representation by either Party that anything made, used, sold
or otherwise disposed of pursuant to any license granted under this Agreement is or
will be free from infringement of patents, copyrights or other rights of third
parties;




(c) any obligations by either Party to bring or prosecute actions or suits against
third








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 22 of 75







Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission



 









 





parties for patent infringement; or parties for patent infringement, or



a grant by implication, estoppel or otherwise of any licenses under patent
applications, patents, plant variety rights applications and/or plant variety rights
of CERES and/or IGER or other person other than as provided in the express provisions
of this Agreement or a SCHEDULE on this Agreement.




	14.	 	TERM AND TERMINATION.





     14.1 The term of this Agreement shall be fifteen (15) years from the Effective Date,
unless sooner terminated in accordance with the following provisions of this Article:




     (a) mutual, written agreement of the Parties;




     (b) failure of one Party to satisfy its material obligations under this Agreement, and
such Party subsequently fails to cure such failure(s) within (i) thirty (30) days for
failures to remit payment for amounts due under this Agreement and (ii) ninety (90) days for
all other obligations in each case after receipt of written notice from the non-breaching
Party specifying such failure(s);




     (c) one (1) year’s written notice of termination by either CERES or IGER to the other
Party in case either the terminating Party or the other Party ceases substantially all
activities in the COLLABORATION CROPS;




     (d) IGER will have the right to terminate this Agreement unilaterally with thirty (30)
days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy,
insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if
any such proceeding is instituted against CERES (and not dismissed within one hundred twenty
(120) days); (ii) in case of dissolution or winding up of CERES (excluding any situation
where all or substantially all of CERES’ assets, stock or business to which this Agreement
relates are acquired by a third party (whether by sale, acquisition, merger, operation of
law or otherwise)); or (iii) with written notice to CERES, if CERES has failed in a
substantial manner, three (3) years after either Party or the Parties jointly have developed
a propagation method for Miscanthus that results in the crop being commercially competitive
in the United States or in Europe as compared to other energy crops being grown at that time
in the relevant geography, to implement the activities set forth in EXHIBIT F, and
does not remedy such failure or offer a remediation plan which is reasonably acceptable to
IGER within ninety (90) days after receipt of a written notice from IGER specifying such
failure;




     (e) CERES will have the right to terminate this Agreement unilaterally: (i) with thirty
(30) days’ written notice to IGER if John Clifton-Brown or Iain Donnison cease(s)
to be associated with IGER and the RESEARCH PROJECTS contemplated by this Agreement, and
IGER has not replaced such person(s) within one hundred twenty (120) days by (a) person(s)
reasonably acceptable to CERES; (ii) with ninety (90) days’ written notice to IGER, if the
institutional mission, purpose, structure or funding of IGER would change substantially and
adversely affect IGER’s ability to satisfy its obligations hereunder; (iii) with one (1)
years’ written notice to IGER, if CERES has a documented compelling business reason to cease
the collaboration, (for example, without limitation, lack of sufficient processing capacity
for COLLABORATION CROPS within the expected timeframe in the United States; COLLABORATION
CROPS are non-competitive with other biomass sources); (iv) with three (3) months’ prior
written notice to IGER, such notice to be given no earlier than eighteen (18)





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 23 of 75







 









 







months after
the Effective Date, if no rights to commercialize (including determination of the
compensation due upon commercialization) COLLABORATION CROPS germplasm provided by IGER
which is included in a RESEARCH PROJECT have been secured to CERES’ reasonable satisfaction
in compliance with the CBD; or (v) with thirty (30) days’ written notice to IGER if Defra
has not assigned to IGER, or granted to IGER an exclusive license reasonably satisfactory to
CERES on, the Intellectual Property vested in Defra or the Crown or the Secretary of State
pursuant to the DEFRA agreement NF 0426 within sixty (60) days from the Effective Date (the
“Assignment/License”).




     (f) either Party will have the right to terminate this Agreement if no active RESEARCH
PROJECTS exist for more than two (2) years, provided that on or after the second anniversary
of the expiration or termination of the last SCHEDULE to expire or terminate, the Parties
have not agreed on any new SCHEDULE despite (i) negotiations in good faith by both Parties
or (ii) diligent, documented attempts by the terminating Party to conduct negotiations in
good faith with respect to one or more new SCHEDULES, to which attempts the other Party has
not been responsive.



     14.2 Promptly upon the delivery of a notice of termination of this Agreement, the Parties will
meet to discuss the ongoing RESEARCH PROJECTS, and each Party will provide to the other Party any
data, information and germplasm that constitutes or is covered by JOINT INTELLECTUAL PROPERTY and
which has not been provided prior to the notice of termination, without prejudice to additional
on-going delivery obligations set forth in any SCHEDULES.



     14.3 Termination of this Agreement shall not affect the rights and obligations of the Parties
accrued prior to termination hereof nor any license grants then in existence, nor either Party’s
non-exclusive rights to commercialize then existing RELEASED VARIETIES in the United Kingdom,
subject to payment of remuneration as set forth in any relevant license/commercialization
agreements. Further, the provisions set forth hereinafter shall apply.




     14.3.1 In case of termination on the basis of Article 14.1 (b) if CERES is the
breaching Party, Article 14.1 (c) if CERES ceases substantially all activities in the
COLLABORATION CROPS, Article 14.1 (d) (i), (ii) or (iii) or Article 14.1. (e) (iii), at or
about the effective date of termination, the Parties will negotiate in good faith to reach
agreement as to the rights to use and commercially exploit JOINT INTELLECTUAL PROPERTY not
covered by any relevant license/commercialization agreement between the Parties, which
rights will be addressed in one or more written agreements. If the Parties fail to reach
agreement within ninety (90) days after the start of such negotiations, which shall be
evidenced by written notice from one Party to the other initiating such negotiations, each
Party shall have the non-exclusive right to use and commercially exploit JOINT INTELLECTUAL
PROPERTY for any and all purposes, with the right to grant sublicenses, subject to the
obligations of the first sentence of Article 14.3, provided that no licenses on any
transgenes or transgenic technologies of the other Party shall be included or implied.




     14.3.2 In case of termination on the basis of Article 14.1 (b) if IGER is the breaching
Party, Article 14.1 (c) if IGER ceases substantially all activities in the COLLABORATION
CROPS, Article 14.1 (e) (i) or (ii) or Article 14.1 (f), subject to the obligations of the
first sentence of Article 14.3, CERES shall have the exclusive right to use and commercially
exploit any JOINT INTELLECTUAL PROPERTY to the extent such JOINT





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 24 of 75







 









 







INTELLECTUAL PROPERTY is
not covered by any relevant license/commercialization
agreement between the Parties. At or about the effective date of termination, the
Parties will negotiate in good faith to reach agreement as to reasonable remuneration
(whether as a royalty or in some other form as the Parties may agree), which will be
addressed in one or more written agreements. If the Parties fail to reach agreement within
ninety (90) days after the start of such negotiations, which shall be evidenced by written
notice from one Party to the other initiating such negotiations, the remuneration shall be
settled in accordance with the dispute resolution procedure in Article 15.



     14.4 Termination of this Agreement for any reason will not relieve either Party of any
obligation or liability accrued under this Agreement before termination or rescind any payments
made or due before termination. Articles 4, 5 (subject to Article 14.3), 6, 7, 8, 9.1, 9.2, 10,
12.3, 13, 14.2, 14.3, 14.4, 14.5, 15, 16 and 18 will survive any termination of this Agreement.



     14.5 Termination of this Agreement shall not automatically terminate any existing RESEARCH
PROJECT, which can only be terminated according to the specific terms of the related SCHEDULE. The
terms and provisions of this Agreement shall continue to apply to the activities and outcomes of
any such RESEARCH PROJECTS, notwithstanding the termination of this Agreement, unless provided
otherwise in the relevant SCHEDULE or by written agreement of the Parties upon termination.




	15.	 	DISPUTE RESOLUTION AND APPLICABLE LAW.





     15.1 All disputes, differences or questions arising out of or in connection with this
Agreement or its SCHEDULES, or related to the alleged breach, termination, validity, interpretation
or violation thereof, shall be submitted to the MANAGEMENT COMMITTEE for resolution, which shall
convene, whether in person or otherwise, to resolve such dispute in a timely manner. Either Party
may initiate a resolution procedure by providing written notice (“Dispute Notice”) to the other
Party, and any such Dispute Notice must set forth the subject matter of the dispute, difference or
question. If after sixty (60) days the dispute remains unresolved, the Chief Scientific Officer of
CERES and the Director of IGER shall seek to resolve the dispute through negotiation. The Parties
agree that at least eight (8) cumulative hours of negotiations will be undertaken. If the dispute
still remains unresolved ninety (90) days after the Dispute Notice, either Party may initiate
proceedings pursuant to Article 15.2.



     15.2 Dispute Resolution and Arbitration.




     In the event of any dispute arising out of or in connection with this Agreement, the
Parties agree to submit the matter to settlement proceedings under the ICC ADR Rules. If the
dispute has not been settled pursuant to the said Rules within forty-five (45) days
following the filing of a Request for ADR or within such other period as the Parties may
agree in writing, such dispute shall be finally settled under the Rules of Arbitration of
the International Chamber of Commerce by three (3) arbitrators appointed in accordance with
the said Rules of Arbitration. The provisions set forth hereinafter shall apply to the
arbitration procedures, without prejudice to the ICC Rules of Arbitration.




     15.2.1 Qualifications of Arbitrators.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 25 of 75







 









 






     Each arbitrator appointed shall have a reputation as being experienced in the
legal and technical matters related to the dispute, shall be required to disclose,
among other disclosures, any prior involvement with the legal and technical matters
related to the dispute and any involvement with a competitor of any Party, and shall
not be presently nor in the past have been affiliated with any Party or a competitor
of any Party. Notwithstanding the method of their appointment, each arbitrator shall
be required to meet the standards contained in the Rules with respect to
independence.




     15.2.2 Location of the Arbitration.




     The seat of arbitration shall be Paris, France. The arbitrators may hold
hearings at such other locations as the arbitrators shall determine, after
consultation with the Parties.




     15.2.3 Language of Arbitration.




     The arbitral proceedings and all pleadings and written evidence shall be in the
English language. Any written evidence originally in a language other than English
shall be submitted in English translation accompanied by the original or true copy
thereof




     15.2.4 Limitation on Remedies.




     The arbitrators are precluded from awarding punitive or exemplary damages. In
no event shall the arbitrators have the powers of an amiable compositeur.



     15.3 Applicable law.




     This Agreement shall be governed by, and construed and interpreted in accordance with,
the laws of the State of New York, United States of America, without regard to the
principles of conflicts of law thereof.




	16.	 	NOTICES.





     Any notices required to be given or which shall be given under this Agreement shall be in
writing and delivered by overnight (trackable) courier addressed to the Parties as follows:


Vice President of Product Development

cc: Legal Department

Ceres, Inc.

1535 Ranch Conejo Blvd.

Thousand Oaks, California 91320

United States of America



Institute Business Manager

OR for legal or financial notices:

Institute Secretary

Institute of Grassland and Environmental Research






	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 26 of 75







 









 







Plas Gogerddan

Aberystwyth

Ceredigion

SY23 3EB

United Kingdom




     Notices under this Agreement sent by overnight courier by one Party to the other Party at its
above address, shall be deemed to have been given or made as of the date following the date so
mailed.



17. GENERAL.




     17.1 Entire Agreement/Modifications.



     This Agreement constitutes the entire agreement between the Parties hereto with respect to the
subject matter hereof, and there are no representations, warranties, covenants or obligations
except as set forth herein. This Agreement supersedes all prior and contemporaneous agreements,
understandings, negotiations and discussions, written or oral, of the Parties hereto relating to
the subject matter hereof. This Agreement and its SCHEDULES may only be amended, modified or
superseded by a writing executed by the authorized representatives of the Parties hereto. It is
anticipated that SCHEDULES will be attached to and become part of this Agreement as new RESEARCH
PROJECTS are undertaken, as described in Article 1.1.



     17.2 Severability.



     This Agreement, to the greatest extent possible, shall be construed so as to give validity to
all of the provisions hereof. If any provision of this Agreement is or becomes invalid, is ruled
illegal by a court of competent jurisdiction or is deemed unenforceable under the current
applicable law from time to time in effect during the term of this Agreement, the remainder of this
Agreement will not be affected or impaired thereby and will continue to be construed to the maximum
extent permitted by law. In lieu of each provision which is invalid, illegal or unenforceable,
there will be substituted or added as part of this Agreement by mutual written agreement of the
Parties, a provision which will be as similar as possible, in economic and business objectives as
intended by the Parties to such invalid, illegal or unenforceable provision, but will be valid,
legal and enforceable.



     17.3 Waiver.



     No failure or delay by either Party in exercising any right or remedy under this Agreement
will waive any provision of this Agreement. Nor will any single or partial exercise by either Party
of any right or remedy under this Agreement preclude it from otherwise or further exercising any
rights or remedies which it may have, or any other rights or remedies granted by any law or any
related document.



     17.4 Enforcement.



     In the event an action is commenced by either Party against the other to enforce any of the
provisions of this Agreement, the prevailing Party shall be entitled to recover from the other
Party reasonable attorneys’ fees, court costs and necessary disbursements incurred in connection
with such action.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 27 of 75







 









 





     17.5 Assignablility.



     This Agreement binds and enures to the benefit of the Parties, their successor or assigns, but
may not be assigned by either Party without the prior written consent of the other Party; provided
however, CERES shall have the right to assign its rights and obligations under this Agreement to
any Affiliated Company without such prior consent. Each Party shall have the right to assign its
rights and obligations under this Agreement to a third party in conjunction with the transfer to
such third party of substantially all of the assets of such Party associated with performance under
this Agreement without such prior consent. “Affiliated Company” defined as any company owned or
controlled by, under common control with or controlling CERES, “control” meaning in this context
the direct or indirect ownership of fifty percent (50%) or more of the voting stock/shares of a
company, or the power to nominate at least half of the directors.



     17.6 Force Majeure.



     No Party shall be responsible to the other Party for delay or failure in performance of any
the obligations imposed by this Agreement, provided such failure shall be occasioned by fire,
flood, explosion, lightning, wind storm, hailstorm, earthquake, subsidence of soil, failure of
machinery or equipment or supply of materials, discontinuity in the supply of power, court order or
governmental interference, terrorist attacks, civil commotion, riot, war, strikes, labor
disturbances, transportation difficulties, labor shortage, natural genetic variation of any living
matter or by any other cause of like or unlike nature beyond the reasonable control and without
fault or negligence of such Party.



18. SPECIAL CONDITIONS IN CONNECTION WITH DEFRA AGREEMENT NF 0426.




     The Parties acknowledge that Defra is expected to assign or license exclusively to IGER any
rights in Intellectual Property which would vest in Defra or the Crown or the Secretary of State
pursuant to the DEFRA agreement NF 0426. If IGER receives an exclusive license from Defra rather
than an assignment of rights, the following will apply.




18.1 To the extent the license grant to CERES on IGER BACKGROUND INTELLECTUAL PROPERTY in
Article 5.3.2 relates to IGER BACKGROUND INTELLECTUAL PROPERTY that constitutes Intellectual
Property to which rights vest in Defra or the Crown or the Secretary of State, the word
“license” will be read as “sublicense” and all other terms of such Article will remain
unchanged.




18.2 To the extent that IGER INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY created in
a RESEARCH PROJECT constitutes or includes Intellectual Property to which rights vest in
Defra or the Crown or the Secretary of State, any conveyance or grant of rights or licenses
by IGER to CERES in this Agreement with respect to such IGER INTELLECTUAL PROPERTY or JOINT
INTELLECTUAL PROPERTY, will be read as the grant of an exclusive sublicense under IGER’s
exclusive license from Defra.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 28 of 75







 









 





     IN WITNESS WHEREOF, IGER and CERES have caused this Agreement to be duly executed as indicated
below.









	 	 	 	 	 	 	 	 	 

	INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH	 	CERES, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Mervyn Humphreys	 	By:	 	/s/ Richard Flavell	 	 
	Name:

	 	 

Professor Mervyn Humphreys
	 	Name:
	 	 

Richard Flavell, CBE, FRS
	 	 
	Title:

	 	Director
	 	Title:
	 	Chief Scientific Officer	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Richard Hamilton	 	 
	 

	 	 	 	Name:
	 	 

Richard Hamilton
	 	 
	 

	 	 	 	Title:
	 	President and Chief Executive
Officer	 	 








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 29 of 75







 









 





EXHIBIT A




to the Collaboration Agreement between IGER and CERES



DEFINITION OF COLLABORATION CROPS


Miscanthus and interbreeding species, including without limitation Saccharum and Erianthus species.









	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 30 of 75







 









 








EXHIBIT B




to the Collaboration Agreement between IGER and CERES



PREFERRED FORM OF RECEIPT FORM



Packing Slip and Receipt Form

for material transferred pursuant to the Collaboration Agreement dated [x] between INSTITUTE OF

GRASSLAND AND ENVIRONMENTAL RESEARCH and CERES, INC. and SCHEDULES to such Agreement.



Material transferred pursuant to SCHEDULE [x] dated [...]



The undersigned [IGER/CERES] signatory certifies that the material and related information set
forth hereinafter are included in the shipment with which this form is enclosed.



The undersigned [IGER/CERES] signatory acknowledges having received in good order the material and
related information set forth hereinafter. The signature does not constitute an acceptance of the
receiving party’s qualification of the intellectual property (IP) status of the material
transferred, such IP status being defined in the Parties’ Collaboration Agreement.



[Include description of material and related information with indication of IP status (e.g.
Background, Joint IP) and any restrictions on transfer to subcontractors.]



THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE
MENTIONED COLLABORATION AGREEMENT AND SCHEDULE. CONFIDENTIALITY OBLIGATIONS APPLY.




	 	 	 	 	 	 	 	 	 

	For sending/receipt,	 	For receipt/sending,	 	 
	 
	 	 	 	 	 	 	 	 
	Signature:

	 	 	 	Signature:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	Date:

	 	 	 	Date:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Name: Walter E. Nelson	 	Name:	 	 
	 

	 	 	 	 	 	 

	 	 
	 
	 	 	 	 	 	 	 	 
	Title: Product Development Manager
CERES, INC.	 	Title:

INSTITUTE OF GRASSLAND AND

ENVIRONMENTAL RESEARCH	 	 








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 31 of 75







 









 






EXHIBIT C




to the Collaboration Agreement between IGER and CERES



PREFERRED FORMS OF VARIETY EVALUATION AGREEMENT



(to be used for field evaluation)



FIELD TRIAL AGREEMENT

(Non transgenic. Fee for service. Academic.)




and




FIELD TRIAL AGREEMENT

(Non transgenic. No payment. Academic.)




PREFERRED FORM OF MATERIAL TRANSFER AGREEMENT

(to be used for transfer of material for other purposes than field evaluation)








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 32 of 75







 









 








FIELD TRIAL AGREEMENT

(Non transgenic. Fee for service. Academic.)





	1.	 	THE PARTIES
	 
	 	 	This Agreement is made effective on [date] (“Effective Date”) by and between [Ceres, Inc., a
Delaware corporation with principal offices at 1535 Rancho Conejo Blvd., Thousand Oaks, CA
91320, United States of America] or [Institute of Grassland and Environmental Research, a
company limited by guarantee, registered in England No. 473456 and a registered Charity No.
272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United
Kingdom] hereinafter “[CERES/IGER],” and [Party information to be completed], hereinafter
“[Party].”
	 
	 	 	THE PARTIES HERETO COVENANT AND AGREE AS FOLLOWS:
	 
	2.	 	FIELD TRIAL PROGRAM






	 	2.1	 	[CERES/IGER] will deliver to [Party] seeds or other propagating material as
described in ANNEX I and related information (jointly referred to as the
“CERES/IGER Plant Material”). The delivery conditions are set forth in ANNEX
I. Promptly upon receipt of the CERES/IGER Plant Material, Party will sign and
return the Receipt Form, in the preferred format attached as ANNEX II to this
Agreement, to [CERES/IGER] (attn: [responsible person at CERES/IGER]).
	 
	 	2.2	 	[Party] agrees to perform the activities defined in ANNEX I which shall
be referred to hereinafter as the “Program.” With reasonable notice [CERES/IGER] may
change the activities to be performed in the Program. If such changes do not result in
additional work to be performed by [Party], but consist for example of changes in
experimental design or in observations to be made or in information to be included in
reports, they shall be set forth in a written document provided by [CERES/IGER] to
[Party] which will be attached to ANNEX I and form part of it. If such changes
result in additional work to be performed by [Party] and require an adaptation of the
remuneration, they shall be set forth in an amendment to this Agreement signed by both
Parties. [CERES/IGER] will consider any suggestions for changes in the Program which
[Party] may suggest.
	 
	 	2.3	 	In performing the Program activities [Party] undertakes to comply with the work
plan and time schedule set forth in ANNEX I.
	 
	 	2.4	 	[Party] undertakes only to use the CERES/IGER Plant Material or any part,
progeny or seeds thereof for performing the Program activities to be carried out under
the Program and not for any other purpose. Specifically, but without limitation,
[Party] shall not use the Plant Material or any progeny, plants, parts of plants, plant
material, seeds or products derived therefrom in any form of reselection, breeding,
sexual crossing, seed production, back crossing, tissue culturing, mutagenesis, genetic
transformation or any biotechnological process, except as specifically approved in this
Agreement.








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 33 of 75







 









 






	 	2.5	 	The CERES/IGER Plant Material will be used only on fields and at premises under
the control of [Party] and identified in ANNEX I.
	 
	 	2.6	 	Upon termination of the Program, [Party] will, at the option of [CERES/IGER],
(i) allow [CERES/IGER] to remove any Plant Material and any progeny, plants, plant
material, seeds or products obtained in the Program or (ii) destroy any remaining
CERES/IGER Plant Material and any plants, plant material and seeds obtained under the
Program within fifteen (15) days from [CERES/IGER]‘s request to destroy, and will send
[CERES/IGER] forthwith an attestation of such destruction.
	 
	 	2.7	 	Subject to giving at least one day’s prior written notice in writing or by
email to [Party], [CERES/IGER] and [CERES/IGER] invitees will have the right to visit
the fields where Program activities are being conducted at any time, to make
observations and to collect samples.






	3.	 	REPORTS






	 	3.1	 	[Party] shall send [CERES/IGER] detailed written reports on the implementation
of the Program activities and the observations made and results obtained during the
implementation of the Program. The frequency of the reports and the type of
information to be included in same is set forth in ANNEX I.
	 
	 	3.2	 	During the entire Program, [Party] will promptly communicate to [CERES/IGER]
any information on the Program activities or the results obtained or observed that
[CERES/IGER] may ask. Between reports, [Party] will also spontaneously communicate to
[CERES/IGER] any unexpected observations or results.






	4.	 	REMUNERATION. PAYMENT






	 	4.1	 	[CERES/IGER] will pay [Party] a remuneration as set forth in ANNEX I
for the implementation of the Program, in accordance with the payment schedule set
forth in such annex. Overhead costs included in the remuneration shall not exceed [x]
percent (x%).
	 
	 	4.2	 	The payments will be made on the dates set forth in the payment schedule in
ANNEX I provided that [CERES/IGER] has received a corresponding invoice from
[Party] at least thirty (30) days in advance, by bank transfer to [Party’s] account
mentioned in its invoice.






	5.	 	OWNERSHIP. INTELLECTUAL PROPERTY RIGHTS. EXPLOITATION






	 	5.1	 	This Agreement does not bring any change to the ownership and intellectual
property rights relating to the CERES/IGER Plant Material. [Party] acknowledges that
the CERES/IGER Plant Material may be covered by patents or patent applications of
[CERES/IGER].
	 
	 	5.2	 	[CERES/IGER] will exclusively own any plants, parts of plants, plant material,
seeds, information, data, technology, or other findings or inventions resulting from
the








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 34 of 75







 









 






	 	 	 	Program that relate to the CERES/IGER Plant Material (hereinafter “Results”).
[CERES/IGER] will have the exclusive rights to protect any of the Results through
patents or plant variety protection rights or similar protection, and any
intellectual property rights arising therefrom will belong exclusively to
[CERES/IGER]. In case [Party] has made or contributed to any invention forming part
of the Results, [Party] shall promptly inform [CERES/IGER] thereof in writing and
shall assign its rights and cause its employees and staff members to assign their
rights in any such invention to [CERES/IGER]. [Party] shall render such assistance
as may be required for assigning any rights [Party] inventors may have in such
invention to [CERES/IGER] or
[CERES/IGER]’s designee and for protecting such
invention, including but not limited to the signing of documents. Any inventor of
[Party] will be recognized in patent applications on an invention which is part of
the Results in accordance with [U.S./U.K. patent law].
	 
	 	5.3	 	[CERES/IGER] will have the exclusive right to commercialize any of the Results.






	6.	 	CONFIDENTIALITY. PUBLICATIONS.






	 	6.1	 	[Party] will treat any and all information and material communicated or
transferred to it by [CERES/IGER] pursuant to this Agreement (including but not limited
to the CERES/IGER Plant Material) and any Results (including without limitation any
progeny, plants, seeds, parts of plants, plant material, or products obtained directly
or indirectly from the Plant Material) as strictly confidential and will not use the
same for any purpose other than as expressly allowed by this Agreement nor disclose or
transfer the same to any third party other than its employees or staff members
necessary to carry out the Program and bound by appropriate secrecy and non-use
undertakings consistent with [Party’s] obligations under this Agreement.
	 
	 	6.2	 	[Party] shall take all precautions to prevent theft or pilferage of the Plant
Material and any progeny, plants, seeds, parts of plants or plant material obtained
directly or indirectly from the Plant Material.
	 
	 	6.3	 	[Party] will not grant access to any field where Plant Material or any progeny,
plants, seeds, parts of plants or plant material obtained directly or indirectly from
the Plant Material can be viewed to any third party except with the prior written
permission of [CERES/IGER].
	 
	 	6.4	 	“Publication” and “Publish” shall include any discussion with or presentation
to a third party, other than parties referred to in Article 6.1. Examples of
Publications include, without limitation: presentation at a conference, submission for
publication to a journal, submission of joint proposals, posting information on a
website, posters, abstracts, Ph.D. dissertations, and informal oral discussions.
Subject to [CERES/IGER]’s prior written approval, which will not unreasonably be
withheld, [Party] may proceed to Publication of selected Results provided that: (i) no
confidential information of [CERES/IGER] is revealed thereby, (ii) [Party] shall take
into account any suggestions which may be formulated by [CERES/IGER], and (iii) at
least thirty (30) days prior to the submission to a publisher or presentation to any
third party, [Party]








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 35 of 75






 









 






	 	 	 	delivers copies of the proposed Publication to [CERES/IGER] for review. At
[CERES/IGER]’s request, [Party] shall, for a reasonable period up to ninety (90) days
from initial delivery to [CERES/IGER], delay revealing any patentable subject matter
in the disclosure in order to permit the filing of patent applications. In any
Publication, the Parties shall consider joint authorship and acknowledge the
contributions and publications of the other as scientifically appropriate.






	7.	 	WARRANTIES. LIMITED LIABILITY






	 	7.1	 	[Party] acknowledges that the CERES/IGER Plant Material is of an experimental
nature and will take all reasonable precautions to prevent any damage or injury by the
CERES/IGER Plant Material and any progeny, plants, parts of plants, plant material,
seeds or products derived therefrom.
	 
	 	7.2	 	[Party] warrants that the CERES/IGER Plant Material will exclusively and
restrictedly be used under suitable containment conditions, and in accordance with all
applicable regulations, and it will not be used on human subjects. In addition,
[Party] will strictly comply with any planting distance, isolation and similar
requirements set forth in ANNEX I. [Party] will obtain any authorizations or
permits or proceed to any notifications which may be required for the Program
activities, [Party] will inform [CERES/IGER] in writing, within thirty (30) days from
the Effective Date, of any such requirements and certify its compliance with same.
	 
	 	7.3	 	[CERES/IGER] declines any liability for any damage which may be caused by the
CERES/IGER Plant Material or the Program activities or Results to [Party] or any third
party.
	 
	 	7.4	 	Neither Party shall be liable for indirect, special, remote, incidental or
consequential damages or loss of profit in connection with this Agreement or its
implementation.






	8.	 	GENERAL CONDITIONS






	 	8.1	 	Amendments: This Agreement, including its annexes, may only be amended
by a written document signed by duly authorized representatives of the Parties.
	 
	 	8.2	 	Ambiguities: In case of ambiguity between this Agreement and its
annexes, the contents of the agreement shall prevail.
	 
	 	8.3	 	Number of copies: This Agreement including its annexes is being made
in two (2) copies, one for each Party.
	 
	 	8.4	 	Assignment / Subcontracts: [CERES/IGER] has concluded this Agreement
with [Party] in view of [Party]’s specific qualifications and [Party] shall not have
the right to assign any of its rights or obligations under this Agreement nor to
sub-contract any part of the Program activities to any third party, except with the
prior written approval of [CERES/IGER]. [CERES/IGER] has the right to assign its
rights and obligations under this Agreement to any third party. Further, [CERES/IGER]
has the right to







	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 36 of 75






 









 






	 	 	 	entrust the implementation of all or part of its obligations under this Agreement to
any of its affiliates.
	 
	 	8.5	 	Equitable Remedies: It is understood and agreed that money damages
would not be a sufficient remedy for any breach of this Agreement by [Party] and that
[CERES/IGER] is entitled to equitable relief, including injunction and specific
performance, as a remedy for any such breach. Such remedies shall not be deemed to be
the exclusive remedies for a breach by [Party] of this Agreement but shall be in
addition to all other remedies available at law or equity to [CERES/IGER].
	 
	 	8.6	 	Governing Law / Jurisdiction: [to be completed]






	9.	 	DURATION






	 	9.1	 	This Agreement will enter into force on the Effective Date and will remain in
full force and effect until the latest of the following dates: (i) the [third]
anniversary of the Effective Date, (ii) the date of delivery by [Party] of the last
report provided for in this Agreement, or (iii) the dates on which the last payment due
by [CERES/IGER] pursuant to this Agreement is made.
	 
	 	9.2	 	Notwithstanding Article 9.3., [CERES/IGER] will have the right to terminate
this Agreement including the Program at any time with [three (3)] months’ prior written
notice. In case of such early termination, [CERES/IGER] will pay the remuneration
provided in this Agreement up to the effective date of termination, and all costs
relating to the implementation of this Agreement which [Party] irrevocably committed to
prior to receipt of the notice of termination.
	 
	 	9.3	 	Either Party will have the rights to terminate this Agreement unilaterally by
registered letter addressed to the other Party in case such other Party has committed a
breach of any of its obligations under this Agreement and has failed to remedy such
breach within thirty (30) days from the receipt of a registered letter specifying the
breach.
	 
	 	9.4	 	The provisions of Articles 2.6, 5, 6, 7.3, 7.4, 8.5 and 8.6 will survive the
expiration or termination of this Agreement.




Made in two (2) copies.




	 	 	 	     	 	 	 

	[Party]	 	 	 	[Institute of Grassland and Environmental Research] or [Ceres, Inc.]
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 







	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 37 of 75






 










 






ANNEX
I

to the Field Trial Agreement between [CERES/IGER] and [Party]




PLANTING / MANAGEMENT PLAN FOR [CERES/IGER] MISCANTHUS EVALUATION TRIAL — [Party]


Trial Scope and Purpose:



1. Planting Material



2. Program Activities



3. Content and timing of reports




	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 38 of 75













 








ANNEX II




to the Field Trial Agreement between [CERES/IGER] and [Party]



FORM OF RECEIPT FORM



Packing Slip and Receipt Form

for material transferred pursuant to the Field Trial Agreement dated
[x] between [CERES/IGER] and [Party].


The undersigned [Party/[CERES/IGER]] signatory certifies that the material and related information
set forth hereinafter are included in the shipment with which this form is enclosed.



The undersigned [Party/[CERES/IGER]] signatory acknowledges having received in good order the
material and related information set forth hereinafter.



[Include description of material and related information.]



THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE
MENTIONED FIELD TRIAL AGREEMENT. CONFIDENTIALITY OBLIGATIONS APPLY.




	 	 	 	 	 	 	 

	For sending/receipt,	 	For receipt/sending,
	 
	 	 	 	 	 	 
	Signature:

	 	 	 	Signature:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	 	 	Date:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 
	 	 	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	[CERES/IGER]	 	[Party]	 	 







	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 39 of 75













 






FIELD TRIAL AGREEMENT

(Non transgenic. No payment. Academic.)





	1.	 	THE PARTIES
	 
	 	 	This Agreement is made effective on [date] (“Effective Date”) by and between [Ceres, Inc., a
Delaware corporation with principal offices at 1535 Rancho Conejo Blvd., Thousand Oaks, CA
91320, United States of America] or [Institute of Grassland and Environmental Research, a
company limited by guarantee, registered in England No. 473456 and a registered Charity No.
272150, having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United
Kingdom] hereinafter “[CERES/IGER],” and [Party information to be completed], hereinafter
“[Party].”
	 
	 	 	WHEREAS, [CERES/IGER] wishes to obtain information from field trialing certain CERES/IGER
plant material;
	 
	 	 	WHEREAS, [Party] wishes to include CERES/IGER’s plant material in field trials in
consideration of its scientific interest in the observations to be made in such trials and
the right to publish certain observations, all subject to the terms and conditions of this
Agreement;
	 
	 	 	[or other introduction as appropriate]
	 
	 	 	NOW THEREFORE, for and in consideration of the covenants, conditions and undertakings
hereinafter set forth, [CERES/IGER] and [Party] hereby agree as follows:
	 
	2.	 	FIELD TRIAL PROGRAM






	 	2.1	 	[CERES/IGER] will deliver to [Party] seeds or other propagating material as
described in ANNEX I and related information (jointly referred to as the
“CERES/IGER Plant Material”). The delivery conditions are set forth in ANNEX
I. Promptly upon receipt of the CERES/IGER Plant Material, Party will sign and
return the Receipt Form, in the preferred format attached as ANNEX II to this
Agreement, to [CERES/IGER] (attn: [responsible person at CERES/IGER]).
	 
	 	2.2	 	[Party] agrees to perform the activities defined in ANNEX I which shall
be referred to hereinafter as the “Program.” With reasonable notice [CERES/IGER] may
change the activities to be performed in the Program. If such changes do not result in
additional work to be performed by [Party], but consist for example of changes in
experimental design or in observations to be made or in information to be included in
reports, they shall be set forth in a written document provided by [CERES/IGER] to
[Party] which will be attached to ANNEX I and form part of it. If such changes
result in additional work to be performed by [Party], they shall be set forth in an
amendment to this Agreement signed by both Parties. [CERES/IGER] will consider any
suggestions for changes in the Program which [Party] may suggest.
	 
	 	2.3	 	In performing the Program activities [Party] undertakes to comply with the work
plan and time schedule set forth in ANNEX I.














	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 40 of 75











 






	 	2.4	 	[Party] undertakes only to use the CERES/IGER Plant Material or any part,
progeny or seeds thereof for performing the Program activities to be carried out under
the Program and not for any other purpose. Specifically, but without limitation,
[Party] shall not use the Plant Material or any progeny, plants, parts of plants, plant
material, seeds or products derived therefrom in any form of reselection, breeding,
sexual crossing, seed production, back crossing, tissue culturing, mutagenesis, genetic
transformation or any biotechnological process, except as specifically approved in this
Agreement.
	 
	 	2.5	 	The CERES/IGER Plant Material will be used only on fields and at premises under
the control of [Party] and identified in ANNEX I.
	 
	 	2.6	 	Upon termination of the Program, [Party] will, at the option of [CERES/IGER],
(i) allow [CERES/IGER] to remove any Plant Material and any progeny, plants, plant
material, seeds or products obtained in the Program or (ii) destroy any remaining
CERES/IGER Plant Material and any plants, plant material and seeds obtained under the
Program within fifteen (15) days from [CERES/IGER]‘s request to destroy, and will send
[CERES/IGER] forthwith an attestation of such destruction.
	 
	 	2.7	 	Subject to giving at least one day’s prior written notice in writing or by
email to [Party], [CERES/IGER] and [CERES/IGER] invitees will have the right to visit
the fields where Program activities are being conducted at any time, to make
observations and to collect samples.






	3.	 	REPORTS






	 	3.1	 	[Party] shall send [CERES/IGER] detailed written reports on the implementation
of the Program activities and the observations made and results obtained during the
implementation of the Program. The frequency of the reports and the type of
information to be included in same is set forth in ANNEX I.
	 
	 	3.2	 	During the entire Program, [Party] will promptly communicate to [CERES/IGER]
any information on the Program activities or the results obtained or observed that
[CERES/IGER] may ask. Between reports, [Party] will also spontaneously communicate to
[CERES/IGER] any unexpected observations or results.






	4.	 	REMUNERATION. PAYMENT
	 
	 	 	No remuneration will be due.






	5.	 	OWNERSHIP. INTELLECTUAL PROPERTY RIGHTS. EXPLOITATION






	 	5.1	 	This Agreement does not bring any change to the ownership and intellectual
property rights relating to the CERES/IGER Plant Material. [Party] acknowledges that
the CERES/IGER Plant Material may be covered by patents or patent applications of
[CERES/IGER].
	 
	 	5.2	 	[CERES/IGER] will exclusively own any plants, parts of plants, plant material,
seeds, information, data, technology, or other findings or inventions resulting from
the









	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 41 of 75











 






	 	 	 	Program that relate to the CERES/IGER Plant Material (hereinafter “Results”).
[CERES/IGER] will have the exclusive rights to protect any of the Results through
patents or plant variety protection rights or similar protection, and any
intellectual property rights arising therefrom will belong exclusively to
[CERES/IGER]. In case [Party] has made or contributed to any invention forming part
of the Results, [Party] shall promptly inform [CERES/IGER] thereof in writing and
shall assign its rights and cause its employees and staff members to assign their
rights in any such invention to [CERES/IGER]. [Party] shall render such assistance
as may be required for assigning any rights [Party] inventors may have in such
invention to [CERES/IGER] or [CERES/IGER]‘s designee and for protecting such
invention, including but not limited to the signing of documents. Any inventor of
[Party] will be recognized in patent applications on an invention which is part of
the Results in accordance with [U.S./U.K. patent law].
	 
	 	5.3	 	[CERES/IGER] will have the exclusive right to commercialize any of the Results.






	6.	 	CONFIDENTIALITY. PUBLICATIONS.






	 	6.1	 	[Party] will treat any and all information and material communicated or
transferred to it by [CERES/IGER] pursuant to this Agreement (including but not limited
to the CERES/IGER Plant Material) and any Results (including without limitation any
progeny, plants, seeds, parts of plants, plant material, or products obtained directly
or indirectly from the Plant Material) as strictly confidential and will not use the
same for any purpose other than as expressly allowed by this Agreement nor disclose or
transfer the same to any third party other than its employees or staff members
necessary to carry out the Program and bound by appropriate secrecy and non-use
undertakings consistent with [Party’s] obligations under this Agreement.
	 
	 	6.2	 	[Party] shall take all precautions to prevent theft or pilferage of the Plant
Material and any progeny, plants, seeds, parts of plants or plant material obtained
directly or indirectly from the Plant Material.
	 
	 	6.3	 	[Party] will not grant access to any field where Plant Material or any progeny,
plants, seeds, parts of plants or plant material obtained directly or indirectly from
the Plant Material can be viewed to any third party except with the prior written
permission of [CERES/IGER].
	 
	 	6.4	 	“Publication” and “Publish” shall include any discussion with or presentation
to a third party, other than parties referred to in Article 6.1. Examples of
Publications include, without limitation: presentation at a conference, submission for
publication to a journal, submission of joint proposals, posting information on a
website, posters, abstracts, Ph.D. dissertations, and informal oral discussions.
Subject to [CERES/IGER]‘s prior written approval, which will not unreasonably be
withheld, [Party] may proceed to Publication of selected Results provided that: (i) no
confidential information of [CERES/IGER] is revealed thereby, (ii) [Party] shall take
into account any suggestions which may be formulated by [CERES/IGER], and (iii) at
least thirty (30) days prior to the submission to a publisher or presentation to any
third party, [Party]












	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 42 of 75











 






	 	 	 	delivers copies of the proposed Publication to [CERES/IGER] for review. At
[CERES/IGER]‘s request, [Party] shall, for a reasonable period up to ninety (90) days
from initial delivery to [CERES/IGER], delay revealing any patentable subject matter
in the disclosure in order to permit the filing of patent applications. In any
Publication, the Parties shall consider joint authorship and acknowledge the
contributions and publications of the other as scientifically appropriate.






	7.	 	WARRANTIES. LIMITED LIABILITY






	 	7.1	 	[Party] acknowledges that the CERES/IGER Plant Material is of an experimental
nature and will take all reasonable precautions to prevent any damage or injury by the
CERES/IGER Plant Material and any progeny, plants, parts of plants, plant material,
seeds or products derived therefrom.
	 
	 	7.2	 	[Party] warrants that the CERES/IGER Plant Material will exclusively and
restrictedly be used under suitable containment conditions, and in accordance with all
applicable regulations, and it will not be used on human subjects. In addition,
[Party] will strictly comply with any planting distance, isolation and similar
requirements set forth in ANNEX I. [Party] will obtain any authorizations or
permits or proceed to any notifications which may be required for the Program
activities, [Party] will inform [CERES/IGER] in writing, within thirty (30) days from
the Effective Date, of any such requirements and certify its compliance with same.
	 
	 	7.3	 	[CERES/IGER] declines any liability for any damage which may be caused by the
CERES/IGER Plant Material or the Program activities or Results to [Party] or any third
party.
	 
	 	7.4	 	Neither Party shall be liable for indirect, special, remote, incidental or
consequential damages or loss of profit in connection with this Agreement or its
implementation.






	8.	 	GENERAL CONDITIONS






	 	8.1	 	Amendments: This Agreement, including its annexes, may only be amended
by a written document signed by duly authorized representatives of the Parties.
	 
	 	8.2	 	Ambiguities: In case of ambiguity between this Agreement and its
annexes, the contents of the agreement shall prevail.
	 
	 	8.3	 	Number of copies: This Agreement including its annexes is being made
in two (2) copies, one for each Party.
	 
	 	8.4	 	Assignment / Subcontracts: [CERES/IGER] has concluded this Agreement
with [Party] in view of [Party]‘s specific qualifications and [Party] shall not have
the right to assign any of its rights or obligations under this Agreement nor to
sub-contract any part of the Program activities to any third party, except with the
prior written approval of [CERES/IGER]. [CERES/IGER] has the right to assign its
rights and obligations under this Agreement to any third party. Further, [CERES/IGER]
has the right to












	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 43 of 75











 






	 	 	 	entrust the implementation of all or part of its obligations under this Agreement to
any of its affiliates.
	 
	 	8.5	 	Equitable Remedies: It is understood and agreed that money damages
would not be a sufficient remedy for any breach of this Agreement by [Party] and that
[CERES/IGER] is entitled to equitable relief, including injunction and specific
performance, as a remedy for any such breach. Such remedies shall not be deemed to be
the exclusive remedies for a breach by [Party] of this Agreement but shall be in
addition to all other remedies available at law or equity to [CERES/IGER].
	 
	 	8.6	 	Governing Law / Jurisdiction: [to be completed]






	9.	 	DURATION






	 	9.1	 	This Agreement will enter into force on the Effective Date and will remain in
full force and effect until the latest of the following dates: (i) the [third]
anniversary of the Effective Date, (ii) the date of delivery by [Party] of the last
report provided for in this Agreement, or (iii) the dates on which the last payment due
by [CERES/IGER] pursuant to this Agreement is made.
	 
	 	9.2	 	Notwithstanding Article 9.3., [CERES/IGER] will have the right to terminate
this Agreement including the Program at any time with [three (3)] months’ prior written
notice.
	 
	 	9.3	 	Either Party will have the rights to terminate this Agreement unilaterally by
registered letter addressed to the other Party in case such other Party has committed a
breach of any of its obligations under this Agreement and has failed to remedy such
breach within thirty (30) days from the receipt of a registered letter specifying the
breach.
	 
	 	9.4	 	The provisions of Articles 2.6, 5, 6, 7.3, 7.4, 8.5 and 8.6 will survive the
expiration or termination of this Agreement.




Made in two (2) copies.




	 	 	 	 	 	 	 

	[Party]	 	 	 	[Institute of Grassland and Environmental Research] or [Ceres, Inc.]
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 













	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 44 of 75











 





ANNEX I




to the Field Trial Agreement between [CERES/IGER] and [Party]




PLANTING / MANAGEMENT PLAN FOR [CERES/IGER] MISCANTHUS EVALUATION TRIAL — [Party]


Trial Scope and Purpose:



1. Planting Material



2. Program Activities



3. Content and timing of reports








	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 45 of 75











 








ANNEX
II

to the Field Trial Agreement between [CERES/IGER] and [Party]




FORM OF RECEIPT FORM



Packing Slip and Receipt Form

for material transferred pursuant to the Field Trial Agreement dated
[x] between [CERES/IGER] and [Party].


The undersigned [Party/[CERES/IGER]] signatory certifies that the material and related information
set forth hereinafter are included in the shipment with which this form is enclosed.



The undersigned [Party/[CERES/IGER]] signatory acknowledges having received in good order the
material and related information set forth hereinafter.



[Include description of material and related information.]



THIS MATERIAL AND RELATED INFORMATION ARE TRANSFERRED ONLY FOR USE IN COMPLIANCE WITH THE ABOVE
MENTIONED FIELD TRIAL AGREEMENT. CONFIDENTIALITY OBLIGATIONS APPLY.




	 	 	 	 	 	 	 
	For sending/receipt,	 	For receipt/sending,
	 
	 	 	 	 	 	 
	Signature:

	 	 	 	Signature:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	 	 	Date:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 
	 	 	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	[CERES/IGER]	 	[Party]	 	 













	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 46 of 75











 






	 	 	 	 	 

	To:

	 	Name:
	 	(the “Recipient”)
	 
	 	 	 	 
	 

	 	Organisation:
	 	(“the Recipient Institution”)
	 
	 	 	 	 
	 

	 	Address:	 	 






Material Transfer Agreement — Biological Material for Research Purposes



You have requested that the Institute of Grassland & Environmental Research (IGER) provides you
with the Biological Material listed in the Schedule. In consideration of providing the Biological
Material, IGER asks you, and you agree, to observe the following conditions, for a period of ten
years from the date hereof:





	1.	 	To use the Biological Material only for the purpose of academic research at the laboratories
of the Recipient and not in any collaboration with a third party. More specifically the
Biological Material will only be used for the following purpose:
	 
	 	 	[to be completed]
	 
	 	 	The Recipient will specifically but without limitation not use the Biological Material
for the following purposes:
	 
	 	 	Generation of plants for use in seed production to increase the volume of seed available;
generation of plants for use in any breeding or back crossing experiments; any tissue culture,
mutagenesis, genetic transformation or any biotechnological process, except if expressly defined
as the purpose of this Agreement.
	 
	 	 	The Biological Material will not be used for production of a commercial product, or for
patent purposes or for applications for plant variety rights.
	 
	2.	 	Not to provide samples of the Biological Material or samples of material extracted from or
derived from the Biological Material or any technical information relating thereto, to third
parties without specific written permission from IGER. Samples may only be provided to
members of your immediate research team, who undertake to respect these conditions.
	 
	3.	 	Not without IGER’s prior written permission (which shall not be unreasonably refused) to
disclose to any third party or publish details of the Biological Material, its manufacture or
use, or details of any other material that could not have been made but for the Biological
Material, or information on results obtained through the use of the Biological Material and to
acknowledge the source of the Biological Material in any such publication for which permission
is granted. The Recipient must provide IGER any proposed publication at least thirty (30)
days prior to submission. IGER will review such proposed publication for the need of
intellectual property protection and/or to identify any inadvertent disclosure of proprietary
information. If necessary, the Recipient agrees to (i) delay publication by no more than sixty
(60) days to enable the filing of an application for intellectual property protection and/or
(ii) remove any proprietary information identified by IGER.











	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 47 of 75











 






	4.	 	The Recipient acknowledges that the Biological Material and any material or information
obtained through the use thereof shall always remain the property of IGER. Upon completion of
the research activities defined herein, the Recipient shall, at the option of IGER, (i) return
to IGER all unused Biological Material supplied by IGER and all materials, regardless of type,
produced from the Biological Material or (ii) destroy all unused Biological Material supplied
by IGER and all materials, regardless of type, produced from the Biological Material.
	 
	5.	 	The Recipient will not obtain, and will not attempt to obtain patent coverage on the
Biological Material or on any use of the Biological Material or on any other material or
information that could not have been made or obtained but for the Biological Material.
	 
	6.	 	The Recipient agrees promptly to disclose to IGER all information relating to research
performed using the Biological Material and all information relating to any modifications or
improvements of the Biological Material or any material derived from the Biological Material.
[specific reporting obligations to be included]
	 
	7.	 	The Recipient and Recipient Institution will use the Biological Material in compliance with
all applicable laws and regulations including current health and safety guidelines for work
with recombinant DNA (if applicable) and for transport of materials and protection of the
environment. The Recipient and Recipient Institution agree to waive all claims against IGER
and to defend and Indemnify IGER from all claims and damages asserted by third parties arising
from the use, storage, handling and disposal of the Biological material by the Recipient.
	 
	8.	 	The Biological Material is experimental in nature and is provided without any warranties
express or implied, including any warranties of merchantability or fitness for any purpose.
	 
	9.	 	IGER makes no representation that the use of the Biological Material will not infringe any
patent or other intellectual property right and the Recipient hereby indemnifies IGER from and
against all actions, claims, proceedings or demands which may be brought against IGER by third
parties in respect of the infringement of any intellectual property right arising out of the
Recipient’s’ exercising of its rights under this Agreement.
	 
	10.	 	The Recipient shall ensure that its employees, officers and agents comply with the
obligations imposed upon the Recipient by this Agreement as if personally bound by such
obligations.





The Schedule




[to be completed]











	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 48 of 75











 





	 	 	 
	 

	 
	Recipient Institution:

	 	Recipient:
	 
	Signature:

	 	Signature:
	 
	Name:

	 	Name:
	 
	Position:

	 	Date:
	 
	Date:
	 	 
	 






Signed for and on behalf of IGER:




Signature:




Name: P.A. Fentem




Title: Institute Business Manager




Date:











	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 49 of 75











 





EXHIBIT D




to the Collaboration Agreement between IGER and CERES



EXTERNAL FUNDING




	•	 	Defra project NF0426 The genetic improvement of miscanthus for Biomass
	 
	 	 	1 April 2004 — 31 March 2009 — see EXHIBIT E
	 
	•	 	Energy crops in the Atlantic space: Possibilities for large scale implementation Interreg
IIIB Atlantic Area
	 
	 	 	1 January 2004 — 31 December 2007 — see EXHIBIT E
	 
	•	 	Supergen — Biomass, Biofuels and Energy Crops Consortium
	 
	 	 	1 April 2003 — 31 March 2007 — see EXHIBIT E
	 
	•	 	BBSRC project: Optimising the development of the energy grass Miscanthus through manipulation
of flowering time
	 
	 	 	1 April 2007 — 31 March 2011 — see EXHIBIT E












	 	 	 

	CERES-IGER Collaboration Agreement
	 	Page 50 of 75











 





EXHIBIT E




to the Collaboration Agreement between IGER and CERES



EXISTING AGREEMENTS


Title: Defra project NF 0426 ‘The genetic improvement of miscanthus for biomass’




Duration: 1/4/04 — 31/3/09



Partners: PRI




Scope and roles of partners





	 	1.	 	Assessment of genetic resources available in UK and elsewhere for yield, canopy
development, flowering time (IGER) overwintering and combustion quality (PRI)
	 
	 	2.	 	Hybridisation and selection based on general and specific combining ability of diploid
accessions (IGER, PRI)
	 
	 	3.	 	Hybridisation of diploid and tetraploid accessions to produce new sterile triploid
hybrids (IGER)
	 
	 	4.	 	Improvement of breeding efficiency based on early morpho-physiological prediction of
productivity and persistence and indirect measurement of chemical composition (IGER)
	 
	 	5.	 	The production of large trait mapping populations and identification of a realistic
cost effective road map to more efficient breeding through the development of
marker-assisted selection (IGER,PRI)
	 
	 	6.	 	Identification with Defra of the exploitation route in UK and Europe taking into
account expertise in large scale production and marketing (IGER,PRI)




Material and information provided and to be provided by IGER: Provision of reports on results to
Defra.



Rights of IGER and PRI on results: IP owned by Defra but now being assigned to IGER. Rights to use
of results by PRI not specified in contract.




Rights of third parties on any IGER background material/information



IGER materials from China subject to rights of GAGE in royalty sharing and in access for research
purposes.




Any exclusivity/non competition



No




Any rights of third parties on results obtained by IGER




Rights of Tinplant with respect to materials developed using their germplasm.


NOTE: any future use of Tinplant germplasm for breeding purposes will be subject to mutual
agreement of IGER and CERES.






	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 51 of 75







 









 




Title: Energy crops in the Atlantic space: Possibilities for large scale implementation
Interreg IIIB Atlantic Area



Duration: 1/1/04 — 31/12/07




Partners and roles:




Instituto Superior de Agronomia (Portugal)

Agronomy and harvesting of Cynara, Arundo, Sorghum




Associacao de Prudutores Florestias (Portugal)

Agronomy, harvesting and conversion of Cynara, Arundo and Sorghum




Universidade de Evora (Portugal)

Agronomy, harvesting of Cynara, Sorghum




Instituto Nacional de Engenharia, Tecnologia e Invacao (Portugal)

Gasification and combustion of Cynara, Arunda, Sorghum




Associacao Florestal da Galizia (Spain)

Agronomy, combustion analysis and alcohol production from Cynara, Arunda, Sorghum




Mid-South Roscommon Rural Development Company Ltd (Ireland)

Identify and monitor farm performance of biomass crops including miscanthus, reed canary grass, and willow.




IGER (UK)

Agronomy and chemical composition analysis of miscanthus. Hybrid miscanthus trials.



Scope: Analysis of technical and economic aspects of installation of Cynara cardunculus, Arundo
donax, Sorghum bicolor and miscanthus in different regions.

Conversion of biomass by burning and through conversion to alcohol




Material and information provided and to be provided by IGER



Agronomy data, hybrid trial data, chemical composition data.




Rights of parties to results



All project results to be left ‘free of all rights’




Rights of third parties on any Background



None




Any exclusivity/non competition



None




Rights of third parties on results obtained by IGR outside of agreement activities



None








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 52 of 75







 









 







Title: Supergen — Biomass, Biofuels and Energy Crops Consortium



Duration: 1/4/03 — 31.3.07



Scope: Feedstock options and meeting criteria of fuel quality for willow, miscanthus, reed canary
grass and switch grass.




Conversion and energy generation — pyrrolysis and combustion

Economics and market issues




Integration of fuel production, conversion and end use

Environmental issues




Partners and roles




University of Leeds

Combustion behaviour of buiomass




Aston University

Mass pyrrolysis for biooil




University of Sheffield

Modelling combustion processes




University of Ulster

Techno-economics of combustion and pyrrolysis




Cranfield University

Corrosion in combustion




University of Manchester

Socio-economic analysis




Rothamsted Research

Agronomy (fertilizer requirements) of reed canary grass, switch grass and miscanthus




Alston Power Ltd

Combustion




Bical Ltd

Miscanthus agronomy




E.ON UK Ltd

Combustion




Rural Regeneration Ltd

Environmental impact






	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 53 of 75







 









 




IGER




Materials and information provided by IGER



Lolium, Dactylis and Festuca material. NIRS calibrations for lignin, ADF and NDF for miscanthus
(material sourced from European Miscanthus Initiative)




Rights of IGER and other parties on results




All parties own their own Resulting IP.

Partners must make their Resulting IP available to other partners for research purposes



Subject to agreement on commercial terms partners grant each other non-exclusive license to use
their IP for commercial purposes



A partner can not unreasonably refuse access on reasonable terms to a second partner to its IP if
access is necessary for that second partner to commercialise its own IP




Rights to IGER Background




Partners may use IGER’s Background for purposes of project and for internal research purposes


IGER’s Background may be made available to another partner for commercial purposes subject to
commercial terms



IGER’s Background to be licensed on fair and reasonable terms when necessary for another partner to
commercially exploit its own Resulting IP.




Exclusivity/non competition



Should partners wish to exploit their own resulting IP with a third party (outside consortium)
during the duration of the project, that party must notify the other partners.




Ay rights of third parties/partners on results obtained outside of agreement activities



None










	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 54 of 75







 









 







Title: BBSRC project: Optimising the development of the energy grass Miscanthus
through manipulation of flowering time



Duration: 1/4/07 — 31/3/11



Scope: Identification of genes involved in flowering time of the two parents of
Miscanthus X giganteus




Roles of partners:





	 	 	IGER —  Assessment of flowering time of miscanthus populations in the
Field. Association of flowering time and senescence QTL with miscanthus
Genes. Identify miscanthus genes which are homologues of Arabidopsis,
maize and rice flowering genes. Build genetic maps around these genes
and map flowering time QTL 



Rothamsted — Assessment of flowering times of miscanthus populations in the field





Materials and information provided and to be provided by IGER:



A range of miscanthus genotypes from Japan, China and Taiwan to be characterised at field sites at
IGER and Rothamsted. M siniensis mapping family will also be assessed
at IGER and Rothamsted. IGER mapping data will be made publicly available through a database which is part of the BBSRC
cross institute programme on monocot genetics.




Rights of parties to results



Each party owns the IP on the results it produces




Rights of third parties to any background



Rights of GAGE to collection covered in GAGE agreement




Exclusivity/non competition



None




Rights of third parties on IGER results outside of agreement activities



None











	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 55 of 75







 









 








EXHIBIT F




to the Collaboration Agreement between IGER and CERES



PRODUCTION AND COMMERCIALIZATION ACTIVITIES


CERES will:





	 	1.	 	Identify growers and establish grower contracts
	 
	 	2.	 	Lease, build or buy production facility
	 
	 	3.	 	Establish quality testing capability
	 
	 	4.	 	Establish a sales force and distribution network and/or distribution
through existing distribution systems and/or establish any other commercialization
system.




CERES shall provide to IGER a detailed, written annual report on its activities in furtherance of
the obligations of this EXHIBIT, such report shall be due at or about March 31 of each year. In
addition, upon the request of IGER at any time, CERES will discuss the progress and results
achieved in regard to such activities; provided however, such contacts and discussions shall be
reasonable in frequency and duration so as not to be disruptive to the respective operations of
either Party.












	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 56 of 75







 









 








EXHIBIT G




to the Collaboration Agreement between IGER and CERES



MODEL LICENSE AGREEMENT FOR NON-TRANSGENIC VARIETIES / NON-UK



EXCLUSIVE LICENSE AGREEMENT FOR [VARIETY X]



     THIS AGREEMENT is made this ___ day of _________, 20— (“Effective Date”), by and between
INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by guarantee,
registered in England No. 473456 and a registered Charity No. 272150, having an office at Plas
Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United Kingdom and CERES, INC. (“CERES”), a Delaware
corporation, having an office at 1535 Rancho Conejo Blvd., Thousand Oaks, California 91320, United
States of America.



     WHEREAS, CERES and IGER entered into a COLLABORATION AGREEMENT, (“CA”), that contemplates a
long-term research relationship by and between the Parties for the enhancement and improvement of
COLLABORATION CROPS (as defined in the CA) for biomass crops;



     WHEREAS, CERES and IGER have jointly developed and jointly own a new MISCANTHUS variety [X]
pursuant to SCHEDULE [1] to the CA;



     WHEREAS, CERES wishes to commercialize MISCANTHUS variety [X];


WHEREAS, CERES has the ability to assume production of and to commercialize MISCANTHUS variety [X]
and wishes to receive an exclusive, world-wide license (except in the United Kingdom) to produce,
use, sell and commercially exploit MISCANTHUS variety [X];




     WHEREAS, in accordance with the provisions of the CA concerning the commercialization of
MISCANTHUS varieties jointly developed and jointly owned by the Parties under the CA, the Parties
have developed this Agreement and its terms in accordance with the terms and obligations set forth
in the CA;



     WHEREAS, CERES and IGER recognize that the rights intended to be granted hereunder can be a
strong incentive for CERES to risk money and other resources needed to produce, use, sell and
commercially exploit MISCANTHUS for wide public enjoyment;



     NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the Parties have agreed and do
hereby agree as follows:




	1.	 	DEFINITIONS.





     1.1 “MISCANTHUS” is defined as “COLLABORATION CROPS” in the CA, and such definition is
incorporated by reference herein.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 57 of 75







 









 





     1.2 “LICENSED VARIETY” shall mean the [NAME] MISCANTHUS variety jointly developed by the
Parties pursuant to SCHEDULE [1] to the CA and released, jointly by IGER and CERES, pursuant to the
terms of SCHEDULE [1].



     1.3 “VARIETY RELEASE DATE” shall mean the date the LICENSED VARIETY was released pursuant to
the terms of SCHEDULE [1].



     1.4 “TERRITORY” shall mean all countries of the world except the United Kingdom.



     1.5 “COMMERCIAL PROPAGULE” shall mean [propagules — seed — reproductive material] of
MISCANTHUS that is sold for purposes other than the production of propagating material.



     1.6 “INTELLECTUAL PROPERTY RIGHTS” shall mean all rights in any plant variety, patent, plant
breeders rights, registration or equivalent intellectual property protection, or any applications
thereof, for the LICENSED VARIETY, which may be filed in any jurisdiction in the TERRITORY, with
the exception of TRADEMARKS. INTELLECTUAL PROPERTY RIGHTS, when applied for or granted, will be
set forth in ANNEX I.



     1.7 “JOINT INTELLECTUAL PROPERTY” is defined in the CA, and such definition is incorporated by
reference herein. Any and all JOINT INTELLECTUAL PROPERTY licensed under this Agreement shall be
set forth in ANNEX I.



     1.8 “IGER INTELLECTUAL PROPERTY” is defined in the CA, and such definition is incorporated by
reference herein. Any and all IGER INTELLECTUAL PROPERTY licensed under this Agreement shall be set
forth in ANNEX I.



     1.9 “OTHER RESEARCH RESULTS” is defined in the CA, and such definition is incorporated by
reference herein.



     1.10 “BACKGROUND INTELLECTUAL PROPERTY” is defined in the CA, and such definition is
incorporated by reference herein. Any and all IGER BACKGROUND INTELLECTUAL PROPERTY licensed under
this Agreement shall be set forth in ANNEX I.



     1.11 “TRADEMARK” shall mean any trademark, trade name or logo owned by CERES and intended for
use with a LICENSED VARIETY.



     1.12 “COMMERCIAL NAME” shall mean the complete, preferred name of a LICENSED VARIETY under
which a specific LICENSED VARIETY will be marketed and sold.



     1.13 “NET SALES” shall mean the actual wholesale price for COMMERCIAL PROPAGULES of the
LICENSED VARIETY received by CERES or any AFFILIATED COMPANY for the sale of such propagules,
excluding propagating material for further production of propagating material, less any (a)
customary trade, quantity, or cash discounts; (b) amounts repaid or credited by reason of rejection
or return; (c) any sales, use, tariff, customs duties, V.A.T. and/or other taxes, duties and
similar governmental assessments (except taxes based on income); (d) outbound transportation,
shipping, packing, costs of insurance in transit paid by CERES or an AFFILIATED COMPANY; and (e)
cost of any coating materials that may have been applied to the COMMERCIAL PROPAGULES.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 58 of 75







 









 




Where there is no identifiable sale price or when a LICENSED VARIETY is sold to other than
bona fide, arms length customers of CERES or any AFFILIATED COMPANY, CERES or the AFFILIATED
COMPANY shall be deemed to have received an amount of NET SALES calculated based on the final sale
of the COMMERCIAL PROPAGULES (wholesale level) to an independent third party, usually referred to
as net wholesale price payable by dealers. If no such current price is available, a hypothetical
fair market value price will be determined by the Parties jointly in good faith for the purpose of
calculating NET SALES. Further, TRAIT FEES, if any, shall be added to NET SALES.




     1.14 “TRAIT FEE” shall mean any upfront or annual fee collected by CERES or any AFFILIATED
COMPANY in conjunction with NET SALES as an additional remuneration for the sale of COMMERCIAL
PROPAGULES that have a particular valuable non-transgenic trait or characteristic.



     1.15 “LICENSE INCOME” shall mean the amount actually received by either CERES or any
AFFILIATED COMPANY in consideration for the grant of SUBLICENSES to SUBLICENSEES that are not
AFFILIATED COMPANIES to produce and sell COMMERCIAL PROPAGULES of the LICENSED VARIETY, including
up-front fees, lump sum payments and any running royalties on a product-by-product and
jurisdiction-by-jurisdiction basis.



     *NOTE: definitions of NET SALES and LICENSE INCOME may vary in function of the business models
that may be developed



     1.16 “AFFILIATED COMPANY” shall mean any company owned or controlled by, under common control
with or controlling CERES, “control” meaning in this context the direct or indirect ownership of
more than fifty percent (50%) of the voting stock/shares of a company, or the power to nominate at
least half of the directors.



     1.17 “SUBLICENSE” shall mean any sublicense granted (a) by CERES to an AFFILIATED COMPANY or
(b) by CERES or an AFFILIATED COMPANY to any third party (“SUBLICENSEE”), as authorized by this
Agreement, to produce and sell a LICENSED VARIETY (or LICENSED VARIETIES).



     1.18 “MARKETING PLAN” shall mean a detailed written plan for production, distribution, sale
and promotion of the LICENSED VARIETY prepared by or on behalf of CERES and submitted to IGER. Each
MARKETING PLAN shall include at least the information outlined in ANNEX II. Actual, adopted
MARKETING PLANS shall be attached as further annexes to this Agreement as adopted.




	2.	 	GRANT OF LICENSE.





     2.1 IGER hereby grants CERES under IGER’S interest in any JOINT INTELLECTUAL PROPERTY and
OTHER RESEARCH RESULTS, the IGER INTELLECTUAL PROPERTY set forth in ANNEX I, and the IGER
BACKGROUND INTELLECTUAL PROPERTY set forth in ANNEX I:




	 	(a)	 	the exclusive right and license to produce COMMERCIAL PROPAGULES
of the LICENSED VARIETY in the TERRITORY, including intermediate propagation
material; and








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 59 of 75







 









 












	 	(b)	 	the exclusive right and license to use, sell and commercially
exploit the COMMERCIAL PROPAGULES of the LICENSED VARIETY in the TERRITORY.





     2.2 Sublicenses. CERES shall have the right to grant SUBLICENSES within the TERRITORY
provided that:




	 	(a)	 	The terms and obligations of any such SUBLICENSE shall be
consistent with the terms and obligations of this Agreement;






	 	(b)	 	CERES shall deliver to IGER (under an obligation of
confidentiality) a written summary of each SUBLICENSE agreement, which shall
include the name and address of the SUBLICENSEE, scope of the SUBLICENSE,
exclusive/non-exclusive status, territory, remuneration, reporting and diligence
obligations, if any. This summary shall be provided within thirty (30) days
after execution, modification or termination of the summarized agreement; and






	 	(c)	 	CERES will use commercially reasonable efforts to collect any and
all amounts due to CERES under any SUBLICENSE for the sale of COMMERCIAL
PROPAGULES of the LICENSED VARIETY.





     2.3 Nothing in this Agreement shall be construed as conferring by implication, estoppel, or
otherwise any license or rights under any INTELLECTUAL PROPERTY RIGHTS, whether owned by IGER or
licensed to IGER, other than the one(s) expressly set forth in this Agreement.




	3.	 	INTELLECTUAL PROPERTY RIGHTS.





     3.1 CERES will prepare and file, in accordance with its best judgment, any and all
applications for plant variety rights or other forms of intellectual property protection or variety
registration for the LICENSED VARIETY in the United States and/or Europe. Applications for
plant variety rights shall be filed in the joint names of CERES and IGER. At CERES’ discretion,
plant variety rights and/or other forms of intellectual property protection may be filed in any
other jurisdiction in the TERRITORY.



     3.2 If CERES intends to abandon any plant variety rights, pending or granted in any
jurisdiction, CERES shall first give sufficient written notice to IGER to permit IGER the
opportunity to assume such filing, examination and/or maintenance.



     3.3 CERES and IGER will consult with regard to INTELLECTUAL PROPERTY RIGHTS.



     3.4 The obligations of this Article 3.4 shall not apply to any jurisdictions in which CERES
has elected not to apply for intellectual property protection. CERES and IGER shall avoid carrying
out any act that would prejudice the grant of INTELLECTUAL PROPERTY RIGHTS. Without limitation,
neither Party shall make available reproductive material of the LICENSED VARIETY at a date or in a
manner that might jeopardize the right to seek INTELLECTUAL PROPERTY RIGHTS protection for the
LICENSED VARIETY. CERES, whether directly or through any SUBLICENSEE, shall not sell any propagules
of the LICENSED VARIETY until such time as the requirements for INTELLECTUAL PROPERTY RIGHTS have
been established.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 60 of 75







 









 





     3.5 CERES shall use all reasonable endeavors to ensure in any sales jurisdiction of the
TERRITORY in which INTELLECTUAL PROPERTY RIGHTS exist that all bags or containers supplied by CERES
and any SUBLICENSEE containing only propagules of such LICENSED VARIETY are clearly labeled to show
that the LICENSED VARIETY is protected by INTELLECTUAL PROPERTY RIGHTS.




	4.	 	LICENSED VARIETY CONSIDERATION.





     4.1 In partial consideration for the rights granted in this Agreement, CERES shall be
responsible for any and all fees and expenses incurred in filing, examining, certifying and
maintaining any INTELLECTUAL PROPERTY RIGHTS for the LICENSED VARIETY, subject to the provisions of
Article 3.



     4.2 In partial consideration for the rights granted in this Agreement, CERES agrees to pay to
IGER, on behalf of CERES and any AFFILIATED COMPANY, for the LICENSED VARIETY, a royalty of:




	 	4.2.1	 	on NET SALES






	 	(a)	 	[***] percent ([***]%) of NET SALES if the LICENSED
VARIETY constitutes IGER INTELLECTUAL PROPERTY, where the genotype exists
before the Effective Date of the CA, no further breeding or selection is
required after the Effective Date of the CA, and the LICENSED VARIETY is
propagated by rhizomes;






	 	(b)	 	[***] percent ([***]%) of NET SALES if the LICENSED
VARIETY constitutes IGER INTELLECTUAL PROPERTY, in all cases not included
in Article 4.2.1 (a); or






	 	(c)	 	[***] percent ([***]%) of NET SALES if the LICENSED
VARIETY constitutes JOINT INTELLECTUAL PROPERTY.






	 	4.2.2	 	on LICENSE INCOME






	 	(a)	 	[x percentage to be determined in function of the
business model] of LICENSE INCOME if the LICENSED VARIETY constitutes
IGER INTELLECTUAL PROPERTY, where the genotype exists before the
Effective Date of the CA, no further breeding or selection is required
after the Effective Date of the CA, and the LICENSED VARIETY is
propagated by rhizomes;






	 	(b)	 	[[***] x%] of LICENSE INCOME if the LICENSED
VARIETY constitutes IGER INTELLECTUAL PROPERTY, in all cases not included
in Article 4.2.2 (a); or
	 
	 	(c)	 	[[***] x%] of LICENSE INCOME if the LICENSED VARIETY constitutes JOINT
INTELLECTUAL PROPERTY.








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 61 of 75







Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission




 









 








     4.3 In addition to the royalty provided in Article 4.2, CERES agrees to pay a royalty on NET
SALES of the LICENSED VARIETY equal to the royalty due, on the basis of the Convention on
Biological Diversity, by IGER to the country or countries where the material on which the LICENSED
VARIETY is based has been collected, up to a maximum of [***] percent ([***]%) of NET SALES, and an
equivalent additional royalty on LICENSE INCOME to be determined.



     4.4 Where any royalty payments are subject to a withholding tax, CERES shall pay the net
royalty and shall provide to IGER proper certificates for such withholding tax.



     4.5 All sums payable by CERES to IGER under this Agreement shall be payable in United States
dollars. Royalties shall be payable by March 31 of each year with respect to the NET SALES and
LICENSE INCOME received by CERES and any AFFILIATED COMPANIES in the preceding calendar year.
Payments shall be made by check to the following address:


Institute Secretary

Institute of Grassland and Environmental Research

Plas Gogerddan

Aberystwyth

Ceredigion

SY23 3EB

United Kingdom




     Such payments shall be accompanied by a written report setting forth the production volumes
and sales by CERES, and each SUBLICENSEE, of COMMERCIAL PROPAGULES during the calendar year,
permitted exclusions, NET SALES, LICENSE INCOME and the royalties due.



     4.6 Payments required under this Agreement shall, if overdue, bear interest at a per annum
rate of one percent (1%) above the prime interest rate in effect on the due date, as reported in
the Wall Street Journal, from the date the payment is due until it is received.




	5.	 	DENOMINATIONS, VARIETY NAMES, TRADE MARKS.





     5.1 The Parties acknowledge that the denomination for the subject variety is established as:
[X].



     5.2 CERES shall use the denomination of the LICENSED VARIETY to identify that variety.



     5.3 CERES will determine a COMMERCIAL NAME for the LICENSED VARIETY under which the COMMERCIAL
PROPAGULES of the LICENSED VARIETY will be marketed and sold.



     5.4 CERES may determine TRADEMARK(s) associated or intended for use with a LICENSED VARIETY.
CERES shall be the owner of all rights in any such TRADEMARK, chosen, applied to, used or
registered in association with the LICENSED VARIETY.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 62 of 75






Confidential Treatment Requested and the Redacted Material has been filed separately field with the Commission

 










 






	6.	 	QUALITY AND PERFORMANCE REGULATIONS.





     6.1 CERES shall be responsible for multiplying propagating material of the LICENSED VARIETY
within the TERRITORY and using commercially reasonable efforts to produce, market and sell the
resultant COMMERCIAL PROPAGULES so as to ensure that COMMERCIAL PROPAGULES of the LICENSED VARIETY
are commercially available in the United States and/or Europe in reasonable quantities and at a
reasonable price no later than [X years — depends on propagation] from the Effective Date.



     6.2 CERES shall meet its own cost of promotion, trials and listing of the LICENSED VARIETY in
the TERRITORY.



     6.3 CERES shall use reasonable endeavors to ensure that all COMMERCIAL PROPAGULES of the
LICENSED VARIETY offered for sale by CERES, any AFFILIATED COMPANY or SUBLICENSEE shall meet the
normally accepted standards of the propagule trade or certifying authorities relating to propagule
quality within the relevant jurisdiction of the TERRITORY.



     6.4 CERES shall at all times comply with and abide by any governing law, rules, regulations,
plant variety rights legislation or the like and/or requirements relating to the quality and sale
of COMMERCIAL PROPAGULES of the LICENSED VARIETY in the relevant jurisdictions of the TERRITORY and
shall use all reasonable commercial endeavors to obtain any necessary regulatory approvals for the
LICENSED VARIETY.




	7.	 	DILIGENCE.





     7.1 CERES will use commercially reasonable efforts to actively market the LICENSED VARIETY in
the United States, and in CERES’ discretion, in other jurisdictions in the TERRITORY, wherein such
efforts shall be appropriately reflected in the MARKETING PLAN.



     7.2 This provision shall apply after the third (3rd) anniversary of the market
introduction of the LICENSED VARIETY in the United States propagated by a method that results in
the LICENSED VARIETY being commercially competitive as compared to other energy crops being grown
at that time in the United States. If IGER identifies a bona fide third party who presents a sound
commercialization plan for the LICENSED VARIETY in a country or countries of the TERRITORY where
the LICENSED VARIETY is not commercially developed by or through CERES, or an AFFILIATED COMPANY
(“COUNTRY”), IGER will refer such opportunity to CERES by written notification and CERES will
diligently investigate such opportunity. No later than one (1) year after the aforementioned
notification from IGER, CERES will inform IGER in writing whether or not CERES wishes to
commercialize the LICENSED VARIETY, directly or indirectly, in the COUNTRY. If CERES declines the
opportunity entirely, without REASONABLE GROUNDS, IGER will be granted a non-exclusive license with
the right to grant sublicenses to test, produce and sell the LICENSED VARIETY in the COUNTRY. If
CERES informs IGER in writing that CERES is planning to commercialize the LICENSED VARIETY in all
or part of the COUNTRY, directly or indirectly (whether or not through the third party identified
by IGER), and CERES has not taken reasonable steps towards the implementation of such
commercialization within two (2) years after so informing IGER, unless CERES informs IGER of
REASONABLE GROUNDS for its failure or delay





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 63 of 75







 









 




to implement commercialization plans, IGER will be granted a non-exclusive license with the
right to grant sublicenses to test, produce and sell the LICENSED VARIETY in the COUNTRY.




     “REASONABLE GROUNDS” shall mean any factors that a reasonable business person would view as
too negative to justify the market opportunity in the light of usual legal business practices in
the United States or Europe, including without limitation factors such as the risk that products
will be sold below a normal market price, the risk that dumping will occur, the risk of
cannibalization of other markets for the LICENSED VARIETY or of other products sold directly or
indirectly by CERES, poor intellectual property protection or enforcement, no propagation method
which allows the LICENSED VARIETY to be commercially competitive in that country, etc.



     7.3 CERES shall submit to IGER with its annual report under Article 4.5 a report of progress
made by CERES (and any AFFILIATED COMPANY), directly or through its SUBLICENSEES, in achieving
marketing goals of previous years and meeting the objectives of the MARKETING PLAN submitted and
agreed upon for the TERRITORY. From time to time, but at least annually, CERES shall submit an
amended and updated MARKETING PLAN.




	8.	 	BOOKS, RECORDS AND RIGHT OF AUDIT.





     8.1 CERES shall keep and shall cause any SUBLICENSEE to keep accurate records of all
production and sales of COMMERCIAL PROPAGULES of the LICENSED VARIETY in each country of the
TERRITORY where such sales are made. These records will include, at least, the number of acres of
LICENSED VARIETY COMMERCIAL PROPAGULES under production, the physical location of the LICENSED
VARIETY production field owned or controlled by CERES, any AFFILIATED COMPANY or any SUBLICENSEE,
the total amount of LICENSED VARIETY COMMERCIAL PROPAGULES produced, the total amount of LICENSED
VARIETY COMMERCIAL PROPAGULES sold and all invoices or shipping documents relating to such sales.



     8.2 CERES shall allow an independent auditor, reasonably acceptable to CERES, appointed by and
paid for by IGER to inspect the records of CERES and any AFFILIATED COMPANY pertaining to the
LICENSED VARIETY for the exclusive purpose of verifying the accuracy of the reports provided. Any
such audit shall occur no more frequently than annually. Any such inspection shall occur during
normal business hours and after IGER has provided written notice at least ten business days prior
to the date of the intended inspection. IGER agrees that it and its representatives will hold the
information obtained from the inspection in confidence, and not use it for any purpose other than
verification of the royalties required to be paid hereunder.




	9.	 	ABATEMENT OF INFRINGEMENT.





     9.1 Each Party shall notify the other of any suspected infringement of any INTELLECTUAL
PROPERTY RIGHTS covering the LICENSED VARIETY. CERES will have the exclusive right, but no
obligation, at its own discretion and expense, to take any action to enforce and to initiate and
prosecute suits for infringement of the INTELLECTUAL PROPERTY RIGHTS. CERES and IGER will consult
with each other upon a course of action and enforcement strategy. CERES will be responsible for the
conduct of any such enforcement action, and IGER will reasonably cooperate with CERES to effect the
enforcement action, and if appropriate, determine a settlement position. CERES shall be responsible
for retaining counsel and shall promptly notify IGER following





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 64 of 75







 









 




retention of counsel, and IGER agrees to be represented by such counsel as may be required for
any enforcement action or settlement. For purposes of settlement, CERES shall be the contact with
the parties’ counsel as well as the opposing party(ies) and shall have the right to enter into
settlements. CERES shall keep IGER advised as to all developments with respect to the enforcement
action and settlement discussions, which includes supplying to IGER copies of all papers received
and filed in sufficient time for IGER to comment thereon. IGER may attend any and all meetings with
the parties’ counsel and the opposing side for settlement purposes. IGER agrees to voluntarily join
in any action brought by CERES as a party plaintiff/defendant, if necessary, at the expense of
CERES. If necessary, IGER agrees to enter into a joint defense agreement.




     9.2 Any damages received by the CERES as a result of an enforcement action of the INTELLECTUAL
PROPERTY RIGHTS, after deduction of all enforcement related costs incurred by CERES, shall be
considered as either NET SALES or LICENSE INCOME for the purpose of remuneration payments to IGER,
to whichever the damages are reasonably deemed equivalent.




	10.	 	CONFIDENTIALITY.





     10.1 As used in this Agreement, the term “Confidential Information” shall mean all
non-public-information received by one Party from the other in the framework of this Agreement.
Confidential Information can include, but is not limited to, information concerning the disclosing
Party’s operations, research, processes, techniques, data, sales, marketing, promotion and other
activities.



     10.2 From receipt to five (5) years after the disclosure of the relevant CONFIDENTIAL
INFORMATION, the receiving Party shall not use, except (a) for the benefit of the Parties’
collaboration, or (b) such use as is expressly allowed by this Agreement, and/or disclose any
Confidential Information to any third party without the prior written consent of the disclosing
Party if the Confidential Information was received from the other Party, or the prior written
consent of both Parties if the Confidential Information was generated during the performance of
this Agreement, excepting that information described in Article 10.3. Confidential Information
shall only be made accessible to each Party’s employees on a need-to-know basis.



     10.3 The receiving Party shall have no obligations of confidentiality for information that:
can be established through written evidence to be in the possession of the receiving Party prior to
the disclosure by the disclosing Party; is or becomes public knowledge through no fault of the
disclosing Party; is acquired from others not under an obligation of confidentiality to the
disclosing Party. In addition, CERES shall have the right to proceed to disclosures of Confidential
Information (a) as required to file for INTELLECTUAL PROPERTY RIGHTS or registration, (b) as
required to exercise its commercialization rights granted in or on the basis of this Agreement and
for related marketing activities, (c) as required by laws, rules or regulation or court ordering
such as, without limitation, SEC regulations, or (d) in CERES’ reasonable judgment, to (potential)
investors and business partners.




	11.	 	NOTICES.





     Any notices required to be given or which shall be given under this Agreement shall be in
writing and delivered by overnight (trackable) courier addressed to the Parties as follows:





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 65 of 75







 









 




Vice President of Product Development

cc: Legal Department

Ceres, Inc.

1535 Ranch Conejo Blvd.

Thousand Oaks, California 91320

United States of America



Institute Business Manager

OR for legal or financial notices:

Institute Secretary

Institute of Grassland and Environmental Research

Plas Gogerddan

Aberystwyth

Ceredigion

SY23 3EB

United Kingdom




     Notices under this Agreement sent by overnight courier by one Party to the other Party at its
above address shall be deemed to have been given or made as of the date following the date so
mailed.




	12.	 	DISCLAIMERS.





     12.1 THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER PARTY HAS MADE ANY REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE.



     12.2 IN NO EVENT SHALL EITHER PARTY BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL
OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFIT ARISING OUT OF THE USE OF ANY INTELLECTUAL PROPERTY
RIGHTS COVERED BY THIS AGREEMENT, OR THE IMPLEMENTATION OF THIS AGREEMENT, EVEN IF SUCH PARTY IS
ADVISED IN ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES.



     12.3 Nothing in this Agreement shall be construed as:




	 	(a)	 	a warranty or representation by either Party as to the validity
or scope of any INTELLECTUAL PROPERTY RIGHTS, patent rights or plant variety
rights;






	 	(b)	 	a warranty or representation by either Party that anything made,
used, sold or otherwise disposed of pursuant to any license granted under this
Agreement is or will be free from infringement of patents of third parties;






	 	(c)	 	any obligations by either Party to bring or prosecute actions or
suits against third parties for patent infringement; and






	 	(d)	 	a grant by implication, estoppel, or otherwise of any licenses
under any intellectual property rights of IGER or other persons other than as
provided in Article 2.1 hereof.







	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 66 of 75







 









 












	13.	 	INDEMNIFICATION.





     Excluding those acts directly attributable to the negligence or willful misconduct of IGER,
CERES agrees to indemnify, hold harmless and defend IGER, its trustees, officers, employees and
agents and the breeders (as named in the INTELLECTUAL PROPERTY RIGHTS, if any) against any and all
liability and/or damages with respect to any claims, suits, demands, judgments or causes arising
out of (a) the production, development, storage, sale or any other use of the LICENSED VARIETY
propagules and/or exercise of rights granted hereunder by CERES, its SUBLICENSEES, distributors,
agents, representatives or AFFILIATED COMPANIES; (b) the use by end-users and other third parties
of LICENSED VARIETY propagules; and/or (c) any representation, warranty or statement by CERES, its
SUBLICENSEES, distributors, agents, representatives or AFFILIATED COMPANIES, concerning IGER,
LICENSED VARIETY propagules or any INTELLECTUAL PROPERTY RIGHTS. In the event any such claims,
demands or actions are made, CERES shall defend IGER at CERES’ sole expense by counsel selected by
CERES and reasonably acceptable to IGER. IGER shall promptly notify CERES, in writing, of any such
claims, suits or demands upon discovery and shall cooperate with CERES in the defense, provided
that CERES shall have the right to lead the defense including entering into any settlement. CERES
will keep IGER informed about the conduct of the defense and consult IGER regarding any settlement
proposals.




	14.	 	PUBLICITY AND USE OF NAMES.





     14.1 Neither Party shall publicize or disclose the terms of this Agreement without the prior
written approval of the other Party, subject to the same exceptions as set forth in Article 10.3(a)
through (d).



     14.2 The Parties intend to issue joint press releases regarding this collaboration. Any such
press release and any press release by either Party will be subject to the prior written approval
of both Parties; provided however, that (i) CERES shall have the right to otherwise disclose
information as may be required in CERES’ judgment to comply with SEC regulations or other laws,
rules or regulations governing disclosure of information and (ii) IGER shall have the right to
otherwise disclose information as may be required in IGER’s judgment to comply with applicable
regulations or other laws, rules or regulations governing disclosure of information.
Notwithstanding the unilateral disclosure rights provided for in this article, the disclosing Party
shall provide the other Party a copy of any such unilateral disclosure preferably prior to its
release.




	15.	 	DISPUTE RESOLUTION AND APPLICABLE LAW.





     15.1 All disputes, differences or questions arising out of or in connection with this
Agreement, or related to the alleged breach, termination, validity, interpretation or violation
thereof, shall be submitted for resolution to the Chief Executive Officer of CERES and the Director
of IGER, who shall convene, whether in person or otherwise, to resolve such dispute through
negotiation in a timely manner. Either Party may initiate a resolution procedure by providing
written notice (“Dispute Notice”) to the other Party, and any such Dispute Notice must set forth
the subject matter of the dispute, difference or question. If the dispute remains unresolved sixty
(60) days after the Dispute Notice, either Party may initiate proceedings pursuant to Article
15.2.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 67 of 75







 









 





     15.2 Dispute Resolution and Arbitration. In the event of any dispute arising out of
or in connection with this Agreement, the Parties agree to submit the matter to settlement
proceedings under the ICC ADR Rules. If the dispute has not been settled pursuant to the said Rules
within forty-five (45) days following the filing of a Request for ADR or within such other period
as the Parties may agree in writing, such dispute shall be finally settled under the Rules of
Arbitration of the International Chamber of Commerce by three (3) arbitrators appointed in
accordance with the said Rules of Arbitration. The provisions set forth hereinafter shall apply to
the arbitration procedures, without prejudice to the ICC Rules of Arbitration.




     15.2.1 Qualifications of Arbitrators. Each arbitrator appointed shall have a
reputation as being experienced in the legal and technical matters related to the dispute,
shall be required to disclose, among other disclosures, any prior involvement with the legal
and technical matters related to the dispute and any involvement with a competitor of any
Party, and shall not be presently nor in the past have been affiliated with any Party or a
competitor of any Party. Notwithstanding the method of their appointment, each arbitrator
shall be required to meet the standards contained in the Rules with respect to independence.




     15.2.2 Location of the Arbitration. The seat of arbitration shall be Paris,
France. The arbitrators may hold hearings at such other locations as the arbitrators shall
determine, after consultation with the Parties.




     15.2.3 Language of Arbitration. The arbitral proceedings and all pleadings and
written evidence shall be in the English language. Any written evidence originally in a
language other than English shall be submitted in English translation accompanied by the
original or true copy thereof




     15.2.4 Limitation on Remedies. The arbitrators are precluded from awarding
punitive or exemplary damages. In no event shall the arbitrators have the powers of an
amiable compositeur.



     15.3 Applicable law. This Agreement shall be governed by, and construed and
interpreted in accordance with, the laws of the State of New York without regard to the principles
of conflicts of law thereof.




	16.	 	TERM AND TERMINATION.





     16.1 Subject to any other rights of termination under this Article, this Agreement shall
remain in full force and effect until:




	 	(a)	 	on a jurisdiction-by-jurisdiction basis, the expiration of the
INTELLECTUAL PROPERTY RIGHTS in the respective jurisdiction covering the
LICENSED VARIETY; or






	 	(b)	 	in those jurisdictions in which the LICENSED VARIETY is sold but
no INTELLECTUAL PROPERTY RIGHTS are obtained, the tenth (10th)
anniversary of the date of the first sale of a LICENSED VARIETY in such
jurisdiction.








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 68 of 75







 









 











     16.2 Each Party shall have the right to terminate this Agreement unilaterally by giving
written notice of termination to the other Party if such other Party fails to satisfy its material
obligations, which shall include but are not limited to, making required reports and making
required payments, under this Agreement, and such Party subsequently fails to cure such failure(s)
within (a) thirty (30) days for failures to remit payment for amounts due under this Agreement and
(b) ninety (90) days for all other obligations after receipt of written notice from the
non-breaching Party specifying such failure.



     16.3 IGER will have the right to terminate this Agreement unilaterally with thirty (30) days’
written notice to CERES, (a) if CERES seeks protection under any bankruptcy, insolvency,
receivership, trust, deed, creditors arrangement or comparable proceeding or if any such proceeding
is instituted against CERES (and not dismissed within one hundred twenty (120) days) or (b) in case
of dissolution or winding up of CERES (excluding any situation where all or substantially all of
CERES’ assets, stock or business to which this Agreement relates are acquired by a third party
(whether by sale, acquisition, merger, operation of law or otherwise)).



     16.4 CERES may after consultation with IGER terminate this Agreement by written notice if in
the commercially reasonable opinion of CERES the markets for the LICENSED VARIETY change or do not
develop as anticipated, so as to render the production, promotion and sale of the LICENSED VARIETY
uneconomical or impractical or if CERES decides to cease substantially all activities in
MISCANTHUS.



     16.5 The Parties may terminate this Agreement at any time by mutual, written agreement.



     16.6 Termination of this Agreement for any reason will not relieve either Party of any
obligation or liability accrued under this Agreement before termination or rescind any payments
made or due before termination. Articles 8, 10, 11, 12, 13, 14, 15, and 17 will survive any
termination of this Agreement.



     16.7 Termination of this Agreement shall not affect the rights and obligations of the Parties
accrued prior to termination hereof.



     16.8 Upon termination of this Agreement, no existing SUBLICENSES granted by CERES or
AFFILIATED COMPANIES to third parties shall be affected by such termination, and all such
sublicenses shall remain in effect according to their terms, pursuant to the election of each
SUBLICENSEE. IGER shall continue to be entitled to payments relating to such SUBLICENSES pursuant
to this Agreement and such SUBLICENSES.



     16.9 Termination of this Agreement shall not prevent:




	 	(a)	 	IGER from recovering any royalties due as of termination; and






	 	(b)	 	either Party from obtaining a remedy for any breach of the
provisions of this Agreement.








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 69 of 75







 









 












	17.	 	GENERAL.





     17.1 Entire Agreement/Modifications. This Agreement constitutes the entire agreement
between the Parties hereto with respect to the subject matter hereof, and there are no
representations, warranties, covenants or obligations except as set forth herein. This Agreement
supersedes all prior and contemporaneous agreements, understandings, negotiations and discussions,
written or oral, of the Parties hereto relating to the subject matter hereof. This Agreement may
only be amended, modified or superseded by a writing executed by the authorized representative of
the Parties hereto.



     17.2 Severability. This Agreement, to the greatest extent possible, shall be construed
so as to give validity to all of the provisions hereof. If any provision of this Agreement is or
becomes invalid, is ruled illegal by a court of competent jurisdiction or is deemed unenforceable
under the current applicable law from time to time in effect during the term of this Agreement, the
remainder of this Agreement will not be affected or impaired thereby and will continue to be
construed to the maximum extent permitted by law. In lieu of each provision which is invalid,
illegal or unenforceable, there will be substituted or added as part of this Agreement by mutual
written agreement of the Parties, a provision which will be as similar as possible, in economic and
business objectives as intended by the Parties to such invalid, illegal or unenforceable provision,
but will be valid, legal and enforceable.



     17.3 Waiver. No failure or delay by either Party in exercising any right or remedy
under this Agreement will waive any provision of this Agreement. Nor will any single or partial
exercise by either Party of any right or remedy under this Agreement preclude it from otherwise or
further exercising any rights or remedies which it may have, or any other rights or remedies
granted by any law or any related document.



     17.4 Enforcement. In the event an action is commenced by either Party against the
other to enforce any of the provisions of this Agreement, the prevailing Party shall be entitled to
recover from the other Party reasonable attorneys’ fees, court costs and necessary disbursements
incurred in connection with such action.



     17.5 Licensor-Licensee Relationship. The relationship of the Parties is that of
independent contractors and licensor-licensee. Nothing herein is intended or will be construed to
establish any agency, partnerships, or joint ventures. Neither Party has any authority to act for
and/or to bind the other Party in any way or to represent that either is in any way responsible for
the acts of the other, except as may be explicitly provided for herein or authorized by the
non-acting Party in writing. Neither Party is authorized or empowered to act as an agent for the
other Party for any purpose, nor shall either Party be bound by the acts or conduct of the other
Party.



     17.6 Assignablility. This Agreement binds and enures to the benefit of the Parties,
their successor or assigns, but may not be assigned by either Party without the prior written
consent of the other Party; provided however, CERES shall have the right to assign its rights and
obligations under this Agreement to any AFFILIATED COMPANY without such prior consent. Each Party
shall have the right to assign its rights and obligations under this Agreement to a third party in
conjunction with the transfer to such third party of substantially all of the assets of such Party
associated with performance under this Agreement without such prior consent.





	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 70 of 75







 









 





     17.7 Force Majeure. No Party shall be responsible to the other Party for delay or
failure in performance of any the obligations imposed by this Agreement, provided such failure
shall be occasioned by fire, flood, explosion, lightning, wind storm, hailstorm, earthquake,
subsidence of soil, failure of machinery or equipment or supply of materials, discontinuity in the
supply of power, court order or governmental interference, terrorist attacks, civil commotion,
riot, war, strikes, labor disturbances, transportation difficulties, labor shortage, natural
genetic variation of any living matter or by any other cause of like or unlike nature beyond the
reasonable control and without fault or negligence of such Party.



     IN WITNESS WHEREOF, IGER and CERES have caused this Agreement to be duly executed as indicated
below.



	 	 	 	 	 	 	 

	INSTITUTE OF GRASSLAND 

AND ENVIRONMENTAL RESEARCH	 	CERES, INC.
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 
	Date:

	 	 	 	Date:	 	 
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 
	Date:

	 	 	 	Date:	 	 
	 

	 	 
	 	 	 	 







	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 71 of 75







 









 






ANNEX I 

INTELLECTUAL PROPERTY




INTELLECTUAL PROPERTY RIGHTS for the LICENSED VARIETY



JOINT INTELLECTUAL PROPERTY




IGER INTELLECTUAL PROPERTY




IGER BACKGROUND INTELLECTUAL PROPERTY








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 72 of 75







 









 








ANNEX II

MARKETING PLAN

(Article 1.18)





	1.	 	TIMING
	 
	 	 	The MARKETING PLAN is to cover a five year period and shall be reviewed annually with
adjustments made for further five year periods in line with market conditions (or
projections of the same) and the agronomic performance of the LICENSED VARIETY.
	 
	2.	 	POSITIONING
	 
	 	 	An assessment of the potential of the LICENSED VARIETY in an identified market.
	 
	3.	 	PROMOTION
	 
	 	 	Details of all project promotional activities, plus anticipated, related expenditures, that
are intended to the LICENSED VARIETY achieves its maximum market potential.
	 
	4.	 	DISTRIBUTION
	 
	 	 	Details of the proposed distribution network and activities for supporting the distributor
or retailer plus anticipated promotion activities of the distributor/retailer. NOTE: If the
anticipated distribution network includes the creation of a new COMMERCIAL PROPAGULES
company, details regarding this important component should be included here.
	 
	5.	 	EVALUATION
	 
	 	 	Details of planned evaluation and demonstration, if any.
	 
	6.	 	PROTECTION
	 
	 	 	Anticipated intellectual property protection requirements.
	 
	7.	 	COMMERCIAL PROPAGULES SALES
	 
	 	 	Estimated sales including grade of COMMERCIAL PROPAGULES, volume and price and country of
destination.
	 
	8.	 	ROYALTY INCOME






	 	a.	 	Estimated royalty payments; and
	 
	 	b.	 	Commencement date of payment.






	9.	 	COMMERCIAL PROPAGULES PRODUCTION
	 
	 	 	Estimated production, including grade of COMMERCIAL PROPAGULES, land area to be sown,
estimated production and harvest date.








	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 73 of 75







 









 











EXHIBIT H




to the Collaboration Agreement between IGER and CERES



CERTAIN REMUNERATION PRINCIPLES


1. If CERES uses germplasm that is IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL
PROPERTY or JOINT INTELLECTUAL PROPERTY to develop varieties of the COLLABORATION CROP outside the
RESEARCH PROJECTS, the following guiding principles will apply to determine the remuneration due to
IGER by CERES upon commercialization of such varieties:





1.1 Royalty on NET SALES (defined as in EXHIBIT H) of varieties resulting from
crosses of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY germplasm
with CERES or third party or public germplasm:




1.1.1 if the variety contains equal to or less than one hundred percent (100%) but
more than seventy-five percent (75%) of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND
INTELLECTUAL PROPERTY germplasm where said germplasm’s genotype exists before the
Effective Date of the CA, no further breeding or selection is done in any RESEARCH
PROJECT and the variety is commercialized by rhizomes: [***] percent ([***]%)




1.1.2 if the variety contains equal to or less than one hundred percent (100%) but
more than seventy-five percent (75%) of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND
INTELLECTUAL PROPERTY germplasm in all cases not included in 1.1.1: [***] percent
([***]%)




1.1.3 if the variety contains equal to or less than one hundred percent (100%) but
more than seventy-five percent (75%) of JOINT INTELLECTUAL PROPERTY germplasm: [***]
percent ([***]%)




1.1.4 if the variety contains equal to or less than seventy-five percent (75%) but
more than twenty-five percent (25%) of IGER INTELLECTUAL PROPERTY or IGER BACKGROUND
INTELLECTUAL PROPERTY germplasm: [***] percent ([***]%)




1.1.5 if the variety contains equal to or less than seventy-five percent (75%) but
more than twenty-five percent (25%) of JOINT INTELLECTUAL PROPERTY germplasm: [***]
percent ([***]%)




1.1.6 if the variety contains twenty-five percent (25%) or less IGER INTELLECTUAL
PROPERTY or IGER BACKGROUND INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY
germplasm, but contains one (1) TRAIT that has been introduced through crossing from
such germplasm: [***] percent ([***]%); if two (2) or more TRAITS introduced through
crossing from such germplasm: [***] percent ([***]%)







	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 74 of 75








Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission



 









 









1.1.7 in cases other than 1.1.1 through 1.1.6 no remuneration will be due (except if
clause 2 hereinafter applies).




	 	 	“TRAIT” shall mean a valuable characteristic of a plant selected by CERES (e.g. drought
tolerance, specific flowering time) where at least seventy percent (70%) of such
characteristic is associated with no more than two (2) identified markers.
	 
	 	 	1.2 Royalty on LICENSE INCOME (defined as in EXHIBIT H) — to be determined in
function of business model.




2. If CERES uses IGER INTELLECTUAL PROPERTY or JOINT INTELLECTUAL PROPERTY other than germplasm to
develop a product, a fair and reasonable remuneration will be due by CERES to IGER, taking into
account the relative contributions of the Parties to the research, development, production,
marketing and sales of the product. Upon CERES’ request, the Parties will negotiate diligently and
in good faith to determine such remuneration for one or more particular inventions or products.



3. Duration of royalty payments will be similar to what is provided in the model license agreement
for non-transgenic varieties (non-UK) in EXHIBIT G.







	 	 	 

	CERES-IGER Collaboration Agreement

	 	Page 75 of 75







 













 





AMENDMENT I



to the Collaboration Agreement effective as of April 1, 2007 between Institute of Grassland and
Environmental Research (“IGER”) and Ceres, Inc. (“CERES”) (the “Agreement”).





	 	1.	 	The Parties agree to replace “sixty (60) days” by “two hundred ten (210) days” in
Article 14.1 (e) (v) of the Agreement.
	 
	 	2.	 	The Parties agree that this Amendment I is effective as of June 1, 2007.
	 
	 	3.	 	For the remainder, the Agreement remains unchanged and this Amendment I shall form an
integral part thereof.




Made in two (2) copies.






	 	 	 	 	 	 	 	 	 	 	 

	INSTITUTE OF GRASSLAND AND ENVIRONMENTAL  RESEARCH

	 	 	 	CERES, INC.	 	 
	 
	By:

	 	/s/ Mervyn Humphreys	 	 	 	By:	 	/s/ Richard Flavell	 	 
	Name:

	 	 

Professor Mervyn Humphreys
	 	 
	 	Name:
	 	 

Richard Flavell, CBE, FRS
	 	  
	Title:

	 	Director
	 	 	 	Title:
	 	Chief Scientific Officer	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By:	 	/s/ Richard Hamilton	 	 
	 

	 	 	 	 	 	Name:
	 	 

Richard Hamilton
	 	 
	 

	 	 	 	 	 	Title:
	 	President and Chief Executive
Officer	 	 






Page 1 of 1 









 





AMENDMENT II



to the Collaboration Agreement effective as of April 1, 2007 between the Institute of Grassland and
Environmental Research (“IGER”) and Ceres, Inc. (“CERES”), as amended (the “Agreement”) and to
SCHEDULE 1 between the Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc.
(“CERES”) and dated April 1, 2007, as amended (“Schedule 1”).




          WHEREAS, the Institute of Grassland and Environmental Research (“IGER”) and CERES entered into
the Agreement and Schedule 1 on April 1, 2007;




          WHEREAS, on April 1, 2008 IGER merged with Aberystwyth University Institutes of Biological
Sciences and Rural Sciences to form the new Institute of Biological, Environmental and Rural
Sciences of Aberystwyth University (“AU”);




          WHEREAS, as a consequence of such merger, the Parties wish to substitute AU in place of IGER
as a contract party to the Agreement;




          WHEREAS, AU and CERES wish to amend the Agreement, as set forth hereinafter.




          NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the Parties have agreed and do
hereby agree as follows:





	 	1.	 	The Parties agree that Aberystwyth University, a Higher Education Establishment
registered in the United Kingdom No. RC000641, having an office at Old College, King
Street, Aberystwyth SY23 2AX (“AU”) should be substituted as a contract party to the
Agreement in place of IGER.
	 
	 	2.	 	The Parties agree to amend Article 14.1 (e) (v) of the Agreement so as to read as
follows:
	 
	 	 	 	“(v) with thirty (30) days’ written notice to AU if Defra has not assigned
to AU, or granted to AU a license reasonably satisfactory to CERES on, the
Intellectual Property vested in Defra or the Crown or the Secretary of State
pursuant to the DEFRA agreement NF 0426 within three (3) years from the
Effective Date (the “Assignment/License”); provided however that Ceres will not
unreasonably refuse to extend such three (3) year term by six (6) months if so
requested by AU by December 31, 2009.”
	 
	 	3.	 	The Parties agree to add the following clause in Article 6 of Schedule 1:
	 
	 	 	 	“As long as the assignment or license grant by Defra to AU, and the
corresponding grant of a license or sublicense to CERES in compliance with
the Agreement, has not occurred, CERES will have the right to withhold [***]





Page 1 of   2 



Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission








 






	 	 	 	percent ([***]%) of the funding payable by CERES to AU pursuant to Attachment B —
Budget, attached to Schedule 1 (as this may be amended from time to time).
CERES’ rights to withhold such payments will terminate:






	 	(i)	 	with respect to [***] percent ([***]%) of the funding,
as of the date CERES effectively receives a license or sublicense
satisfactory to CERES on CERTAIN MISCANTHUS ACCESSIONS (defined in
Article 3.2.1 b. of the Agreement) and related information.
	 
	 	(ii)	 	with respect to [***] percent ([***]%) of the funding as
of the date CERES effectively receives a license or sublicense
satisfactory to CERES on the Intellectual Property vested in Defra or
the Crown or the Secretary of State pursuant to the Defra agreement
NF0426.”






	 	4.	 	The Parties agree that this Amendment II is deemed to have become effective as of May
1, 2008.
	 
	 	5.	 	For the remainder, the Agreement and Schedule 1 remain unchanged and this Amendment II
shall form an integral part thereof.




Made in two (2) copies.









	 	 	 	 	 	 	 	 	 	 	 

	ABERYSTWYTH UNIVERSITY 

	 	 	 	CERES, INC.	 	 
	 
	By: 

Name:

	 	/s/ S.G.A. Durbin
 

S.G.A. Durbin
	 	 
	 	By:

Name:
	 	/s/ Richard Flavell
 

Richard Flavell, CBE, FRS
	 	 
	Title:

	 	Director, Risk & Research Finance
	 	 	 	Title:
	 	Chief Scientific Officer	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By:

Name:
	 	/s/ Richard Hamilton
 

Richard Hamilton
	 	 
	 

	 	 	 	 	 	Title:
	 	President and Chief
Executive Officer	 	 







Page 2 of 2 






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 




Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].




SCHEDULE
1—Plant Breeding, Markers, Composition, Agronomy and Propagation



THIS SCHEDULE is made this 1st day of April, 2007.




	 	 	 

	BETWEEN

	 	CERES, INC. (“CERES”), a Delaware corporation,
having its principal place of business at 1535
Rancho Conejo Blvd., Thousand Oaks, CA 91320,
United States of America, and
	 
	 	 
	 

	 	INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH (“IGER”), a company limited by
guarantee, registered in England No. 473456 and a registered Charity No. 272150,
having an office at Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, United
Kingdom





WHEREAS, CERES and IGER have entered into a Collaboration Agreement (“CA”), dated April 1, 2007,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being
defined in the CA; and



THEREFORE, the Parties have agreed to undertake the following RESEARCH PROJECT as defined herein on
the following terms and conditions:



GENERAL





	A.	 	Unless otherwise specified herein, the terms of the CA shall apply to this SCHEDULE.
	 
	B.	 	In the event of any difference between the terms of this SCHEDULE and the CA, then the terms
of this SCHEDULE shall prevail.





RESEARCH
PROJECT TITLE: Developing Miscanthus Cultivars for Use in
Bioenergy Production




     Development of Miscanthus Species for Energy Crops — Scientific Overview



     Miscanthus species are capable of producing large quantities of biomass with minimal inputs
over a wide geographic range. CERES and IGER aim to develop commercial biomass crops from leading
Miscanthus lines via a collaboration with 2 major foci: I)
propagation; and II) breeding. These are
described in turn below.



I.
Propagation.





	I.A.	 	 Rationale:





     The
major barrier to profitable Miscanthus cropping is efficient and
inexpensive propagation. In
the UK, subsidy support makes [***]of Miscanthus x giganteus an economically viable planting method.
This is not the case in [***], where there is no government support for the crop and initial [***]
from which to generate planting material is extremely limited.



     It
is not commercially feasible to produce Miscanthus on a large scale in [***] from traditional
[***] schemes. Success of Miscanthus crops for large markets will be determined by development of


CERES-IGER SCHEDULE 1




Page 1 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 







cost-effective
propagation technology, and the magnitude of success depends on the speed with which
this technology can be developed.



All other lines of crop development research in this collaboration will be dependent on success
with propagation.




     To be successful,
Miscanthus must be planted from small, homogenous propagules that can be cheaply
and rapidly produced, flow-ably transported, stored for months and consistently emerge after
planting. In theory, the best propagule for Miscanthus production
is seed. However, propagation of Miscanthus
from seed is complicated and difficult. Development of [***] Miscanthus varieties will be a [***] of the
[***] of this collaboration.



     An
alternative approach to seed in the short term is to [***] Miscanthus from [***]as is
common in [***]. [***] is more feasible with decreasing [***] and has not been thoroughly explored
in Europe. The potential of [***] should be investigated from both an applied and basic perspective.
It was agreed that while the approach is more likely to work in [***], it should also include x
[***] and at least initially [***].



     Development
of [***] and [***] techniques for [***]
Miscanthus cropping systems will utilize a combination of
theoretical and applied methods in the lab, glasshouse and field.




	I.B.	 	 Goal: Applied methods for effective [***] of
Miscanthus hybrids.






	 	 	 	I.B.i. Objective 1: Identify [***] techniques and
optimize them with existing hybrids.
	 
	 	 	 	Methods: Screen [***], x [***] and other
species at least initially for [***] ability with
multiple techniques in a broad range of factorial field and glasshouse experiments.
Glasshouse experiments can be conducted year-round at IGER and at CERES in Thousand Oaks,
CA. Additional experiments may be conducted at other CERES locations added at a later date.
Field experiments will be conducted [***] at IGER and begin in multiple locations in [***]
during the three (3) year period of this SCHEDULE.
	 
	 	 	 	I.B.ii. Objective 2: More basic genetic and physiological work aimed at characterising
and understanding [***].
	 
	 	 	 	Methods: A series of experiments into the [***] of [***] with a focus on inducing plant
growth from [***] ([***] and [***]) [***]. Work should explore [***] cues ([***], [***],
[***]) as well as [***] ([***]). Explore [***] and score in [***] if possible,
to locate [***]. Evaluate candidate [***] (from Arabidopsis, [***] if possible and other
species) promoting [***] frequency.






	I.C.	 	 Goal: Applied methods for effective [***] of
Miscanthus hybrids.






	 	 	 	I.C.i. Objective 1: Demonstrate potential of [***] and create protocols.
	 
	 	 	 	Methods: Check [***] of [***] and [***] of a wide range of [***] in response to [***] and
[***] with a combination of [***], glasshouse and finally field experiments. Interpret
results in context of [***] range, genotype and [***] conditions under which the [***] was
[***]. Produce guidelines for effective [***] and [***].






	I.D.	 	 Goal: [***] based systems for rapid
[***] of germplasm and plants to be used in [***].




CERES-IGER SCHEDULE 1





Page 2 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 









	 	 	 	I.D.i. Objective 1: Provide plants for [***] based [***].
	 
	 	 	 	Methods: [***] plants using clean systems for shipment to [***] in accordance with
international regulations.
	 
	 	 	 	I.D.ii. Objective 2: Investigate [***] in [***] of lines potentially useful in
breeding, including hybrids.
	 
	 	 	 	Methods: Evaluate the [***] capacity of breeding line candidates in response to standard or
improved [***] techniques.
	 
	 	 	 	I.D.iii. Objective 3: Develop estimates of time and cost required to [***] plants in [***]
based systems.
	 
	 	 	 	Methods: Conduct a desk study to compare the costs/benefits and barriers associated with
large scale [***] methodology including [***].






	I.E.	 	 Goal: Proof of Concept field trials of research findings in target locations.






	 	 	 	I.E.i. Objective 1: Evaluate and optimize propagation
techniques under commercially relevant conditions.
	 
	 	 	 	Methods: Use IGER and CERES infrastructure for field trialing methods in the UK and at
multiple locations in [***] and elsewhere. These should expand on research performed at
IGER and test genotype by environment interactions, with a focus on
potentially commercial genotypes.
	 
	 	 	 	I.E.ii. Objective 2: Evaluate and optimize germplasm performance in the UK and in multiple
[***].
	 
	 	 	 	Methods: Use IGER and CERES infrastructure for field trialing at multiple locations in the
UK, [***] and elsewhere. These should expand on research performed at IGER and test
genotype by environment interactions with a focus on potentially
commercial genotypes.





II.
Breeding





	II.A.	 	  Rationale:





     Miscanthus is an unimproved plant species with great potential as an energy crop. [***] has
not yet been fully collected and characterized. Miscanthus species
are capable of crossing with [***] —
a characteristic that has long been exploited in [***]
where Miscanthus germplasm is used to [***].
The use of Miscanthus for biomass is a relatively new area, thus
initial collection and evaluation of
germplasm may discover lines already suited to the commercial market, and will certainly provide the base
for the breeding needed to develop [***] into dedicated
bioenergy crops. This breeding programme
will employ traditional methodology to [***] and
[***] for traits of interest. Molecular markers
will be developed to assist identification of traits and expedite development of elite lines. Major
traits of interest include increased biomass production, altered
composition for improved conversion to fuel, tolerance
and seed suitable to produce [***] ([***]) [***].


As lines
with commercial potential are identified they will be selected for direct field trialing at
IGER and/or at CERES locations in [***] to speed up
commercial variety development.





	II.	 	B. Goal: A complete and documented Miscanthus [***].




CERES-IGER SCHEDULE 1




Confidential Treatment Requested and the Redacted Material 
has been separately filed with the Commission




Page 3 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






	 	 	 	II.B.i. Objective 1: [***] to [***] in [***].
	 
	 	 	 	Methods: In accordance with international conventions, e.g., the Convention on Biodiversity
(CBD), [***] Miscanthus [***] from the [***] of [***]. Document the phenotype and growing [***],
using [***] to accurately record the [***]. [***] to [***] for [***] and subsequent
phenotype documentation.
	 
	 	 	 	II B.ii. Objective 2: Characterize full [***].
	 
	 	 	 	Methods: Document the morphological, physiological and [***] of interest in the [***] using
consistent phenotyping nomenclature and [***] compositional analysis. Develop molecular markers
associated with phenotypic traits.
	 
	 	 	 	II.B.iii. Objective 3: Assess relatedness of plants
identified as useful parents for hybrids.
	 
	 	 	 	Methods: Use molecular markers developed for traits of
interest in combination with germplasm characterization data,
particularly [***], to select parents with desired traits that are also
likely to present [***].
	 
	 	 	 	II.B.iv. Objective 4: Develop a dynamic warehouse to store data and develop systems to
analyse data and support multidisciplinary collaborative research.
	 
	 	 	 	Methods: IGER and CERES to consider best options for developing the database. Populate the
database with the [***] and [***] information
[***]. As germplasm is characterized, integrate
phenotype and marker data and use to facilitate choice of promising [***] lines as well as
inform the preparation needed to ensure [***] (e.g. [***]). As data become available from
other components of the collaborative research, such as field
trialing and conversion analysis,
it will be added to the database to allow PIs to synergistically design next step
experiments.






	II.C.	 	   Goal: Improved Miscanthus hybrids for
commercial use.






	 	 	 	II.C.i. Objective: Select improved parents.
	 
	 	 	 	Methods: [***] within [***] using
information from molecular markers and composition analysis to
shorten and streamline the selection of parents. Cross between
[***] and evaluate hybrids to
identify improved parents.
	 
	 	 	 	II.C.ii. Objective: Make crosses of selected [***] lines.
	 
	 	 	 	Methods: Appropriate germplasm will be selected for crossing using the database decision tool.
Plants will be [***] to [***] in glasshouses and [***] made both in the glasshouse and
outdoors at IGER, depending on time of year. Improve efficiency of [***] and, for [***],
[***]. Determine [***] — and
[***]. Send seed of [***] candidates and [***] to CERES
locations for trialing.
	 
	 	 	 	II.C. iii Objective: Selection of superior [***].
	 
	 	 	 	Methods: [***] will be transplanted to field.
Important morpho-physiological traits will be
recorded over [***] years after which the best genotypes will be selected, [***] and [***]
into rhizomes. The value of early prediction of traits will be assessed. A mass selection
reservoir (MSR) will be maintained as a safety net and to contain interesting genotypes that
do not justify commercial development.





CERES-IGER SCHEDULE 1





Page 4 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






	 	 	 	II.C.iv. Objective: Field evaluation of hybrids.
	 
	 	 	 	Methods: From rhizomes taken in iii, replicated trials will be established. After [***] (or
[***]) years, the best genotypes will be provided to CERES to test at diverse locations for
commercially relevant evaluation.






	 	 	 	II D. Goal: Improved Miscanthus Varieties.
	 
	 	 	 	II.D.i. Objective: Explore new methods of breeding.
	 
	 	 	 	Methods: Set up and test [***] in terms of [***] and [***]. Set up
and test [***] in terms of [***] and [***] to determine whether
[***] will be acceptable. The results will guide applications for the setting up of Plant
Breeders’ Rights schemes.






	3.	 	RESEARCH AND DEVELOPMENT PLAN






	 	 	The RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE) contains:






	 	•	 	Research and evaluation activities to be performed by each Party in
detail, including locations for such activities
	 
	 	•	 	Timelines of such activities
	 
	 	•	 	Goals, expected results and deliverables
	 
	 	•	 	Milestones and go/no-go decision points, if applicable
	 
	 	•	 	FTEs






	4.	 	LOCATION OF WORK:






	 	 	IGER Work:
	 
	 	 	IGER laboratory and glasshouse facilities and properties at its Welsh location and potential
subcontractor locations.
	 
	 	 	CERES Work:
	 
	 	 	Thousand Oaks, CA and potential subcontractor locations.
	 
	5.	 	PHD LEVEL SCIENTIFIC STAFF:
	 
	 	 	Dr. John Clifton-Brown (IGER)

Dr. Iain Donnison (IGER)
	 
	 	 	Dr. Richard Flavell (CERES)

Dr. Bonnie Hames (CERES)

Dr. Emily Heaton (CERES)

Dr. Peter Mascia (CERES)

Dr. Steve Thomas (CERES)
	 
	 	 	The Parties agree to complete this list within three (3) months from the commencement date
of this SCHEDULE.




CERES-IGER SCHEDULE 1





Page 5 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 









	6.	 	FUNDING APPROVED:
	 
	 	 	See attached Budget (Attachment B).
	 
	7.	 	REPORTS:
	 
	 	 	All reports shall be delivered to the MANAGEMENT COMMITTEE on or before the required
delivery dates for the same.
	 
	 	 	IGER and CERES will deliver at each quarterly MANAGEMENT COMMITTEE meeting (or annual
meeting, as the case may be):






	 	•	 	Quarterly status update and FTE breakout based on attached planning
document.
	 
	 	•	 	Actual spending relative to budget.
	 
	 	•	 	INTELLECTUAL PROPERTY generated during the period.
	 
	 	•	 	Copies of slide presentations summarizing research progress (template
attached as Attachment C to this SCHEDULE).
	 
	 	•	 	Annual Report (compilation of slide presentations and quarterly
minutes) (annual meeting).






	 	 	Additional information, if not specifically included in the delivered information (above),
shall be delivered (or later provided, wherein the delivering Party shall indicate the
delivery method and time) as supporting information at the related quarterly meeting, if
available:






	 	•	 	Breeding records.
	 
	 	•	 	Copies of field or glasshouse books and records.
	 
	 	•	 	Copies of raw field trial data.
	 
	 	•	 	Biological material, including [***] lines from
crosses and/or [***].






	8.	 	REPORT DATES:
	 
	 	 	Annual report: Due at annual meeting in January.
	 
	 	 	Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT
COMMITTEE per the CA (e.g., April, July, October, January).
	 
	9.	 	SUBCONTRACTORS AND LOCATIONS:
	 
	 	 	Actual locations and work at the locations will be decided by the MANAGEMENT COMMITTEE at
the quarterly meetings.
	 
	10.	 	MAJOR CONSUMABLES TO BE PURCHASED:
	 
	 	 	None designated at the commencement date of this SCHEDULE.
	 
	11.	 	ASSETS:




CERES-IGER SCHEDULE 1




Page 6 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 









	 	 	Not applicable.
	 
	12.	 	INSURANCE:
	 
	 	 	Not applicable.
	 
	13.	 	INTELLECTUAL PROPERTY RIGHTS:






	13.1	 	IGER Background Intellectual Property:






	 	 	See Attachment D. The Parties agree that Attachment D will be worked out in
more detail and completed within thirty (30) days of the commencement date of this SCHEDULE.






	 	13.2.	 	CERES Background Intellectual Property:






	 	•	 	Molecular markers
	 
	 	•	 	Genome sequence information
	 
	 	•	 	[***]
	 
	 	•	 	[***] information
	 
	 	•	 	Proprietary software






	14.	 	USE AND COMMERCIALIZATION RIGHTS:
	 
	 	 	Controlled by CA. License agreements for non-transgenic varieties developed pursuant to
this SCHEDULE 1 will be based on the Model License Agreement for Non-transgenic Varieties in
EXHIBIT G to the CA.
	 
	15.	 	CONFIDENTIALITY/PUBLICATION:
	 
	 	 	Controlled by CA.
	 
	16.	 	COMMENCEMENT/TERM:
	 
	 	 	Commencement: April 1, 2007
	 
	 	 	Term: Three (3) years provided however, at least one (1) year before the end of the
term of this SCHEDULE, the Parties shall decide whether to extend it for one (1) or more
years, with appropriate updates to the RESEARCH AND DEVELOPMENT PLAN (Attachment A),
and FUNDING (Article 6 of this SCHEDULE).
	 
	17.	 	PROVISIONS FOR EARLY TERMINATION:
	 
	 	 	This SCHEDULE does not terminate automatically upon termination of the CA.




CERES-IGER SCHEDULE 1





Page 7 of 10





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 









	 	 	This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the Parties, or unless sooner terminated in accordance with the
following provisions of this Article:






	 		 	(a) mutual, written agreement of the Parties;






	 		 	(b) failure of one Party to satisfy its material obligations under this SCHEDULE, and
such Party subsequently fails to cure such failure(s) within (i) thirty (30) days for
failures to remit payment for amounts due under this SCHEDULE and (ii) ninety (90) days
for all other obligations in each case after receipt of written notice from the
non-breaching Party specifying such failure(s);
	 
	 		 	(c) one (1) year’s written notice of termination by either CERES or IGER to the other
Party in case either the terminating Party or the other Party ceases substantially all
activities in the COLLABORATION CROPS;
	 
	 		 	(d) IGER will have the right to terminate this SCHEDULE unilaterally with thirty (30)
days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy,
insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or
if any such proceeding is instituted against CERES (and not dismissed within one hundred
twenty (120) days); (ii) in case of dissolution or winding up of CERES (excluding any
situation where all or substantially all of CERES’ assets, stock or business to which
the CA relates are acquired by a third party (whether by sale, acquisition, merger,
operation of law or otherwise)); (iii) with written notice to CERES, if CERES has failed
in a substantial manner, three (3) years after either Party or the Parties jointly have
developed a [***] method for Miscanthus that results in the
crop being commercially competitive
in the United States or in Europe as compared to other energy crops being grown at that
time in the relevant geography, to implement the activities set forth in EXHIBIT
F to the CA, and does not remedy such failure or offer a remediation plan which is
reasonably acceptable to IGER within ninety (90) days after receipt of a written notice
from IGER specifying such failure;
	 
	 		 	(e) CERES will have the right to terminate this SCHEDULE unilaterally: (i) with thirty
(30) days’ written notice to IGER if John Clifton-Brown or Iain Donnison cease(s) to be
associated with IGER and the research activities associated with this SCHEDULE, and IGER
has not replaced such person(s) within one hundred twenty (120) days by (a) person(s)
reasonably acceptable to CERES; (ii) with ninety (90) days’ written notice to IGER, if
the institutional mission, purpose, structure or funding of IGER would change
substantially and adversely affect IGER’s ability to satisfy its obligations hereunder;
(iii) with one (1) years’ written notice to IGER, if CERES has a documented compelling
business reason to cease the collaboration, (for example, without limitation, lack of
sufficient processing capacity for COLLABORATION CROPS within the expected timeframe in
the United States; COLLABORATION CROPS are non-competitive with other biomass sources);
(iv) with three (3) months’ prior written notice to IGER, such notice to be given no
earlier than eighteen (18) months after the Effective Date of the CA, if no rights to
commercialize (including determination of the compensation due upon commercialization)
COLLABORATION CROPS germplasm provided by IGER which is included in the RESEARCH PROJECT
covered by this SCHEDULE have been




CERES-IGER SCHEDULE 1





Page 8 of 10




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 









	 	 	 	secured to CERES’ reasonable satisfaction in compliance with the CBD; or (v) with thirty
(30) days’ written notice to IGER if Defra has not assigned to IGER, or granted to IGER
an exclusive license reasonably satisfactory to CERES on, the Intellectual Property
vested in Defra or the Crown or the Secretary of State pursuant to the DEFRA agreement
NF 0426 within sixty (60) days from the Effective Date (the “Assignment/License”),
provided however that such termination may be for the entirety of this SCHEDULE or only
for certain parts of the RESEARCH PROJECT covered by this SCHEDULE.






	18.	 	SPECIAL CONDITIONS:






	 	18.1	 	VARIETY RELEASE






	 		 	18.1.1 “RELEASE DATE” shall mean the date that CERES determines that a variety
developed, tested and evaluated pursuant to the terms of this SCHEDULE is ready for
release, wherein upon such decision, such variety will be formally released by IGER
and CERES jointly (if the variety constitutes JOINT INTELLECTUAL PROPERTY) or by
IGER (if the variety constitutes IGER INTELLECTUAL PROPERTY) or by CERES (if the
variety constitutes CERES INTELLECTUAL PROPERTY).
	 
	 	 	 	18.1.2 For the purposes of this SCHEDULE, CERES, on advice of the breeder(s) of each
variety via the MANAGEMENT COMMITTEE, shall establish, in its sole discretion, an
appropriate RELEASE DATE for such varieties.
	 
	 		 	18.1.3 At or about the RELEASE DATE for a variety, CERES will determine a COMMERCIAL
NAME for such variety under which the seed of the same will be marketed and sold.
“COMMERCIAL NAME” means the complete, preferred name of a released variety under
which it will be marketed and sold.
	 
	 		 	18.1.4 The Parties agree that the development of new varieties will not always
result in varieties that are commercially acceptable or releasable. Provided all
Parties execute their respective obligations under this SCHEDULE in an appropriate
and reasonable manner, no one Party shall be liable to the other for any refund or
other recompense because no commercially acceptable new variety is produced.






	 	18.2	 	BBSRC project: Optimizing the development of the energy grass Miscanthus
through manipulation of the flowering time.






	 	 	 	Reference to this project (“BBSRC grant”) is included in EXHIBIT E to the
CA.
	 
	 	 	 	The RESEARCH AND DEVELOPMENT PLAN in Attachment A hereto refers to certain
activities to be conducted by IGER pursuant to the BBSRC grant. The Parties
expressly acknowledge and agree that:







CERES-IGER SCHEDULE 1



Page 9 of 10




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 












	 	(i)	 	the results of such activities shall constitute
IGER INTELLECTUAL PROPERTY, and
	 
	 	(ii)	 	IGER may make certain data resulting from such
activities publicly available in compliance with the BBSRC grant.




IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered.




	 	 	 	 	 	 	 

	INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH	 	CERES, INC.
	 
	 	 	 	 	 	 
	By:

	 	/s/ M. Humphries
	 	By:
	 	/s/ Richard Flavell
	 	 	 
	 	 	 	 
	Name: Professor Mervyn Humphreys
	 	Name: Richard Flavell, CBE, FRS
	Title: Director
	 	Title: Chief Scientific Officer
	 
	 	 	 	 	 	 
	 

	 	 	 	By:
	 	/s/ Richard Hamilton
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Richard Hamilton
	 

	 	 	 	Title: President and Chief
Executive Officer






CERES-IGER SCHEDULE 1



Page 10 of 10











 





     





			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Breeding Project Plan









	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	A	 	 	B	 	 	 	 	 	C	 	 	D	 	 	E	 	 	F	 	 	G	 	 	H	 	 	I	 	 	J	 	 	K	 	 	L	 	 	M	 	 	N	 	 	O	 	 	P	 	 	Q	 	 	R	 	 	S	 	 	T	 	 	U	 	 	V	 	 	W	 	 	X	 	 	Y	 	 	Z	 	 	AA	 	 	AB	 	 	AC	 	 	AD	 	 	AE	 	 	AF	 	 	AG	 	 	Ah	 	 	AI	 	 	AJ	 	 	Ak	 	 	Al	 	 	AM	 	 	AN	 	 	AO	 	 
	1
	 	 	 	 	 	IGER	 	 	 	 	 	Task	 	Objective	 	Comments	 	 	 	 	 	year 1	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	year 2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	year 3	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	2
	 	 	 	 	 	Ceres	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	FTE	 	 	 	 	 	Ceres	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	FTE	 	 	 	 	 	Ceres	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	FTE	 	 	 	 	 	Ceres	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER	 	 	[***]	 	 	 	 	 	 	 	 	 
	3
	 	 	 	 	 	CIGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	1	 	 	 	2	 	 	 	3	 	 	 	4	 	 	 	5	 	 	 	6	 	 	 	7	 	 	 	8	 	 	 	9	 	 	 	10	 	 	 	11	 	 	 	12	 	 	 	1	 	 	 	2	 	 	 	3	 	 	 	4	 	 	 	5	 	 	 	6	 	 	 	7	 	 	 	8	 	 	 	9	 	 	 	10	 	 	 	11	 	 	 	12	 	 	 	1	 	 	 	2	 	 	 	3	 	 	 	4	 	 	 	5	 	 	 	6	 	 	 	7	 	 	 	8	 	 	 	9	 	 	 	10	 	 	 	11	 	 	 
	4
	 	 	1	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	5
	 	 	 	 	 	IGER	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	6
	 	 	A	 	 	IGER	 	 	 	 	 	[***]	 	 	 	To capture important [***] to improve productivity and [***] (re [***] for climate
change). Particular [***] are geographical including [***] where [***]. [***] can
demonstrate Google map showing [***]
	 	The earliest this could be done in Oct/Nov 20[***]. It may be
possible to continue to work with our [***] of 20[***]. Target countries
are [***] (incl [***], [***] and [***]. EH would also like to know about
ethnobiology.
	 	This needs to be included in the budget at £30-40K.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	7
	 	 	B	 	 	IGER	 	 	 	 	 	[***] 	 	Ensure these can be used without importation of disease outside [***]

	 	[***] will be inspected in Sept [***] by DEFRA. I have
contacted DEFRA about [***]
import and await a reply. [***] could be [***] in [***] to 1)  fulfil [***]
  requirements 2) make a modest level of multiplication so that [***]
 can be compared on different
 sides of the [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	8
	 	 	 	 	 	IGER	 	 	 	 	 	Sample leaf material	 	Detailed genetic analysis	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	from 1 rep, extract DNA,	 	using markers	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	send to Ceres	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	9
	 	 	 	 	 	Ceres	 	 	 	 	 	SNPmarker analysis	 	Evaluate material for	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	markers, send results to	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	10
	 	 	C	 	 	IGER	 	 	 	 	 	[***] and send subset of about [***] to [***] for
further evaluation. Decide which lines Nov 20[***]. Also see [***] sheet.
	 	Characterise morphological  and physiological [***]
relevant [***] in [***]

	 	This obviously would link to the Trials worksheet. It is
practical to start identifying key material in 20[***] - which perhaps
should be put [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	11
	 	 	 	 	 	Ceres	 	 	 	 	 	Evaluate [***] in [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	12
	 	 	 	 	 	IGER	 	 	 	 	 	Identify G X E	 	Analyse if G has a [***]	 	Completion may be beyond	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	interactions and	 	effect in [***]	 	[***] year workplan	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	identify climatic zones	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	13
	 	 	 	 	 	IGER	 	 	 	 	 	Develop supporting	 	 	 	 	 	I guess we mean the	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	techniques for phenotype	 	 	 	 	 	protocols, which I suggest	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	trials	 	 	 	 	 	we base on EMI. These can be	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	drawn up with statistical	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	advice ro test 30 genotypes	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	well in advance of the [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	multiplication stage	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	14
	 	 	C	 	 	IGER	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	15
	 	 	 	 	 	IGER	 	 	 	 	 	Dig samples of [***] key	 	Test [***] to [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Miscanthus genotypes	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	from EMI plots, [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	and transfer to [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	16
	 	 	 	 	 	Ceres	 	 	 	 	 	[***] in [***]	 	Test [***] and [***] in [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	17
	 	 	D	 	 	CIGER JCB	 	WvA and	 	Obtain Commecialization Rights	 	Freedom to commercialize [***] developed in program	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	18
	 	 	2	 	 	 	 	 	 	 	 	 	 	Characterise	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	A) existing and	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	B) new [***] at	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER C) selected [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	in [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	19
	 	 	A	 	 	IGER	 	 	 	 	 	Assess phenotype trial (planted at IGER in
April [***]) for morphological and physiological [***]
relevant [***]. Include [***],  [***] status etc
in [***].
	 	Record important morphometric characters including winter [***],
spring [***], [***] to [***] spring [***] and summer
[***] (incl [***]),  [***]/ [***], [***] and intensity,
[***] and [***], [***], [***], [***] and [***],
visual assessment of [***]
	 	Scoring systems need to be transferable. Bar code
reading needs to be investigated.
	 	This is the [***] year following [***] so the mature
phenotype is ready for the 20[***] season. It should be repeated in 20[***] to check
the impact of [***] in [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007





 





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 




     






			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Breeding Project Plan










	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	A	 	 	B	 	 	 	 	 	C	 	D	 	E	 	F	 	G	 	H	 	I	 	J	 	K	 	L	 	 	M	 	 	N	 	 	O	 	 	P	 	 	Q	 	 	R	 	 	S	 	 	T	 	 	U	 	 	V	 	 	W	 	 	X	 	 	Y	 	 	Z	 	 	AA	 	 	AB	 	 	AC	 	 	AD	 	 	AE	 	 	AF	 	 	AG	 	 	Ah	 	 	AI	 	 	AJ	 	 	Ak	 	 	Al	 	 	AM	 	 	AN	 	AO	 
	20
	 	 	 	 	 	IGER	 	 	 	 	 	Sample leaf material
from 1 rep, extract DNA, send to Ceres	 	Detailed genetic analysis using markers	 	NB One sacc was received as four plants and may not be a clone	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	21
	 	 	 	 	 	Ceres	 	 	 	 	 	SNPmarker analysis	 	Evaluate material for markers, send results to IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	22
	 	 	B	 	 	IGER	 	 	 	 	 	New phenotype trial to be [***] 20[***] based
on [***].NB [***] material will consist of
[***] plants per [***] derived from [***].	 	Characterise morphological and physiological [***] relevant [***]
	 	We plan to follow the design of Phenotype Trial [***] above with the [***] at
IGER. If [***] through [***] works (we have started this), we may get this trial started in June [***].
However, it is also likely planting will be delayed until May [***]. We could
then include the [***] which should have cleared [***].
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	23
	 	 	3	 	 	 	 	 	 	 	 	 	 	[***] for [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	24
	 	 	 	 	 	CIGER	 	 	 	 	 	Set [***] protocols for [***] analysis	 	Method harmonization for future [***] analysis	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	25
	 	 	 	 	 	IGER	 	 	 	 	 	Sample whole plant material harvested at [***], analyze using [***], send [***] to Ceres	 	More detailed [***] characterisation will reveal important [***]	 	Samples to be taken for 20[***] spring harvest from [***] and [***] (this is earlier than ideal - and should be repeated in
20[***])	 	SuperGen  funds work on [***] phenotype trial for [***], [***] and [***]. CERES will
provide added value to this (eg [***],
[***], [***], [***], [***])	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	26
	 	 	 	 	 	Ceres	 	 	 	 	 	Obtain [***] and/or [***]	 	Enable review of IGER [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	27
	 	 	 	 	 	Ceres	 	 	 	 	 	Review [***] phenotype trial [***] and choose
samples to analyze for [***] set	 	Choose subset of samples to analyze with [***] from
[***] x [***] reps = ~ [***]	 	IGER will review as well as part of Supergen project.
SuperGen will concentrate on combustion and gasification.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	28
	 	 	 	 	 	IGER	 	 	 	 	 	Send selected samples to Ceres for [***] analysis	 	Develop [***] sets at Ceres and IGER to harmonise [***] analysis	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	29
	 	 	 	 	 	CIGER	 	 	 	 	 	[***] analysis of samples for [***] of
[***] models	 	Develop models of biomass [***] to harmonise
Ceres/IGER [***] analysis	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	30
	 	 	 	 	 	CIGER	 	 	 	 	 	[***] analytical methods
	 	Protocol development and
harmonisation so that [***]
data sent to Ceres can be translated to [***] data as collected by Ceres.	 	IGER can perform some [***] based assays for which [***] already exist ([***], [***],
and [***] for calculation of [***] and [***]) or those
being developed ([***] and [***]) however Ceres may wish to perform additional
analyses and there will be a need to standardise protocols and equipment between sites at Aberystwyth
and Thousand Oaks	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	31
	 	 	 	 	 	Ceres	 	 	 	 	 	send [***] results from [***] set to IGER	 	 	 	 	 	includes [***] results of the [***] set, the
validation data for the [***] and the [***] of the
[***] samples in 05 phenotype trial (total [***] x [***])	 	Joint publication?	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	32
	 	 	 	 	 	 	 	 	 	 	 	 	 	sample whole plant material, analyze using [***], send [***] to Ceres	 	More detailed [***] characterisation will reveal important [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	33
	 	 	 	 	 	Ceres	 	 	 	 	 	Use developed model to determine [***] from [***]. Send results to IGER	 	Provide timely detailed information on [***] of
phenotype trial [***]	 	May need additional samples to ensure accuracy/expand [***] set	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	34
	 	 	 	 	 	CIGER	 	 	 	 	 	Develop database and analytical tools to assist in making [***] decisions	 	To assist [***] and recording of [***] data	 	We are currently developing the tools to integrate different types of datasets
and to query them.	 	CERES and IGER to share inforamtion on this using both IT parties.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	35
	 	 	4	 	 	 	 	 	 	 	 	 	 	[***] 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	36
	 	 	a	 	 	IGER	 	 	 	 	 	Plan [***]
programme according phenotypic, genotypic and [***] data	 	Make useful [***]	 	Use preliminary database as a decision support tool.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	37
	 	 	 	 	 	IGER	 	 	 	 	 	Plant maintenance and	 	 	 	 	 	We prototyped large	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	set up including	 	 	 	 	 	containers in 20[***]. These	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	staggering of plant	 	 	 	 	 	lead to plants with more	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	development	 	 	 	 	 	[***] - improving the [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007






 




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





     






			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Breeding Project Plan










	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	A	 	 	B	 	 	 	 	 	 	C	 	 	D	 	E	 	 	F	 	 	G	 	 	H	 	 	I	 	 	J	 	 	K	 	 	L	 	 	M	 	 	N	 	 	O	 	 	P	 	 	Q	 	 	R	 	 	S	 	 	T	 	 	U	 	 	V	 	 	W	 	 	X	 	 	Y	 	 	Z	 	 	AA	 	 	AB	 	 	AC	 	 	AD	 	 	AE	 	 	AF	 	 	AG	 	 	AH	 	 	AI	 	 	AJ	 	 	AK	 	 	AL	 	 	AM	 	 	AN	 	 	AO	 	 	 	 	 	 
	38
	 	 	 	 	 	IGER	 	 	 	 	 	Carry out the [***] - a)	 	 	 	 	 	[***] additional [***] for CERES ([***]) Sub-samples of
[***] (if available) protected by agreement  to be sent to Ceres to inform IGER selection.	 	(Material from	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] glasshouses	 	 	 	 	 	 	 	CIGER shall not be	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	used to create	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	CERES material.)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	39
	 	 	 	 	 	IGER	 	 	 	 	 	b) [***] (outside)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	40
	 	 	 	 	 	IGER	 	 	 	 	 	c) [***] (inside)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	41
	 	 	 	 	 	IGER	 	 	 	 	 	Development of [***]	 	 	 	 	 	a) [***] of [***]. With M.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] this is easier. With	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	M. [***] we have now	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	modified the [***] on the	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	glass house to follow the	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] - [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	42
	 	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	b) detached [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	43
	 	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	c) optimising [***] incl.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] and [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	44
	 	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	d) [***] with [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	45
	 	 	b	 	 	IGER	 	 	 	 	 	Carry out and optimise [***]	 	Increase [***] of [***] from [***]	 	Optimise media and [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	46
	 	 	 	 	 	IGER	 	 	 	 	 	Make [***] x [***]	 	Make [***]	 	[***] with [***] and [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	(JML to help?)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	47
	 	 	 	 	 	IGER	 	 	 	 	 	[***] from  [***].	 	Obtain [***] for selection	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	phase. Determine [***]- and	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] relationships	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	48
	 	 	5	 	 	IGER	 	 	 	 	 	Test alternative [***]	 	 	 	 	 	A step in [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	systems as proof of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	principle	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	49
	 	 	 	 	 	IGER	 	 	 	 	 	Plan [***]	 	Produce [***]	 	Make [***] in 20[***] using	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	database for [***] etc.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Include [***] if possible in	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	20[***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	50
	 	 	 	 	 	IGER	 	 	 	 	 	Carry out [***] in	 	 	 	 	 	The emphasis would be on	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] chambers	 	 	 	 	 	[***] genotypes but we would	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	test several [***] of [***],	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] and [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	51
	 	 	 	 	 	CIGER	 	 	 	 	 	Test [***], [***] and	 	 	 	 	 	see [***] tab for methodology	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] characteristics	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	52
	 	 	 	 	 	CIGER	 	 	 	 	 	[***] and/or [***] from	 	Evaluate [***] in IGER and [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	relevant [***] to [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	53
	 	 	 	 	 	CIGER	 	 	 	 	 	Assess [***] in field	 	Determine if [***] is	 	Field scale phenotypic	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	acceptable	 	assessments for above [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	54
	 	 	d	 	 	IGER	 	 	 	 	 	Create [***]	 	Develop methods for large	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	scale [***] with [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	advantages	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	55
	 	 	 	 	 	IGER	 	 	 	 	 	Harvest [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	56
	 	 	 	 	 	CIGER	 	 	 	 	 	[***] of [***] to [***]	 	Evaluate [***] in IGER and	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	57
	 	 	 	 	 	CIGER	 	 	 	 	 	Assess phenotype in field	 	Record important	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	morphometric characters as described in 2A i.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	58
	 	 	 	 	 	CIGER	 	 	 	 	 	Evaluate [***] relative	 	Determine levels of [***],	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	to [***] in field	 	[***] of [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	59
	 	 	6	 	 	 	 	 	 	 	 	 	 	Selection from [***]	 	To identify superior	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	genotypes	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Raise plants from [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	60
	 	 	 	 	 	IGER	 	 	 	 	 	in Glasshouse	 	Select best on basis of [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	61
	 	 	 	 	 	IGER	 	 	 	 	 	Sample, extract DNA,	 	Use marker analysis to aid	 	[***]-[***] samples x	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	send to Ceres for marker	 	selection	 	[***]-[***] markers.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	analysis	 	 	 	 	 	Throughput of [***] needs to	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	be confirmed. Include [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	trial, [***] x [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	material and [***] of all	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]. See marker section.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	62
	 	 	 	 	 	Ceres	 	 	 	 	 	SNP marker analysis	 	evaluate material for	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	markers, send results to	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	63
	 	 	 	 	 	IGER	 	 	 	 	 	Transplant to field	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	64
	 	 	 	 	 	IGER	 	 	 	 	 	Raise plants from [***].	 	Select [***].	 	[***] MORE [***] TO BE [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Also [***] to [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	65
	 	 	 	 	 	CIGER	 	 	 	 	 	Assess phenotype	 	Recaord important	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	morphometric characters	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	including winter [***],	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	spring [***], [***] to [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	spring [***] and summer	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] (incl [***]),  [***]/	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***], [***] and intensity,	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] and [***], [***],	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***], [***] and [***],	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	visual assessment of [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007





 




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






     







			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Breeding Project Plan









	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	A	 	 	B	 	 	 	 	 	 	C	 	D	 	E	 	F	 	G	 	 	H	 	 	I	 	 	J	 	 	K	 	 	L	 	 	M	 	 	N	 	 	O	 	 	P	 	 	Q	 	 	R	 	 	S	 	 	T	 	 	U	 	 	V	 	 	W	 	 	X	 	 	Y	 	 	Z	 	 	AA	 	 	AB	 	 	AC	 	 	AD	 	 	AE	 	 	AF	 	 	AG	 	 	AH	 	 	AI	 	 	AJ	 	 	AK	 	 	AL	 	 	AM	 	 	AN	 	 	AO	 	 
	66
	 	 	 	 	 	IGER	 	 	 	 	 	Sample whole plant	 	More detailed [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	material, analyze using	 	characterisation will reveal	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***], send [***] to	 	important [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Ceres	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	67
	 	 	 	 	 	IGER	 	 	 	 	 	Select, [***] and [***] (or [***]	 	 	 	 	 	This depends on the success

 of the  early morphometirc	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 best genotypes for replicated trials.	 	 	 	 	 	selection. If selections	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Interesting plants not	 	 	 	 	 	after year [***] are	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	quite making the grade	 	 	 	 	 	reliable reflection of the	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	will be transferred to a	 	 	 	 	 	mature phenotype, then we	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	mass selection	 	 	 	 	 	could start this in 20[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	reservoir to continue 	 	 	 	 	 	- making plots.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	montoring for [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	68
	 	 	 	 	 	Ceres	 	 	 	 	 	Use developed model to	 	Provide timely detailed	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	determine [***] from	 	information on [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]. Send results to	 	of [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	69
	 	 	7	 	 	 	 	 	 	 	 	 	 	[***] Trials	 	 	 	 	 	NEED TO DETERMINE WHAT IS	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	DONE OUTSIDE [***] PROGRAM	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Small plot yield	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	assessments in	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	replicated ([***] or	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]) single or	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	multiple rows ([***]) of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] or [***] plants	 	 	 	 	 	Promising lines to be [***].	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	per row, depending on	 	To test [***] on an area	 	Connects to [***] and	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	70
	 	 	 	 	 	IGER	 	 	 	 	 	[***] on [***].	 	basis and scale up	 	Trialling project schedules	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	71
	 	 	 	 	 	IGER	 	 	 	 	 	After [***] years, the	 	 	 	 	 	I suspect we will need help	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	best genotypes will be	 	 	 	 	 	from [***] to multiply	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	provided to [***] and 	 	 	 	 	 	promising plants for	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	UK for testing at [***]	 	 	 	 	 	agronomic trials since [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	locations as part of	 	 	 	 	 	is [***] only about [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***] relevant	 	 	 	 	 	[***] after [***] growing	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	evaluation.	 	 	 	 	 	seasons.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	72
	 	 	 	 	 	IGER	 	 	 	 	 	Evaluate green cut of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	Miscanthus in terms of	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	[***], [***] and [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	73
	 	 	 	 	 	IGER	 	 	 	 	 	To investigate [***]	 	 	 	 	 	Several suitable [***] were	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	not tested in 20[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	application.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	74
	 	 	 	 	 	IGER	 	 	 	 	 	To investigate methods	 	 	 	 	 	This is practical issue and	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	of preventing [***] at	 	 	 	 	 	may be sorted by [***] or	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	field borders (applies	 	 	 	 	 	more likely by [***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	to M. [***])	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	75
	 	 	8	 	 	 	 	 	 	 	 	 	 	Project Management	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Telemeetings would be fine	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	every quarter - with an	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	76
	 	 	 	 	 	 	 	 	 	 	 	 	 	Telemeetings	 	 	 	 	 	annual visit.	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	77
	 	 	 	 	 	 	 	 	 	 	 	 	 	Face to face meetings	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	78
	 	 	 	 	 	 	 	 	 	 	 	 	 	Reporting	 	 	 	 	 	based on these project plans	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007






 





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission








 






			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Marker Project Plan








	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	CERES	 	 	 	 	 	year 1	 	 	 	 	 	year 2	 	 	 	 	 	year 3	 		 	 
	 	 	 	 	CIGER	 	 	 	 	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE FTE	 	Ceres [***]	 	IGER [***]	 	FTE	 	Ceres [***]	 	IGER [***]
	 	1	 	 	Marker Development ( Year 1-)

	 	Objectives
	 	Notes
	 	1 2 3 4
	 	5 6 7 8
	 	9 10 11 12
	 	1 2 3 4
	 	5 6 7 8
	 	9 10 11 12
	 	1 2 3 4
	 	5 6 7 8
	 	9 10 11 12
	 	A	 	 	Identify target [***] for mapping including [***], [***],

[***], [***], [***], [***], [***], [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	B	 	 	Compare and share candidate gene sequences. Use [***] and
proprietary gene databases to predict Miscanthus variants
of genes of interest.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	C	 	 	Agree on joint list and determine long-term strategy
including complementation of BBSRC funded work
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	D	 	 	Grow plants of [***] and mapping [***]. Take samples from
[***]. DNA extractions to be made at IGER using Autogen
and sent to Ceres
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	a) [***] Planted April [***]; grow out in field
	 	 	 	 	 	[***]	 	 	 	 	 	[***]	 	 	 	 	 	[***]	 	 	 	 
	 	 	 	 	[***] planted April [***]; sample, extract, send DNA to
Ceres
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	b)
~[***] in November [***], timing dependent on
[***];
 grow plants in field
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	~[***] in November [***], timing dependent on  [***];
sample, extract, send DNA to Ceres
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	c) [***] mapping [***] individuals, for [***]; grow
plants in field
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	[***] mapping [***] individuals; sample, extract, send
DNA to Ceres
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	d) [***] ([***]), for [***], [***], [***] and [***]; grow
plants in field
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	[***] ([***]; [***] + [***] plants); sample, extract,
send DNA to Ceres
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	e) [***] ([***]), for [***], [***]; grow plants in field
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	[***] ([***]; [***]); sample, extract, send DNA to Ceres
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	E	 	 	DNA to be used at IGER for AFLP analysis (a and b above)

	 	determine [***] diversity and [***]
structure	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 






			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007





 




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 








			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Marker Project Plan








	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		 	 	 	 
	 	 	 	 	CERES	 	 	 	 	 	year 1	 	 	 	 	 	year 2	 	 	 	 	 	year 3	 	 
	 	 	 	 	CIGER	 	 	 	 	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE FTE	 	Ceres [***]	 	IGER [***]	 	FTE	 	Ceres [***]	 	IGER [***]
	 	F	 	 	Define primers [[***] to be tested] for “[***]” carefully
selected and agreed genes such that PCR [***] can be
sequenced and results unequivocally interpreted.

	 	Develop markers for consensus genes	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	G	 	 	Evaluate polymorphisms in selected [***]. Assay ~[***]
DNA samples from [***] in a) c) d) and e) supplied by
IGER to search for SNP polymorphisms in [***] genes using
primers, PCR and Sequencing. Define additional [***]
(?)primers for genes that show insufficient polymorphisms
in key materials
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Evaluate polymorphisms in selected [***]. Assay ~[***]
DNA samples from [***] in [***] supplied by IGER to
search for SNP polymorphisms in [***] genes using
primers, PCR and Sequencing.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	H	 	 	Compare and share strategies for association mapping
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	I	 	 	Conduct association mapping with field phenotype data for
a)
Conduct association mapping with [***] and field
phenotype data for b)

	 	 	 	 	 	[***]
	 	 	 	[***]
	 	 	 	 	 	[***]	 	 	 	 	 	 
	 	J	 	 	DNA to be used at IGER for SSR analysis using primers
from [***], [***] and [***] (BBSRC [***] grant) ([***]
and [***] from [***] and [***])

	 	integration of [***] maps	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	K	 	 	Construct private and public [***] maps and associate
marker polymorphisms with [***] in [***] and mapping
[***]. [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	L	 	 	Review results, write-up in confidential reports and
non-confidential papers and devise strategies for
implentation
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	2	 	 	Marker validation and implementation (Year 2-)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	A	 	 	Phenotype mapping [***] for the target [***] selected in
1A (start in year [***] to enable early morphometric
analyses) and grown in 1D
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	B	 	 	Map [***] and relate to markers particularly those
derived from candidate genes
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 








			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007




 




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 







			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Marker Project Plan







	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	IGER	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		 	 	 	 
	 	 	 	 	CERES	 	 	 	 	 	year 1	 	 	 	 	 	year 2	 	 	 	 	 	year 3	 	 
	 	 	 	 	CIGER	 	 	 	 	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE FTE	 	Ceres [***]	 	IGER [***]	 	FTE	 	Ceres [***]	 	IGER [***]
	 	3	 	 	Develop new mapping [***] of >[***] plants
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	A	 	 	Agree on [***] for new mapping [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	B	 	 	Assess results of [***] for target [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	C	 	 	Grow and phenotype new mapping [***] for agreed [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	D	 	 	make maps from new [***] from mapping [***] d) and e)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	4	 	 	Use markers ‘routinely’ in the [***] programme
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	A	 	 	Assess relatedness of plants as useful [***] in [***]
program based on correlations with [***], conclusions
from Items 1-3 and [***] data and [***] in field
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	B	 	 	IGER to extract DNA from [***] of [***] for marker
analysis
	 	 	 	 	 	[***]	 	 	 	 	 	[***]	 	 	 	 	 	[***]	 	 	 	 
	 	C	 	 	Assay all [***] from all [***] for a subset of markers (
[***]) based on results from Items1-3, [***] required and
[***] of plants in field. Aim is to discover if we can
[***] many of the [***] early on from marker work.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	D	 	 	Compare performance of using markers on [***] of [***]
from the [***] programme with [***] where no markers are
used
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	5	 	 	Functional analysis of target genes which map to [***]
(from association or QTL mapping)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	A	 	 	Q-PCR using a range of [***] from selected genotypes
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	B	 	 	[***] of Miscanthus with selected target genes which map
to [***]
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	6	 	 	Development of BAC libraries (BBSRC)

	 	Identification of [***] gene sequences and
generation of a physical map	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007




 




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 









			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Propagation Project Plan








	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	IGER	 	Consultant	 	 	 	year 1	 	 	 	 	 	year 2	 	 	 	 	 	year 3	 	 	 	 
	 	 	Ceres	 	CIGER	 	 	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE	Ceres [***]	IGER [***]
	 

	 	Task
	 	Objective
	 	Comment
	 	 	1        2        3        4	 	 	5        6        7        8
	 	     9        10        11        12
	 	     1        2        3        4
	 	     5        6        7        8
	 	     9        10        11        12
	 	     1        2        3        4
	 	     5        6        7        8
	 	     9        10        11        12
	1

	 	[***]	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	A

	 	Assess [***] for

[***]
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Quantify [***]
number and size by
[***] individual
[***] from
	 	Assessing [***] and
[***] in [***]
	 	Investigate [***]
conditions to
dicipher G x E
impacts on [***]
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	a) in the

20[***] [***] Trial

at IGER
	 	Existing range of
[***] in [***],
[***]
	 	Mature 20[***]
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	b) 20[***]

[***] as [***]
	 	new range of [***]
in [***], [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	c) from

20[***] [***]

in

field / glasshouse

at IGER
	 	new range
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	d) on [***]
([***] and [***]
from [***] to
[***])
	 	[***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	 	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	[***] to [***]
number of [***]
plants
	 	Increase the

identified

promising genotypes

for [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	 	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	B

	 	A series of field
relevant
experiments to
guide Best
Management
Practices
	 	Demonstrate
potential of [***]
and create
protocols. Find
[***] associated
with [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	[***] from all

[***]
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Typically
[***] from each
[***] which are
[***] in trays for
raising [***] for
field selection
will be monitored.
We intend to
datalog [***]
(order for
equipment in
progress)
	 	To screen all [***]
for [***] and rate
of [***] under
monitored [***]
	 	Year 1 data will be
less detailed than
in later years.
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Greenhouse /CE
experiments to
investigate [***]
best practice
	 	to determine [***]
in [***] under
controlled [***]
and optimise [***]
	 	depends on a PhD

student
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Test [***] on
[***] of selected
genotypes
	 	Characteristaion of
[***] conditions to
stimulate [***] in
different
genotypes. This
provides
information about
[***] where [***]
could be
considereds (based
on [***]).
	 	One can test [***]
over [***] days of
[***] genotypes
(each in one lane)
at [***] different
[***] ([***] has
[***] wells). [***]
per [***] therefore
we can only do this
with genotypes that
produce >[***].
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Field bed

preparation ([***])

at [***] (use [***]

as a control)
	 	scale up to real
conditions
including effect of
[***] & [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Record [***] &

[***]
	 	relate laboratory
tests to field
conditions
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Monitoring

[***] + winter

[***]
	 	ensure proper
quantification of
conditions
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007




 




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 










			
	 	 	 
	Attachment A - RESEARCH AND DEVELOPMENT PLAN


	 	Propagation Project Plan










	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	IGER	 	Consultant	 	 	 	year 1	 	 	 	 	 	year 2	 	 	 	 	 	year 3	 	 	 	 
	 	 	Ceres	 	CIGER	 	 	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE	 	Ceres [***]	 	IGER [***]	 	FTE	Ceres [***]	IGER [***]
	 

	 	Development of
[***] techniques
	 	Precision [***]
considerations.
Optimising [***]
and [***] at field
scale.
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	 	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	2

	 	[***]
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Establish
[***] capacity of
certain genotypes
and protocols
	 	Identify [***]
amenable lines.
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Send lines to
external contractor
for [***].
	 	[***] promising
[***] lines
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Send [***] to
Ceres
	 	Provide [***]

successfully

produced in [***]

program for

additional research

activities,[***]

field planting
	 	dependent on [***]

success
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	3

	 	[***]
	 	Demonstrate
potential of [***]
and create
protocols. Explore
timing of basic
research to inform
applied work.
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	A

	 	Applied [***]
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	visit global

[***] experts
	 	benefit from
expertise and tie
into the project
([***])
	 	done during [***]
trip to [***]
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	[***] global

experts visit IGER
	 	benefit from

expertise ([***])
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Expert

Consultancy ([***])
	 	provide guidance

for [***] projects,

possibly advise

student
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	gather
information to
develop field and
glasshouse
protocols
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	assess [***]
in Miscanthus [***]
characteristics of
[***] and [***]
	 	optimise [***],

inform [***]
	 	20[***] assessment
will be include
[***]. 20[***]+
[***] will be [***]
	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	treatments to
[***], e.g. [***]
	 	optimise [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Glasshouse
tests of [***]
growth conditions
	 	to predict

conditions in which

[***] can be used
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Field tests of
[***]
	 	survivorship of
[***] plants and G
by E interactions
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Iterative
field testing of
[***] techniques
	 	Evaluate field
suitability of
[***] techniques
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	B

	 	Basic [***] Research
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Assess [***]
leading to [***]
growth
	 	develop articicial
[***] of [***]
growth and [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Assess [***]
cues leading to
[***] growth.
	 	develop articicial
[***] of [***]
growth and [***]
	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	4

	 	[***]/[***]
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	A

	 	[***] Lines, [***]
lines
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Desk study of
state of art in
industry
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 

	 	Discuss with
PM what could be
done quickly to
demonstrate
feasibility
	 	 	 	 	 	 	[***] [***] [***] [***]	 	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]
	 	[***] [***] [***] [***]







			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007





 






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





Attachment B - Budget




	 	 	 	 	 	 	 
	 	 	2007/8	 	2008/9	 	2009/10
	No of Months	 	12.00	 	12.00	 	12.00
	SALARY
	 	[***]	 	[***]	 	[***]
	NI [***]%
	 	[***]	 	[***]	 	[***]
	super [***]%
	 	[***]	 	[***]	 	[***]
	PAY COSTS
	 	[***]	 	[***]	 	[***]
	 
	OTHER RECURRENT
	 	 	 	 	 	 
	CONSUMABLES
	 	[***]	 	[***]	 	[***]
	CONSUMABLES MOLECULAR BIO
	 	[***]	 	[***]	 	[***]
	CASUAL & OVERTIME
	 	[***]	 	[***]	 	[***]
	TRAVEL & SUBSISTENCE
	 	[***]	 	[***]	 	[***]
	STUDENTSHIP (PhD)
	 	[***]	 	[***]	 	[***]
	SUB- TOTAL
	 	[***]	 	[***]	 	[***]
	 
	OTHER COSTS
	 	 	 	 	 	 
	ESTATES COST
	 	[***]	 	[***]	 	[***]
	RECRUITMENT
	 	[***]	 	[***]	 	[***]
	ANALYTICAL CHEMISTRY
	 	[***]	 	[***]	 	[***]
	CONTROLLED ENVIRONMENT
	 	[***]	 	[***]	 	[***]
	BIOINFORMATICS
	 	[***]	 	[***]	 	[***]
	ULTRASTRUCTURE & IMMUNOLOGY
	 	[***]	 	[***]	 	[***]
	MASS SPECTOMETRY
	 	[***]	 	[***]	 	[***]
	SEQUENCING
	 	[***]	 	[***]	 	[***]
	EXTENSION TECHNOLOGIES
	 	[***]	 	[***]	 	[***]
	TRANSFORMATION TECHNOLOGIES
	 	[***]	 	[***]	 	[***]
	SEED STORE
	 	[***]	 	[***]	 	[***]
	ROAD VEHICLES
	 	[***]	 	[***]	 	[***]
	AGRI VEHICLES
	 	[***]	 	[***]	 	[***]
	FARM
	 	[***]	 	[***]	 	[***]
	GLASSHOUSE
	 	[***]	 	[***]	 	[***]
	SUB CONT
	 	[***]	 	[***]	 	[***]
	TOTAL OTHER COSTS
	 	[***]	 	[***]	 	[***]
	 
	OVERHEAD COSTS*
	 	 	 	 	 	 
	ESTABLISHMENT SERVICES
	 	[***]	 	[***]	 	[***]
	ADMIN SERVICES
	 	[***]	 	[***]	 	[***]
	INSTITUTE & SITE MANAGEMENT
	 	[***]	 	[***]	 	[***]
	FEC NOTIONAL INSURANCE
	 	[***]	 	[***]	 	[***]
	CAPITAL CHARGE
	 	[***]	 	[***]	 	[***]
	DEPARTMENT
	 	[***]	 	[***]	 	[***]
	TOTAL OVERHEAD COSTS
	 	[***]	 	[***]	 	[***]
	TOTAL
	 	[***]	 	[***]	 	[***]
	CERES payment for reasonable perf
	 	[***]	 	[***]	 	[***]
	CERES payment for full completion
	 	[***]	 	[***]	 	[***]
	TOTAL paid by CERES
	 	[***]	 	[***]	 	[***]
	SURPLUS OVER TOC
	 	[***]	 	[***]	 	[***]






 



 *      See page 2




			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007





Page 1




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





Attachment B — Budget



This Budget is agreed upon for contract years 1 through 3. A contract year (“Year”) is April 1 —
March 31, starting April 1, 2007. CERES agrees to provide funding for IGER’s RESEARCH PROJECT
activities covered by this SCHEDULE in accordance with Article 1.8 of the CA as set forth in the
Budget in page 1 of this Attachment B, taking into account what is provided hereinafter.
Pay Costs, Other Recurrent and Other Costs are as in the Budget. Overhead Costs will be payable as
follows:





	 	- 	 	Each contract year CERES will pay [***]% of the overheads asked, (e.g. of the [***]
pounds in Year 1), for the expected reasonable performance in the various aspects of the
program Year by Year and especially for all the items listed in the attached document.
This [***]% amounts to [***] pounds in contract Year 1.
	 
	 	- 	 	Furthermore, CERES will pay for Year 1 an additional [***]% of the asked overhead (
i.e.[***]% in total of the asked overhead) for full completion of the Year 1 items A and B
listed hereinafter. This additional [***]% equals [***] pounds.
	 
	 	- 	 	For Year 2 CERES will pay an additional [***]% of the overhead costs asked for full and
successful completion of Year 2 items A and C hereinafter.
	 
	 	- 	 	 For Year 3 CERES will pay an additional [***]% of the overhead costs asked for full and
successful completion of Year 3 items A, B, C and D listed hereinafter.
	 
	 	- 	 	 The MANAGEMENT COMMITTEE will bring forth recommendations to the Parties at the
beginning of each Year for the items that IGER should satisfy to obtain extra overheads,
outlined in the framework above.
	 
	 	- 	 	 Assessment on achievements of the nominated items will be made at the end of each Year
by the MANAGEMENT COMMITTEE and recommendations made to the Parties. Upon agreement,
CERES will respond to an invoice from IGER as agreed. Should some items in a section not
be achieved then the amount paid will be reduced on a pro-rata basis on the number of
items in the section.





			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007






Page 2




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






Attachment B — Budget




Suggested milestones, for discussion, for full overhead payments



The Parties agree to finalize this document within thirty (30) days from the commencement
date of this SCHEDULE.




Year 1 (April 1 to March 31):




A. [***] research to create an economically viable business



1. [***] and [***] variation affecting [***] amongst available (numbers?) [***] and
their behaviour through the season/[***] reported; any clear winners [***]



2. [***] and [***] variation affecting [***] (numbers?) [***] and early [***] across
different [***] and [***] reported; any clear leaders [***] and sent to Ceres



3. XXX [***] of Miscanthus [***] ([***]?) (good [***]) with Miscanthus [***] made and
followed by [***] where necessary. [***] of [***] sent to Ceres by early 20[***].



4. First [***] of [***] x [***] made based on results from 20[***] field [***] and [***]




B. [***] to Ceres to help [***] in [***] as early as possible



1. [***] of latest [***] of [***] from [***] via [***] (how many?) sent into [***] in
20[***] when requested by Ceres



2. Selected set of promising [***] including [***] lines and [***] trialled to date
sent to Ceres in [***]in 20[***] for trial in [***]



3. Samples of [***] of Year 1 [***] sent to Ceres, including a sample of [***] (Numbers of
[***]?)



4. Approximately [***] from [***] (how many?) occurring in the field in 20[***] believed to
be [***]x x [***]x sent to Ceres




C. Advancing the [***] assisted [***] program as early as possible



1. DNA from about [***] plant [***] phenotyped in the field since 20[***] and first [***]
delivered to Ceres in 20[***].



2. DNA from about new [***] plant [***] in [***] in 20[***], other [***] and other
selected [***] delivered to Ceres in 20[***]




D. Advancing the [***] program



1. xxx new [***] of [***] x [***] made based on phenotypes and presumed [***]



2. xxx [***] of M [***] x other made




			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007






Page 3




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






Attachment B — Budget



3. [***] phenotype/[***] assessments of material in [***] since 20[***]
reported and correlations made with assessments in years 1 and 2 and with [***]




E. Advancing [***] research



1. Samples (how many?) and [***] (how many?) sent to Ceres




F. Enhancing [***]



1. Additional [***] made and materials brought into [***] in IGER to fill in specific
[***] needed for likely commercialization locations




Year 2 (April 1 to March 31):



A. [***] research to create an economically viable business



1. [***]/[***] variation affecting [***] amongst large range of [***] (numbers?) and
their behaviour through the season/[***] reported; any clear winners [***]



2. [***]/[***] variation affecting [***] (numbers?) [***] and early growth across
different [***] and [***] reported; any clear leaders [***] and sent to Ceres



3. XXX [***] of Miscanthus [***] ([***]) (good [***]) with Miscanthus [***] made and
followed by [***] where necessary. [***] of [***] sent to Ceres by early 20[***].



4. Next [***] of [***] x [***] made based on results from 20[***] field [***] and [***]



5. Synthesis of best practice for [***] of miscanthus based on [***] and [***], [***] and
other methods to meet market costs and commercialization in different geographies




B. [***] to Ceres to help [***] in [***] as early as possible



1. Approximately [***] from [***] occurring in the field in 20[***] believed to be [***]x x
[***]x sent to Ceres



2. Samples of [***] of Year 2 [***] (numbers?) sent to Ceres, including a sample
of [***]



3. Promising selected genotypes from [***]/[***]/[***] program [***] in [***] and sent to
Ceres




C. Advancing the [***] assisted [***] program as early as possible



1. DNA from relevant [***] from [***] program, [***] etc delivered to Ceres in 20[***]



2. Preliminary phenotyping of [***] in field and preliminary [***] made with Ceres



3. [***] and [***] aligned with [***] and [***] and [***]




			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007






Page 4




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






Attachment B — Budget




D. Advancing the [***] program



1. xxx new [***] of [***] x [***] made based on phenotypes, presumed [***], [***] and
other characters



2. xxx new [***] of M [***] x other made



3. [***] phenotype/[***] assessments of material in [***] since 20[***] reported
and correlations made with assessments in previous years and with [***]



4. Selection and [***] of genotypes for further trialing for potential commercialization
based on geography, [***] and [***]



5. Report on methods to [***] large scale [***] with commercial advantages




Year 3 (April 1 to March 31):



A. [***] research to create an economically viable business



1. [***]/[***] variation affecting [***] amongst available [***] (how many?) and their
behaviour through the season/[***] reported; any clear winners [***]



2. [***]/[***] variation affecting [***] ( how many?) [***] and early [***] across
different [***] and [***] reported; any clear leaders [***] and sent to Ceres.



3. Synthesis of best practice for [***] of miscanthus based on [***] and [***], [***] and
other methods to meet market costs and commercialization in different geographies.



4. XXX [***] of Miscanthus [***] ([***]) (good [***]) with Miscanthus [***] made and
followed by [***] where necessary. [***] of [***] sent to Ceres by early 20[***].



5. Next [***] of [***] x [***] made based on results from 20[***] field [***] and [***]




B. [***] to Ceres to help [***] in [***] as early as possible



1. Approximately [***] from [***] occurring in the field in 20[***] believed to be [***]x x
[***]x sent to Ceres



2. Samples of [***] of Year 3 [***] (how many?) sent to Ceres, including a sample
of [***]



3. Promising selected genotypes from [***]/[***] program [***] in [***] and sent to Ceres




C. Advancing the [***] assisted [***] program as early as possible



1. DNA from relevant [***] from [***] program, [***] etc delivered to Ceres in 20[***]



2. Advanced phenotyping of [***] in field and [***] made with Ceres




D. Advancing the [***] program




			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007






Page 5




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





Attachment B — Budget



1. xxx new [***] of [***] x [***] made based on phenotypes and presumed [***], [***]
and [***] and [***] samples transferred to Ceres



2. xxx new [***] of M [***] x other made and [***] samples transferred to Ceres



4. Initial evaluation of [***] in field; report on [***], and
commercial feasibility of [***]



5. Selection and [***] of promising genotypes from all [***] to date for further
trialing for potential commercialization based on geography, [***] and [***] and selections
transferred to Ceres



6. Establishment of multisite trial of promising genotypes




			
	 	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007








Page 6


Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission









 





			
	Attachment C	 	 
	CERES-IGER SCHEDULE 1
	 	April 1, 2007















Quarterly Report Format



Prepared by

Date



			
	 	 	 
	Confidential     Project # and name
	 	






1









 






Concept and Goals





	•	 	Concept





















	•	 	Goals



















			
	 	 	 
	Confidential     Project # and name
	 	






2









 






FTEs and Budget Projected vs. Actual





	•	 	People and activities





Dollars









FTEs







			
	 	 	 
	Confidential     Project # and name
	 	






3









 






Action Items and Deliverables for the Period




	 	 	 	 	 	 	 	 	 
	 	 	Expected	 	 	Actual	 
	Action Item or Deliverable	 	Finish	 	 	Finish	 
	 
	 	 	 	 	 	 	 	 





			
	 	 	 
	Confidential     Project # and name
	 	






4









 






Key Milestones or Deliverables for the Period





	•	 	Progress on Key Milestones and Deliverables
	 
	•	 	Are we on, ahead or behind schedule





			
	 	 	 
	Confidential     Project # and name
	 	






5









 






Technical Highlights





	•	 	1 or 2 slides covering technical highlights





			
	 	 	 
	Confidential     Project # and name
	 	






6









 






Results





	•	 	Several slides summarizing results (if applicable)





			
	 	 	 
	Confidential     Project # and name
	 	






7









 






What’s Ahead: Key Milestones and Deliverables Next 4 Quarters





	•	 	Quarter 1
	 
	•	 	Quarter 2
	 
	•	 	Quarter 3
	 
	•	 	Quarter 4





			
	 	 	 
	Confidential     Project # and name
	 	






8









 






Research Plan





	•	 	Goal






	 	—	 	Impact
	 
	 	—	 	Tasks
	 
	 	—	 	 Milestones
	 
	 	—	 	 Deliverables






	•	 	Duplicate this slide as needed to cover each goal for the next
period





			
	 	 	 
	Confidential     Project # and name
	 	






9









 






Timeline Summary







	Time to achieve Milestone 1 2 3 4 5 6 7 8 9 10 11 12
Milestone 1
Milestone 2
Milestone 3
Etc






	•	 	Assumptions and risk factors
	 
	•	 	Use additional slide if necessary
	 
	•	 	Use red if behind schedule until completed or otherwise resolved
	 
	•	 	Should be indicated in red as soon as the delay is identified
	 
	•	 	See issue resolution if behind schedule





			
	 	 	 
	Confidential     Project # and name
	 	






10









 






IP





	•	 	Filings during the period





















	•	 	Applications in progress




















			
	 	 	 
	Confidential     Project # and name
	 	






11









 






SOPs





	•	 	List SOPS for all Key processes





			
	 	 	 
	Confidential     Project # and name
	 	






12









 






Issue Resolution and Decision Making Slides




These can be used to address new issues or

implement corrective action or assist in decision

making such as variety release, etc.



			
	 	 	 
	Confidential     Project # and name
	 	






13









 






Issue Resolution and Decision Making







	•	 	Issue (e.g. milestone 3 behind schedule)











	 	 	Actual
	 
	•	 	What is happening




 









	 	 	Expected
	 
	•	 	What should be happening












			
	 	 	 
	Confidential     Project # and name
	 	






14









 






Issue Resolution and Decision Making





	•	 	Issue (e.g. milestone 3 behind schedule)
	 
	•	 	Possible alternative slide to address new issues









Needs







Wants









			
	 	 	 
	Confidential     Project # and name
	 	






15









 






Decision





	•	 	Summary of decision to be made





			
	 	 	 
	Confidential     Project # and name
	 	






16









 






Options





	•	 	Summary of options





			
	 	 	 
	Confidential     Project # and name
	 	






17









 






Recommendations





	•	 	What do we need to do to get back on track or address new issue





			
	 	 	 
	Confidential     Project # and name
	 	






18









 






Resources Required




			
	 	 	 
	Confidential     Project # and name
	 	






19









 






Plan and Schedule




	 	 	 	 	 	 	 	 	 
	Action Items	 	Who	 	 	When	 
	 
	 	 	 	 	 	 	 	 





			
	 	 	 
	Confidential     Project # and name
	 	






20









 






Attachment
D


IGER BACKGROUND INTELLECTUAL PROPERTY




	 	 	 	 	 
	Miscanthus accessions from the following sources:	 	Number
	IGER collection from [***] ([***]), [***] and [***] in 20[***]

	 	approx. [***]	 	 
	 
	 	 	 	 
	Kew/ADAS (BRL agreement)

	 	-see attached list	 	 
	 
	 	 	 	 
	[***]

	 	-see attached list	 	 
	 
	 	 	 	 
	[***]

	 	-see attached list	 	 
	 
	 	 	 	 
	Other European sources

	 	-see attached list	 	 
	 
	 	 	 	 
	CERES-IGER SCHEDULE 1

	 	 	 	April 1, 2007






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission





 









 





List of Donated Accessions




	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AccID	 	Accession	 	Species	 	SuppliedBy	 	PreviousID	 	Restrictions	 	[***]	 	Type	 	[***]	 	Comments
	1

	 	Mb 1
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	2

	 	Mb 2
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	3

	 	Mb 3
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	4

	 	Mb 4
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	5

	 	Mb 5
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	6

	 	Mb 6
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	7

	 	Mb 7
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	8

	 	Mb 8
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	9

	 	Mb 9
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	10

	 	Mb 10
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	11

	 	Mb 11
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	12

	 	Mb 12
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	13

	 	Mb 13
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	14

	 	Mb 14
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	15

	 	Mb 15
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	16

	 	Mb 16
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	17

	 	Mb 17
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	18

	 	Mb 18
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	19

	 	Mb 19
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	20

	 	Mb 20
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	21

	 	Mb 21
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	22

	 	Mb 22
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	23

	 	Mb 23
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	24

	 	Mb 24
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	25

	 	Mb 25
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	26

	 	Mb 26
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	27

	 	Mb 27
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	28

	 	Mb 28
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	29

	 	Mb 29
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	30

	 	Mb 30
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	31

	 	Mb 31
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	32

	 	Mb 32
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	33

	 	Mb 33
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	34

	 	Mb 34
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	35

	 	Mb 35
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	36

	 	Mb 36
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	37

	 	Mb 37
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	38

	 	Mb 38
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	39

	 	Mb 39
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	40

	 	Mb 40
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	41

	 	Mb 41
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	42

	 	Mb 42
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	43

	 	Mb 43
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	44

	 	Mb 44
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	45

	 	Mb 45
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	46

	 	Mb 46
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	47

	 	Mb 47
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	48

	 	Mb 48
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	49

	 	Mb 49
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	50

	 	Mb 50
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	51

	 	Mb 51
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	52

	 	Mb 52
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	53

	 	Mb 53
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	54

	 	Mb 54
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	55

	 	Mb 55
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	56

	 	Mb 56
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	57

	 	Mb 57
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	58

	 	Mb 58
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	59

	 	Mb 59
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	60

	 	Mb 60
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	61

	 	Mb 61
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	62

	 	Mb 62
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	63

	 	Mb 63
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	64

	 	Mb 64
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	65

	 	Mb 65
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	66

	 	Mb 66
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	67

	 	Mb 67
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	68

	 	Mb 68
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	69

	 	Mb 69
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	70

	 	Mb 70
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	71

	 	Mb 71
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	72

	 	Mb 72
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	73

	 	Mb 73
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	74

	 	Mb 74
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	75

	 	Mb 75
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	76

	 	Mb 76
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	77

	 	Mb 77
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	78

	 	Mb 78
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	79

	 	Mb 79
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	80

	 	Mb 80
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	81

	 	Mb 81
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	82

	 	Mb 82
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	83

	 	Mb 83
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	84

	 	Mb 84
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	85

	 	Mb 85
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	86

	 	Mb 86
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	87

	 	Mb 87
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	88

	 	Mb 88
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	89

	 	Mb 89
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	90

	 	Mb 90
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	91

	 	Mb 91
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	92

	 	Mb 92
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	93

	 	Mb 93
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	94

	 	Mb 94
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	95

	 	Mb 95
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	96

	 	Mb 96
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	97

	 	Mb 97
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 






Page 1





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





List of Donated Accessions





	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AccID	 	Accession	 	Species	 	SuppliedBy	 	PreviousID	 	Restrictions	 	[***]	 	Type	 	[***]	 	Comments
	98

	 	Mb 98
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	99

	 	Mb 99
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	100

	 	Mb 100
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	101

	 	Mb 101
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	102

	 	Mb 102
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	103

	 	Mb 103
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	104

	 	Mb 104
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	105

	 	Mb 105
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	106

	 	Mb 106
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	107

	 	Mb 107
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	108

	 	Mb 108
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	109

	 	Mb 109
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	110

	 	Mb 110
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	111

	 	Mb 111
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	112

	 	Mb 112
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	113

	 	Mb 113
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	114

	 	Mb 114
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	115

	 	Mb 115
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	116

	 	Mb 116
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	117

	 	Mb 117
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	118

	 	Mb 118
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	119

	 	Mb 119
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	120

	 	Mb 120
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	121

	 	Mb 121
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	122

	 	Mb 122
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	123

	 	Mb 123
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	124

	 	Mb 124
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	125

	 	Mb 125
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	126

	 	Mb 126
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	127

	 	Mb 127
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	128

	 	Mb 128
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	129

	 	Mb 129
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	130

	 	Mb 130
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	131

	 	Mb 131
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	132

	 	Mb 132
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	133

	 	Mb 133
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	134

	 	Mb 134
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	135

	 	Mb 135
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	136

	 	Mb 136
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	137

	 	Mb 137
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	138

	 	Mb 138
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	139

	 	Mb 139
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	140

	 	Mb 140
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	141

	 	Mb 141
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	142

	 	Mb 142
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	143

	 	Mb 143
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	144

	 	Mb 144
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	145

	 	Mb 145
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	146

	 	Mb 146
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	147

	 	Mb 147
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	148

	 	Mb 148
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	149

	 	Mb 149
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	150

	 	Mb 150
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	151

	 	Mb 151
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	152

	 	Mb 152
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	153

	 	Mb 153
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	154

	 	Mb 154
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	155

	 	Mb 155
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	156

	 	Mb 156
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	157

	 	Mb 157
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	158

	 	Mb 158
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	159

	 	Mb 159
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	160

	 	Mb 160
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	161

	 	Mb 161
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	162

	 	Mb 162
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	163

	 	Mb 163
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	164

	 	Mb 164
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	165

	 	Mb 165
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	166

	 	Mb 166
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	167

	 	Mb 167
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	168

	 	Mb 168
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	169

	 	Mb 169
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	170

	 	Mb 170
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	171

	 	Mb 171
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	172

	 	Mb 172
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	173

	 	Mb 173
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	174

	 	Mb 174
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	175

	 	Mb 175
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	176

	 	Mb 176
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	177

	 	Mb 177
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	178

	 	Mb 178
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	179

	 	Mb 179
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	180

	 	Mb 180
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	181

	 	Mb 181
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	182

	 	Mb 182
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	183

	 	Mb 183
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	184

	 	Mb 184
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	185

	 	Mb 185
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	186

	 	Mb 186
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	187

	 	Mb 187
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	188

	 	Mb 188
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	189

	 	Mb 189
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	190

	 	Mb 190
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	191

	 	Mb 191
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	192

	 	Mb 192
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	193

	 	Mb 193
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	194

	 	Mb 194
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	195

	 	Mb 195
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 






Page 2




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission








 





List of Donated Accessions



	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AccID	 	Accession	 	Species	 	SuppliedBy	 	PreviousID	 	Restrictions	 	[***]	 	Type	 	[***]	 	Comments
	196

	 	Mb 196
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	197

	 	Mb 197
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	198

	 	Mb 198
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	199

	 	Mb 199
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	200

	 	Mb 200
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	201

	 	Mb 201
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	202

	 	Mb 202
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	203

	 	Mb 203
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	204

	 	Mb 204
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	205

	 	Mb 205
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	206

	 	Mb 206
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	207

	 	Mb 207
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	208

	 	Mb 208
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	209

	 	Mb 209
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	210

	 	Mb 210
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	211

	 	Mb 211
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	212

	 	Mb 212
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	213

	 	Mb 213
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	214

	 	Mb 214
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	215

	 	Mb 215
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	216

	 	Mb 216
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	217

	 	Mb 217
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	218

	 	Mb 218
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	219

	 	Mb 219
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	220

	 	Mb 220
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	221

	 	Mb 221
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	222

	 	Mb 222
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	223

	 	Mb 223
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	224

	 	Mb 224
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	225

	 	Mb 225
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	226

	 	Mb 226
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	227

	 	Mb 227
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	228

	 	Mb 228
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	229

	 	Mb 229
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	230

	 	Mb 230
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	231

	 	Mb 231
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	232

	 	Mb 232
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	233

	 	Mb 233
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	234

	 	Mb 234
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	235

	 	Mb 235
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	236

	 	Mb 236
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	237

	 	Mb 237
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	238

	 	Mb 238
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	239

	 	Mb 239
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	240

	 	Mb 240
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	241

	 	Mb 241
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	242

	 	Mb 242
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	243

	 	Mb 243
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	244

	 	Mb 244
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	245

	 	Mb 245
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	246

	 	Mb 246
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	247

	 	Mb 247
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	248

	 	Mb 248
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	249

	 	Mb 249
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	250

	 	Mb 250
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	251

	 	Mb 251
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	252

	 	Mb 252
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	253

	 	Mb 253
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	254

	 	Mb 254
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	255

	 	Mb 255
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	256

	 	Mb 256
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	257

	 	Mb 257
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	258

	 	Mb 258
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	259

	 	Mb 259
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	260

	 	Mb 260
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	261

	 	Mb 261
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	262

	 	Mb 262
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	263

	 	Mb 263
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	264

	 	Mb 264
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	265

	 	Mb 265
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	266

	 	Mb 266
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	267

	 	Mb 267
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	268

	 	Mb 268
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	269

	 	Mb 269
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	270

	 	Mb 270
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	271

	 	Mb 271
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	272

	 	Mb 272
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	273

	 	Mb 273
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	274

	 	Mb 274
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	275

	 	Mb 275
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	276

	 	Mb 276
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	277

	 	Mb 277
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	278

	 	Mb 278
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	279

	 	Mb 279
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	280

	 	Mb 280
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	281

	 	Mb 281
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	282

	 	Mb 282
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	283

	 	Mb 283
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	284

	 	Mb 284
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	285

	 	Mb 285
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	286

	 	Mb 286
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	287

	 	Mb 287
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	288

	 	Mb 288
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	289

	 	Mb 289
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	290

	 	Mb 290
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	291

	 	Mb 291
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	292

	 	Mb 292
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	293

	 	Mb 293
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 






Page 3




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





List of Donated Accessions



	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AccID	 	Accession	 	Species	 	SuppliedBy	 	PreviousID	 	Restrictions	 	[***]	 	Type	 	[***]	 	Comments
	294

	 	Mb 294
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	295

	 	Mb 295
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	unclear
	 	[***]
	 	[***]
	 	[***]	 	 
	296

	 	Mb 296
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	297

	 	Mb 297
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	298

	 	Mb 298
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	299

	 	Mb 299
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	300

	 	Mb 300
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	301

	 	Mb 301
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	302

	 	Mb 302
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	303

	 	Mb 303
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	304

	 	Mb 304
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	305

	 	Mb 305
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	Mix of accessions
	306

	 	Mb 306
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	Mix of accessions
	307

	 	Mb 307
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	308

	 	Mb 308
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	309

	 	Mb 309
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	310

	 	Mb 310
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	311

	 	Mb 311
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	312

	 	Mb 312
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	313

	 	Mb 313
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	314

	 	Mb 314
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	315

	 	Mb 315
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	316

	 	Mb 316
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	317

	 	Mb 317
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	318

	 	Mb 318
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	319

	 	Mb 319
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	320

	 	Mb 320
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	321

	 	Mb 321
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	322

	 	Mb 322
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	323

	 	Mb 323
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	324

	 	Mb 324
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	under MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	325

	 	Mb 325
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	326

	 	Mb 326
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	327

	 	Mb 327
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	328

	 	Mb 328
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	329

	 	Mb 329
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]	 	 
	330

	 	Mb 330
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	no MTA
	 	[***]
	 	[***]
	 	[***]
	 	No longer retained.
	331

	 	Mb 331
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	332

	 	Mb 332
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	333

	 	Mb 333
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	334

	 	Mb 334
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 
	335

	 	Mb 335
	 	Miscanthus [***]
	 	[***]
	 	[***]
	 	none
	 	[***]
	 	[***]
	 	[***]	 	 







Page 4




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission









 





Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].




AMENDMENT I




to SCHEDULE 1 between CERES, INC. and INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH dated April
1, 2007 (the “Schedule”).





	 	1.	 	The Parties agree to replace the suggested Year 1 (April 1 to March 31) milestones in
Attachment B of the Schedule in their entirety by the Ceres-IGER Milestones — Year
1, as attached hereto. For clarity, no change is made to pages 1 and 2 of such
Attachment B. Any changes to the suggested Year 2 and Year 3 milestones will be
addressed in separate amendments to the Schedule.
	 
	 	2.	 	The Parties agree that this Amendment I is effective as of January 1, 2008.
	 
	 	3.	 	For the remainder, the Schedule remains unchanged and this Amendment I shall form an
integral part thereof.





Made in two (2) copies.




	 	 	 	 	 	 	 	 	 

	INSTITUTE OF GRASSLAND AND ENVIRONMENTAL RESEARCH	 	CERES, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ M Humphries
	 	By:
	 	/s/ Peter Mascia	 	 
	 

	 	 

Name: Professor Mervyn Humphreys
	 	 	 	 

Name: Peter Mascia
	 	 
	 

	 	Title: Director
	 	 	 	Title: Vice President of
Product Development	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:
	 	/s/ Richard Flavell	 	 
	 

	 	 	 	 	 	 

Name: Richard Flavell, CBE, FRS
	 	 
	 

	 	 	 	 	 	Title: Chief Scientific Officer	 	 






Page 1 of 3









 






Ceres-IGER Milestones — Year 1




	 	 	 	 	 	 	 
	Contract Year	 	 	 	 	 	 
	(April 1 - March 31)	 	Schedule	 	Milestone	 	See key
	Year 1

	 	Agronomy
	 	Characterise [***] in the potential for [***] amongst [***]

from the [***]
	 	A
	 
	 	 	 	 	 	 
	Year 1

	 	Agronomy
	 	Survey of [***] capacity of [***] genotypes taken from the
[***] trial during July 20[***].
	 	A
	 
	 	 	 	 	 	 
	Year 1

	 	Agronomy
	 	Understand [***] affecting [***] across different [***] of
[***] different [***].
	 	A
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	[***] of [***] controlled [***] of Miscanthus [***] ([***])
with Miscanthus [***]. [***] of [***] or [***] to [***] by
early 20[***].
	 	A
	 
	 	 	 	 	 	 
	Year 1

	 	Agronomy
	 	[***] of [***] (additional to [***] required by DEFRA) [***]
of [***] x [***] made based on staggered [***].
	 	D
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	[***]of [***] x [***] will be made based on results from
20[***] field [***] and [***].
	 	A
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	[***] based on outstanding phenotype and [***] geography at
[***] from [***] put into [***]. In [***] or [***] or
[***] (multiples per [***]) available to put into [***] in
20[***] when requested by Ceres
	 	B
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	[***] promising [***] including [***] lines and [***]
trialed to date [***] to [***] in [***] or [***] or [***]
for trial in [***] when requested.
	 	B
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	Samples of [***] from Year 1 [***] and [***] sent to Ceres.
At a minimum [***] + [***] = [***]; more if possible from
[***] of [***] x [***] and [***] x [***] and [***] of [***]
x [***] ([***]).
	 	B
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	[***] to Ceres from M.
[***] ([***]) x M. [***]
([***]) in the
field in 20[***]; believed to be [***] .
	 	B
	 
	 	 	 	 	 	 
	Year 1

	 	Markers
	 	[***]/DNA from [***] plant [***] phenotyped in the field
since 20[***] and first [***] delivered to Ceres in 20[***].
	 	C
	 
	 	 	 	 	 	 
	Year 1

	 	Markers
	 	[***]/DNA from plant [***] in [***] in 20[***] where
material is available, plus other [***] individuals (numbers
defined in Marker schedule) and other selected genotypes
where material is available delivered to Ceres in 20[***]
	 	C
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	Year 2 and [***] phenotype/[***] assessments of material in
[***] trials reported for Ceres to make correlations between
assessments and markers
	 	D
	 
	 	 	 	 	 	 
	Year 1

	 	Markers
	 	[***] sent to Ceres, samples as requested by Ceres for [***].
	 	E
	 
	 	 	 	 	 	 
	Year 1

	 	[***]
	 	[***] made in 20[***] and materials brought into [***] in
IGER to fill in specific [***] needed for likely [***].
	 	F






Page 2 of 3




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






KEY





	A  	 	[***] research to create an economically viable business
	 
	B  	 	[***] to Ceres to help [***] in [***] as early as possible
	 
	C  	 	Advancing the marker assisted [***] program as early as possible
	 
	D 	 	 Advancing the [***] program
	 
	E  	 	Advancing [***] research
	 
	F  	 	Enhancing [***]






Page 3 of 3



Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission










 




Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].




AMENDMENT II



to the Collaboration Agreement effective as of April 1, 2007 between the Institute of Grassland and
Environmental Research (“IGER”) and Ceres, Inc. (“CERES”), as amended (the “Agreement”) and to
SCHEDULE 1 between the Institute of Grassland and Environmental Research (“IGER”) and Ceres, Inc.
(“CERES”) and dated April 1, 2007, as amended (“Schedule 1”).




          WHEREAS, the Institute of Grassland and Environmental Research (“IGER”) and CERES entered into
the Agreement and Schedule 1 on April 1, 2007;




          WHEREAS, on April 1, 2008 IGER merged with Aberystwyth University Institutes of Biological
Sciences and Rural Sciences to form the new Institute of Biological, Environmental and Rural
Sciences of Aberystwyth University (“AU”);




          WHEREAS, as a consequence of such merger, the Parties wish to substitute AU in place of IGER
as a contract party to the Agreement;




          WHEREAS, AU and CERES wish to amend the Agreement, as set forth hereinafter.




          NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the Parties have agreed and do
hereby agree as follows:





	 	1.	 	The Parties agree that Aberystwyth University, a Higher Education Establishment
registered in the United Kingdom No. RC000641, having an office at Old College, King
Street, Aberystwyth SY23 2AX (“AU”) should be substituted as a contract party to the
Agreement in place of IGER.
	 
	 	2.	 	The Parties agree to amend Article 14.1 (e) (v) of the Agreement so as to read as
follows:
	 
	 	 	 	“(v) with thirty (30) days’ written notice to AU if Defra has not assigned
to AU, or granted to AU a license reasonably satisfactory to CERES on, the
Intellectual Property vested in Defra or the Crown or the Secretary of State
pursuant to the DEFRA agreement NF 0426 within three (3) years from the
Effective Date (the “Assignment/License”); provided however that Ceres will not
unreasonably refuse to extend such three (3) year term by six (6) months if so
requested by AU by December 31, 2009.”
	 
	 	3.	 	The Parties agree to add the following clause in Article 6 of Schedule 1:





Page 1 of 2




 









 









	 	 	 	“As long as the assignment or license grant by Defra to AU, and the
corresponding grant of a license or sublicense to CERES in compliance with the
Agreement, has not occurred, CERES will have the right to withhold [***] percent
([***]%) of the funding payable by CERES to AU pursuant to Attachment B —
Budget, attached to Schedule 1 (as this may be amended from time to time).
CERES’ rights to withhold such payments will terminate:






	 	(i)	 	with respect to [***] percent ([***]%) of the funding,
as of the date CERES effectively receives a license or sublicense
satisfactory to CERES on CERTAIN MISCANTHUS ACCESSIONS (defined in
Article 3.2.1 b. of the Agreement) and related information.
	 
	 	(ii)	 	with respect to [***] percent ([***]%) of the funding
as of the date CERES effectively receives a license or sublicense
satisfactory to CERES on the Intellectual Property vested in Defra or
the Crown or the Secretary of State pursuant to the Defra agreement
NF0426.”






	 	4.	 	The Parties agree that this Amendment II is deemed to have become effective as of May
1, 2008.
	 
	 	5.	 	For the remainder, the Agreement and Schedule 1 remain unchanged and this Amendment II
shall form an integral part thereof.




Made in two (2) copies.




	 	 	 	 	 	 	 

	 
	ABERYSTWYTH UNIVERSITY	 	CERES, INC.
	 
	By: 	 /s/ S.G.A. Durbin	 	By: 	         /s/ Richard Flavell
	 	Name: 	 S.G.A. Durbin	 	 	Name: 	       Richard Flavell, CBE, FRS
	 	Title:	 Director, Risk & Research Finance	 	 	Title:	      Chief Scientific Officer
	 
	 	 	 	 	By: 	         /s/ Richard Hamilton
	 	 	 	 	 	Name: 	       Richard Hamilton
	 	 	 	 	 	Title:	      President and Chief
	 	 	 	 	 	 	Executive Officer







Page 2 of 2




Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 




Pages where confidential treatment has been requested are stamped ‘Confidential Treatment
Requested and the Redacted Material has been separately filed with the Commission,’ and the
confidential section has been marked as follows: [***].



CONFIDENTIAL




AMENDMENT III



to the SCHEDULE 1 between the Institute of Biological, Environmental and Rural Sciences (“IBERS”)
of Aberystwyth University and Ceres, Inc. (“CERES”) and dated April 1, 2007, as amended (“Schedule
1”).




          WHEREAS, IBERS and CERES entered into Schedule 1 on April 1, 2007;




          WHEREAS, the initial term of Schedule 1 was for three (3) years;




          WHEREAS, the Parties wish to extend the term of Schedule 1 to cover additional research and
development activities;




          WHEREAS, IBERS and CERES further wish to amend Schedule 1, as set forth hereinafter.




          NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements
contained herein and of other good and valuable consideration, the Parties have agreed and do
hereby agree as follows:





	 	1.	 	The Parties agree to substitute the RESEARCH AND DEVELOPMENT PLAN referred to in
Article 3 of Schedule 1 and attached as Attachment A to Schedule 1 by a new
Attachment A/2010 revision, as attached to this Amendment III.
	 
	 	2.	 	The Parties agree to amend Article 5 PHD LEVEL SCIENTIFIC STAFF for CERES staff so as
to read as follows:




Richard Flavell (CERES)

Jeff Gwyn (CERES)

Charlie Rodgers (CERES)

Timothy Swaller (CERES)





	 	3.	 	The Parties agree to substitute the Budget referred to in Article 6 of Schedule 1 and
attached as Attachment B to Schedule 1 by a new Attachment B/2010 revision,
as attached to this Amendment III.
	 
	 	4.	 	The Parties agree to amend Article 16 Term of Schedule 1 so as to read as
follows:






	 	 	 	“Term: Five (5) years provided however, at least one (1)
year before the end of the term of this SCHEDULE, the Parties shall
decide whether to extend it for one (1) or more years, with
appropriate updates to the RESEARCH AND DEVELOPMENT





Page 1 of 9



 









 






	 	 	 	PLAN
(Attachment A/2010 revision), and FUNDING (Article 6 of this
SCHEDULE).”






	 	5.	 	The Parties agree that this Amendment III is deemed to have become effective as of
March 31, 2010.
	 
	 	6.	 	For the remainder, Schedule 1 remains unchanged and this Amendment III shall form an
integral part thereof.




Made in two (2) copies.




	 	 	 	 	 	 	 

	 
	ABERYSTWYTH UNIVERSITY	 	CERES, INC.
	 
	By: 	 /s/ E. Reynolds	 	By: 	         /s/ Jefferson Gwyn
	 	Name: 	 Emyr Reynolds	 	 	Name: 	       Jefferson Gwyn
	 	Title:	 Head of Research Grants	 	 	Title:	      Vice President of Breeding & Genomics
	 
	 	 	 	 	By: 	         /s/ Richard Flavell
	 	 	 	 	 	Name: 	       Richard Flavell, CBE, FRS
	 	 	 	 	 	Title:	      Chief Scientific Officer






Page 2 of 9



 









 






Attachment A/2010 revision




RESEARCH AND DEVELOPMENT PLAN



April 1, 2010 — March 31, 2011 workplan




	 	 	 	 	 
	Action proposed	 	Dates Performed	 	Summary of action taken
	1. Supply [***]
from the [***]
best [***] to
CERES partners in
[***]

	 	April 2010
	 	Supplied [***], [***] checked [***] to [***] company as
directed by CERES
	 
	 	 	 	 
	2. Supply plants
for [***]
observation and
miniplot trials

	 	April to July 2010
	 	Supplied [***] for the establishment of the following trials
[***] 4 ON ([***])
[***] 5 MP (best lines — [***] and [***])
[***] 1 ON (best lines — [***] and [***])
[***] 4 ON
[***] 13 MP (best [***] from [***], JKI etc.)
[***] A9 ON ([***] survivors, [***], [***])
[***] A 10 ([***] survivors, [***], [***])
[***] A11 RP (small plots of [***])
	 
	 	 	 	 
	3. Gather
phenotyping data
from [***] trials
to identify the
most promising
[***] to be used
in [***]

	 	July to November
	 	Best [***] was identified based on autumn [***] scores.
[***] ‘Generic high [***]’ [***] found in [***] at [***] and
[***].


Technical enabling

A new [***] field nomenclature was developed to ensure
clear communication so that each plant or plot in the [***]
trials was identified by a UID. 


Photographs and data loaded to MSCAN and discussed at the
January 2011 quarterly. 


Development of the controlled vocabularies for phenotyping
fields is ongoing.


[***] data was recorded in [***] and [***] on the [***]


[***] data in Feb 2011 gathered but needs developed of the
controlled vocabularies before this can be loaded to MSCAN
and analysed.






Page 3 of 9





Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





	 	 	 	 	 
	Action proposed	 	Dates Performed	 	Summary of action taken
	4. Send [***] of
the best
selections from
[***] and [***] to
[***] identified
by June 2010

	 	October
	 	[***] Miscanthus samples for [***] under [***] on behalf of
Dr. Charlie Rodgers. The Miscanthus [***] in this package
are provided under a research agreement between IBERS and
CERES and are restricted to release only to CERES, Inc.
They are not [***].
	 
	 	 	 	 






5. Create [***] based on a
knowledge of
[***] available






All year and ongoing






Table shows number of
[***] attempted by [***] types.




	 	 	 	 	 	 	 
	[***] Type	 	Number	 	% [***]	 	Produced >[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 

	Total

	 	[***]
	 	[***]
	 	[***]




Restricted: a form of [***] where [***] within a [***] has occurred and the plants have been [***] to
[***]. The potential [***] contributors can be short listed from the [***] monitoring data.
[***]: [***] wise [***] produce two [***] records since [***] contain both [***] and [***] parts.
[***]: single [***]
[***]: Here the [***] from [***] are registered as [***] ops.



In 2010 encumbrances ([***] and [***]) stopped us going down the route of [***] M. [***] with the well
characterized [***] from [***].









	 	 	 	 	 

	6. Develop knowledge of [***] for [***] in a wide range of [***] in order to [***]

	 	April — Oct
	 	[***] experiments were run in 2010.
Discovery of the [***] effect when plants
were grown under simulated [***] conditions.






Page 4 of 9






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






	 	 	 	 	 
	Action proposed	 	Dates Performed	 	Summary of action taken
	7. [***] experiments

	 	April to Oct
	 	A small trial revealed the value of [***] in
[***] of [***] M. [***] from [***].
	 
	 	 	 	 
	8. Leaf samples from DNA to develop the [***]

	 	Oct
	 	Freeze dried samples sent to CERES from [***]
	 
	 	 	 	 
	9. [***] from 2010 [***] raised for planting in [***] trials

	 	Jan — March
	 	[***] tests identified successful [***]. A
tray of each [***] was raised where possible
(1 tray = [***] plants)
	 
	 	 	 	 
	10. [***] from 2010 [***] sent to CERES

	 	April 2011
	 	From these [***] from [***] with interesting
[***] were sent to Charlie.
	 
	 	 	 	 
	11. Reporting

	 	 	 	Powerpoints of July 13 meeting sent 

Powerpoints of August 28 meeting sent 

Powerpoints of 1 and 2 Nov meeting sent 

Document on forward plans (Nov 2010) 

Powerpoints of meeting 20-21 Jan 2011






April 1, 2011 — March 31, 2012 workplan




	 	 	 	 	 
	milestone	 	Projected Dates	 	Summary of planned actions
	1. Characterise [***] from the [***] to inform
development tracks 1 to 4

	 	Ongoing
	 	For [***] from the [***] we will perform
measurements to collect:
	 

	 	 	 	[***] (when plants are [***] ([***]
years from planting)
[***] status in autumn
[***] (scores and measurements)
	 
	 	 	 	 
	2. Development of [***]/ [***] with desirable characters

	 	Ongoing
	 	Attempt >[***] exploratory [***]
between [***] in [***] of the [***]
Perform at least [***] with best [***]
identified in [***] using the [***] and
[***] in 2010
From these [***] of [***] and [***] with
interesting [***] to be sent to Charlie.






Page 5 of 9






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






	 	 	 	 	 
	milestone	 	Projected Dates	 	Summary of planned actions
	3. Development of [***] (CERES, IBERS)

	 	 	 	Organize [***] phenotype data for use by
CERES in collaboration with [***] (on a
BBSRC funded flowering grant) and [***] (on the [***]).
Monitor [***] planted in 20[***] through
collaboration with [***] and the [***].
Supply of further leaf samples as
requested for [***] analysis.






Page 6 of 9






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






	 	 	 	 	 	 	 
	milestone	 	Projected Dates	 	Summary of planned actions
	4. Initiate field
evaluation of
selected potential
new Miscanthus
[***] and [***],
measure [***] and
other key [***].

	 	April to
Aug 2011
	 	Notes

[***]
and [***]


for [***] selections
	 	Putative Trial name

[***] 6 ST
	 

	 	 	 	plus [***] controls
	 	[***] 7 MP
	 

	 	 	 	[***]	 	 
	 

	 	 	 	based on best	 	 
	 

	 	 	 	[***]
	 	[***] 5 CB
	 

	 	 	 	[***] blocks	 	 
	 

	 	 	 	based on best	 	 
	 

	 	 	 	[***]
	 	[***] 6 CB
	 

	 	 	 	[***] blocks	 	 
	 

	 	 	 	based on best	 	 
	 

	 	 	 	[***]
	 	[***] 7 CB
	 

	 	 	 	[***] blocks	 	 
	 

	 	 	 	based on best	 	 
	 

	 	 	 	[***]
	 	[***] 8 CB
	 

	 	 	 	[***] testing
	 	[***] 9 ON
	 

	 	 	 	miniplots, sue’s	 	 
	 

	 	 	 	choices
	 	[***] 3 MP
	 

	 	 	 	miniplots, sue’s	 	 
	 

	 	 	 	choices
	 	[***] 25 MP
	 

	 	 	 	[***] from	 	 
	 

	 	 	 	2010 [***]
	 	[***] 26 ST
	 

	 	 	 	[***]
	 	[***] 27 CB
	 

	 	 	 	[***]
	 	[***] 28 CB
	 

	 	 	 	[***]	 	 
	 

	 	 	 	which are now	 	 
	 

	 	 	 	in [***]”
	 	[***] 29 ON
	 

	 	 	 	Library of [***]	 	 
	 

	 	 	 	[***]	 	 
	 

	 	 	 	used	 	 
	 

	 	 	 	in [***] (E.G.	 	 
	 

	 	 	 	#1 To 5’S)
	 	[***] 30 ON
	 

	 	 	 	Selected lines	 	 
	 

	 	 	 	into [***]
	 	[***] 3 ON
	 

	 	 	 	Sue’s MP	 	 
	 

	 	 	 	selections
	 	[***] 1 MP
	 

	 	 	 	 	 	 





Page 7 of 9






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 





	 	 	 	 	 
	milestone	 	Projected Dates	 	Summary of planned actions
	5. [***] and
[***]

	 	Ongoing
	 	[***] of [***] currently being raised from use
in [***] will be supplied to [***].


[***] screens on [***] to be performed and added
to MSCAN.
	 
	 	 	 	 
	6. [***] experiments

	 	 	 	Field experiments with direct sowing using [***].
	 
	 	 	 	 
	7. Reporting

	 	 	 	Minutes and powerpoints from meetings






Page 8 of 9






Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission







 






Attachment B/2010 revision




Budget


CERES shall pay IBERS £[***] (GBP) per year for the implementation of the RESEARCH AND
DEVELOPMENT PLAN set forth in Attachment A/2010 revision. Annual payments from CERES to IBERS
shall not exceed £[***] (GBP).



Payment details shall be as set forth in Article 1.8 of the Collaboration Agreement.



“1.8 Where a SCHEDULE provides that CERES will make a financial contribution to certain RESEARCH
PROJECT activities performed by IBERS, unless agreed otherwise in the appropriate SCHEDULE, IBERS
will submit invoices after the end of each calendar quarter for the work performed during that
quarter. Each such invoice shall reflect only those costs that have been incurred in performance
of the RESEARCH PROJECT and shall provide a breakdown of costs similar to the detail set forth in
the budget of the related SCHEDULE. CERES will pay all such invoices within thirty (30) days after
the invoice date. Payments shall be remitted to:



Institute of Biological, Environmental and Rural Sciences (“IBERS”) of

Aberystwyth University

Plas Gogerddan

Aberystwyth

Ceredigion

SY23 3EB

United Kingdom”





Page 9 of 9




	 	 	 
	Confidential Treatment Requested and the Redacted Material has been separately filed with
the Commission.